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Abstract: A study of the transcriptional regulation of the defensin genes
The defensin genes are expressed almost exclusively within a narrow window 
of myeloid differentiation, namely at the myelocyte stage of granulopoiesis. These 
genes encode peptides which are involved in the granulocytes response to infection 
and inflammation, being capable of destroying a wide range of organisms. The limited 
expression pattern of these genes suggests they would provide a good model to study 
mechanisms of both myeloid and differentiation-stage-specific gene expression. By 
studying the regulation of these genes, it may be possible to identify transcription 
factors which control both lineage-specific gene expression and differentiation in the 
myeloid compartment. This information may provide an insight into the process of 
maturation arrest and leukaemogenesis.
Initial work was undertaken to identify a system in which to study the 
regulation of these genes. However, despite previous reports, no expression could be 
detected or induced in any myeloid cell line tested. DNAse 1 hypersensitivity analysis 
was carried out on a range of primary samples and both myeloid and non-myeloid cell 
lines. This analysis identified a number of DNAse 1 hypersensitive sites in the 
chromatin. One of these sites spanned the promoter and this was analysed in some 
detail. Both in vitro binding studies and transfection of reporter constructs were used to 
investigate if this promoter could mediate myeloid and/or differentiation-stage- 
specific activity. A number of DNA binding activities were identified which were 
markedly regulated during myeloid differentiation. This, in conjunction with the 
transfection data? allows models to be produced to explain both the myeloid and 
differentiation-stage-specific activity of these genes.
Evidence is provided implicating the defensin genes as targets for regulation by 
the transcription factor c-Myb. This factor acts through a composite element within the 
defensin promoter which also binds a C/EBP-like factor. In addition, Ets-like 
transcription factors are implicated in mediating the myeloid specificity of these genes.
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Part 1: Introduction
Chapter 1: Haemopoiesis
Haemopoiesis in the adult human takes place principally in the bone marrow 
and lymphoid organs and is responsible for the regulated production of blood cells. 
This is a continuous process with more than 1011 cells per day being generated in 
the average adult (reviewed in Dexter and Spooncer 1987). The haemopoietic 
system is conventionally classified into three compartments: stem cells, progenitor 
cells and maturing end cells. Stem cells are defined by their ability to reconstitute 
the entire haemopoietic system, and these are capable of both self renewal and 
differentiation with proliferation to generate the precursor cells. These cells 
undergo a further series of poorly understood differentiation steps to generate 
committed maturing end cells. These mature 'end' cells are comprised of 
erythrocytes, monocytes, neutrophils, eosinophils, megakaryoctes, mast cells, B 
lymphocytes and T lymphocytes. The characteristics of the differentiation of 
macrophages and neutrophils are described in more detail in sections 1.1 (i) and
1.1 (ii), as these cells are most relevant to the work described here.
1.1 ( i) Monocytic differentiation
The monocytic/macrophage lineage develops initially in the bone marrow. 
Monocytes are released into the circulation where they later seed tissues and develop 
further into tissue macrophages. Monocytes are less common than neutrophils, 
making up 2-10 % of leukocytes in the peripheral blood.
The monoblast is the first cell defined in the monocytic lineage and is 
morphologically similar to the myeloblast. These cells are characterised by a round 
nucleus with fine chromatin and prominent nucleoli and a cytoplasm containing 
numerous mitochondria, show little motility or adhesiveness to glass surfaces. 
When these cells develop a complex golgi and a granule population they can be 
described with certainty as promonocytes. The promonocyte is characterised by a
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relatively large diameter (10-20|im) and a high ratio of nucleus to cytoplasm. These 
cells have a conspicuous golgi complex, relatively few cisternae of the endoplasmic 
reticulum, numerous free polysomes and a large number of granules. Promonocytes 
have peroxidase activity, adhere to glass and can endocytose but show little 
phagocytosis.
Monocytes are found in the circulation and are smaller in size than 
promonocytes. The centrally located nucleus is indented or horse-shoe shaped, the 
cytoplasm contains many lyzosomal granules and have increased activity for a 
number of hydrolases. Monocytes further develop in tissues into the large 
macrophage c e ll . These macrophage are not end cells; immature macrophages are 
capable of division and give rise to long lived non-replicating macrophages. 
Maturation is accompanied by an increase in cell size and in numbers of cytoplasmic 
organelles including lyzosomes and mitochondria. The precise pattern of 
development is determined by the tissue in which the macrophage matures. This 
produces sub-populations of macrophage with distinct biochemical properties e.g. 
alveolar macrophage and peritoneal macrophages (for review see Williams et al., 
1986).
1.1 (ii) Neutrophil differentiation
The polymorphonuclear neutrophil (PMN) when released into the blood 
stream is a terminally differentiated cell, no longer capable of proliferation and with 
a limited capacity for protein synthesis. These PMNs account for around 50-60 % 
of circulating white blood cells, and have a relatively short life-span - circulating for 
hours before migrating to the tissues, where they normally live for 1-2 days before 
senescing.
The first cell described in the neutrophil lineage is the myeloblast; this 
cannot be reliably distinguished by morphological criteria from other primitive 
haemopoietic cells, and is normally identified by 'the company it keeps' i.e. the
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surrounding cells in the marrow. This primitive cell is restricted to the bone 
marrow, contains a large nucleus which is round or slightly oval with one or more 
prominent nucleoli. The cytoplasm contains no granules and the endoplasmic 
reticulum is poorly developed. The promyelocyte is the first cell that can be reliably 
identified as a neutrophil precursor, and is characterised by a large round nucleus 
with diffuse chromatin and a large number of nucleoli. Often the nucleus is indented 
opposite the golgi apparatus and has a smaller nuclear/cytoplasmic ratio than the 
myeloblast. Characteristic of the promyelocyte is the accumulation of peroxidase 
positive granules (primary granules) in the cytoplasm and a more developed 
endoplasmic reticulum.
As the cells mature through the myelocyte and metamyelocyte stages the 
chromatin condenses and the nucleoli become less prominent and eventually 
disappear. The nucleus shrinks and the cells become progressively smaller. The 
endoplasmic reticulum is less developed than in the promyelocyte, polyribosomes 
are less abundant and mitochondria are smaller and fewer in number. A second 
population of granules appear (secondary or specific) and the manufacture of the 
primary granules ceases and are diluted with division until the secondary granules 
become predominant. Division takes place only during the myeloblast, 
promyelocyte and myelocyte stages. The mature PMN is characterised by a lobed 
nucleus and marked condensation of the chromatin. The endoplasmic reticulum is 
not well developed, and there are relatively few mitochondria and ribosomes in 
comparison to precursors - reflecting the diminished protein synthesis capacity of 
the mature PMNs (for review see Williams et al., 1986).
1.1 (iii) Neutrophil function
Neutrophils are phagocytic cells whose primary function is the ingestion and 
destruction of invading micro-organisms. In the blood, neutrophils are attracted to 
sites of infection by chemotactic factors, which are generated by interaction of
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antibodies with antigen or pathogens. These cells then ingest opsonized particles 
(antibody and complement coated) by surrounding them with pseudopodia which 
eventually meet and fuse to enclose the micro-organism within an intracellular 
vesicle termed the phagosome. The cytoplasmic granules then fuse and release their 
contents into this phagosome.
Neutrophils contain two types of granule; the primary (or azurophilic) and 
the secondary (or specific granules). Primary granules are similar to lysozmes i.e. 
membrane bound particles storing acid hydrolases in a latent form, but also contain 
a number of specialised microbicidal proteins not found in other tissues. These 
include myeloperoxidase, involved in the oxidative destruction of ingested particles 
and a number of cationic peptides which include the bactericidal / permeability 
inducing protein and the defensins which are microbicidal (see section 1.2).
While the primary granules are largely used intracellularly, the secondary 
granules are released into the extracellular space. Proteins contained in these 
granules include collagenase, plasminogen activator, lysozyme and lactoferrin. 
Collagenase and plasminogen activator are involved in the destruction of tissue prior 
to repair at sites of inflammation, lysozyme is present in the secondary as well as 
in the primary granules and both this and lactoferrin are involved in the destruction 
of micro-organisms.
1.2 Defensins
Defensins are small cationic, arginine-rich peptides of 29-34 amino acids in 
length. With the exception of the so-called p-defensins identified in cow PMN 
(Selsted et al., 1993), all defensins contain an invariant six cysteine residue motif. 
The connectivity of their three disulphide bridges has been determined by direct 
chemical analysis (Selsted and Harwig 1989) and confirmed by 2D nuclear 
magnetic resonance (Pardi et al., 1992). Defensins have been identified in the 
PMNs of human, guinea pig, rabbit, cow and rat but surprisingly seem to be
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absent from mice (Eisenhauer and Lehrer 1992).
These molecules are found predominantly in the primary granules of 
neutrophils where they account for approximately 30% (Greenwald and Ganz 1987) 
of total primary granule protein. However these peptides have also been found in 
pulmonary macrophages of rabbits and related proteins have been identified in 
paneth cells of the mouse small intestine (Ganz et al., 1989; Ouellette et al., 1989). 
Homologous molecules have also been found in the haemolymph of certain insects 
after injury or infection (Lambert et al., 1989).
Human and rabbit defensins are synthesised as a 93-95 amino acid 
preprodefensin with a characteristic 19 amino acid signal sequence probably 
necessary for insertion into the endoplasmic reticulum, and a 40-45 amino acid 
anionic propeptide which must be cleaved to yield the mature defensin molecule 
(Valore and Ganz 1992).
1.2 (i) Antimicrobial activities of defensins
Defensins have potent antimicrobial activity against a wide variety of both 
gram-positive and gram-negative bacteria, fungi, enveloped viruses and tumour cell 
lines. Four human peptides have been isolated termed HNP1, HNP2, HNP3 and 
HNP4. HNP1 and HNP3 are identical except for the N-terminal amino acid, and 
HNP2 lacks this amino acid. Only cDNAs corresponding to HNP1 and HNP3 
peptides were isolated from an HL60 cDNA library suggesting that HNP2 may be 
derived by cleavage of HNP1 or HNP3 (Daher et al., 1988). HNP4 was later 
purified from the granules of neutrophils (Wilde et al., 1989). HNP4 contains the 
conserved cysteine motif, however it is considerably diverged from the other 
human defensins. Of the 33 amino acids, 22 and are different from HNP1, and 
many of these changes require more than a single nucleotide change indicating the 
genes encoding these peptides are not the result of a recent duplication event, as 
may be the case for the genes encoding HNP1 and HNP3.
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Differential activities have been found for the HNP peptides against a panel 
of bacteria; HNP3 has lower activity than HNP1 and HNP2 for four out of five 
strains (Daher et al., 1986). HNP1 was also found to have activity against a number 
of other enveloped viruses but was not active against the non-enveloped echovirus 
and reovirus (Daher et al., 1986). HNP1 and HNP2 were also found to be active 
against the fungi C.albicans (Wilde et al., 1989). HNP4 was shown to kill E.coli, 
Streptococcus faecalis and C.albicans. Compared to a mixture of the other human 
defensins, HNP4 was a hundred-fold more active against E.coli and four-fold 
more active against S.faecalis (Wilde et al., 1989). Similar experiments have 
demonstrated antimicrobial activities for rabbit and rat defensins (Lehrer et al., 
1989). Activities of defensin molecules when assayed in vitro have demonstrated up 
to a 1000-fold variation in killing efficiency of various species of bacteria by 
different defensins. Variations in the potencies of these molecules may depend on 
the assay conditions as well as the target organisms. In in vitro assays, the level of 
defensin molecules is very low in comparison to that which may be achieved in the 
phagosomes, and in vivo defensins do not act in isolation but in concert with other 
antimicrobial defences which may help potentiate defensin activity.
The mechanism of defensin activity is unknown, however binding to a lipid 
bilayer is a prerequisite. A membrane potential is required as cells can be destroyed 
only when metabolically active, and can be protected by membrane depolarising 
agents such as carbonylcyanide M chlorophylhydrazone and 2,4-dinitrophenol 
(Kagan et al., 1990). This result is consistent with the observation that defensins 
form voltage-dependent channels in lipid bilayers, a process which appears to 
involve an aggregation of 2-4 molecules. The crystal structure of HNP 1 and HNP3 
have been determined. This molecule crystalises as a dimer and unlike other 
channel-forming proteins contains no a-helical regions. The structure suggests a 
number of possible mechanisms of action, but no data are as yet available to judge 
between them (Hill et al., 1991; Stanfield et al., 1988).
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1.2 (ii) Other activities of defensins
Other than the destruction of micro-organisms during phagocytosis, 
defensin molecules have a number of other activities. They may play a role in 
cytotoxicity at the site of infection and/or inflammation as they may be released at 
active concentrations into the extra-cellular environment (Ganz 1987). These 
molecules also display strong chemotactic activity for monocytes in vitro, and hence 
may be involved in the recruitment of monocytes to the site of infection and/or 
inflammation (Territo et al., 1989). Defensins have been reported to act as 
corticostatins i.e. agents that interfere with the effect of adrenal corticotropin 
hormone (ACTH) on adrenal cortical cells by binding specifically to the ACTH 
receptor (Qinzhang et al., 1987). An in vitro assay has demonstrated that defensins 
non-competitively inhibit protein kinase C activity, but what role if any this plays 
in vivo is unclear (Charp et al., 1988).
1.3 Leukaemia
Leukaemia can be defined as the uncontrolled proliferation or expansion of 
haemopoietic cells that do not retain the capacity to differentiate normally into 
mature end cells. This distinguishes leukaemia from other haematological disorders 
that do not display a full leukaemic phenotype - either myeloproliferative 
(characterised by growth expansion) or myelodysplastic syndromes (which show 
abnormal differentiation). Both, however, can progress to acute leukaemia.
1.3 ( i) Maturation Arrest
Most evidence supports the theory of leukaemia being monoclonal in origin, 
with the original transforming event taking place within the stem cell or immature 
progenitor compartments. For example chronic myeloid leukaemia (CML) is a
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disease of the pluripotent stem cell, this disease is characterised in the chronic 
phase by an expansion in the myeloid compartment. The Philadelphia chromosome 
(a reciprocal translocation between chromosomes 9 and 22) characteristic of CML is 
found in all the haemopoietic lineages, but not in fibroblasts or bone marrow 
stromal cells indicating an origin of this lesion in the haemopoietic stem cell.
Comparison of the phenotypes of leukaemic and normal haemopoietic cells 
has revealed that the leukaemic cells have a phenotype similar to a precursor cell in 
normal haemopoiesis Greaves et al., 1981; Foon and Todd 1986). This precursor 
under normal circumstances is restricted to the bone marrow, present in low 
numbers and is often transient in nature. In the leukaemic cell the processes of 
proliferation and differentiation have been uncoupled, leaving the cells 'maturation 
arrested’ at a stage similar to that occurring during normal haematopoesis. It is this 
loss of the ability to differentiate terminally together with the capacity for continued 
proliferation that produces the leukaemic phenotype. This uncoupling of 
proliferation and differentiation may not be absolute, but may vary in stringency. 
The greater the uncoupling the less mature the phenotype of the transformed clone 
(Greaves et al., 1982; Sachs 1982). If a relatively small shift in the balance 
between proliferation and differentiation occurs in the stem cell compartment, this 
may result in a gradual clonal expansion allowing cells to differentiate almost 
terminally. This pattern is seen in CML during the chronic phase, which is 
characterised by an expansion in the myeloid compartment with the presence of 
relatively mature cells in the peripheral blood. A more stringent uncoupling would 
explain the presence of leukaemic blast cells in the blood of acute leukaemia patients 
and during the blast crisis of CML. What are the candidate genes responsible for 
the phenomena of maturation arrest ? Possible targets are genes which are involved 
in the control of proliferation and differentiation.
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1.3 (ii) Disorders of growth and differentiation
In acute leukaemia there is an increase in the number of circulating white 
blood cells and a defect in their normal maturation. The existence of 
myelodysplastic and myeloproliferative disorders suggests that these processes may 
be separable and full leukaemic transformation requires defects in both 
differentiation and growth control. Possible m olecular mechanisms of 
leukaemogenesis are discussed in sections 1.3 (iii-iv). These are separated into 
defects in growth promoting genes and differentiation genes. However it should be 
remembered that in many systems, the processes of terminal differentiation and 
growth inhibition are normally stringently coupled.
1.3 (iii) Growth factors and leukaemia
Obvious candidates for oncogenes involved in leukaemogenesis are the 
haemopoietic growth factors and their cognate receptors. Reconstitution of mouse 
bone marrow and transgenic mice have been used assess the effect of constitutive 
expression of GM-CSF and IL-3. These generate a myeloproliferative disorders but 
not full leukaemia (Chang et al., 1989; Johnson et al., 1988; Wong et al., 1989). 
Obviously another oncogenic change is necessary to generate full leukaemia. As 
well as over-expression of the growth factor itself, a number of other changes can 
result in growth factor independence. These include constitutive activation of the 
receptor or activation of a tyrosine kinase oncogene such as abl. CML is 
characterised at the molecular level by the generation of a fusion between the bcr 
and the abl gene. Introduction of the bcr-abl oncogene into haemopoietic cells 
renders them growth factor independent and tumourigenic in mice. The property of 
rendering cells growth factor independent is common to growth factor/tyrosine 
kinase oncogenes. However this growth factor independence does not always 
correlate with tumourgenicity in vivo and many tumourigenic myeloid cell lines
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remain dependent on exogenous growth factors for growth in vitro. Clearly as 
growth factor over-expression alone is not sufficient to confer the complete 
leukaemic phenotype, is there evidence for an involvement in leukaemia in vivo ?
The first proto-oncogene identified as a haemopoietic growth factor receptor 
was c-fms, the cellular homologue of the v-fms - the transforming gene of the 
Feline Sarcoma Virus. V-fms was transduced from the cellular M-CSF receptor 
gene (Sherr et al., 1985). The M-CSF receptor is active only in the presence of M- 
CSF. The viral form has constitutive tyrosine kinase activity, and reconstitution of 
mouse bone marrow with bone marrow infected with v-fms containing retrovirus 
results in malignancies of multiple haemopoietic lineages (Ridge et al., 1990). 
Analysis of the mutations necessary for c-fms to be converted to an oncogenic form 
allowed the analysis of leukaemias for activated c-fms. This revealed that 
transforming mutations in c-fms were found in approximately 10% of AML and 
MDS patients tested (Ridge et al., 1990)
IL-3 has also been implicated in the development of a sub-type of acute 
preB-cell leukaemia with a characteristic t(5:14) translocation. In two patients this 
was found to deregulate IL-3 expression by bringing the IL-3 promoter in close 
proximity to the immunoglobulin heavy chain gene (Meeker et al., 1990).
1.3 (iv) Differentiation genes and leukaemia
Characterisation of retroviral insertion sites and cloning of chromosomal 
translocation break points in leukaemia has identified a number of genes which are 
strong candidates for playing a role in leukaemogenesis. A large number of these 
genes have similarity to genes encoding proteins of known transcription factor 
families, whose members are expressed in a developmental and differentiation- 
specific manner. These translocations often result in the abnormal expression, or 
alter the transcriptional properties of these genes by the generation of chimeric or 
truncated genes. This suggests that they may play a causal role in the process of
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maturation arrest by interfering with normal differentiation.
An instructive and well characterised example is the translocation t( 15:17) 
found in all patients with a sub-type of acute myeloid leukaemia, acute 
promyelocytic leukaemia. Cloning of the translocation site (de The et al., 1991) 
defined the gene on chromosome 15 as my I or PML, whose sequence suggests it 
may encode a protein which forms a zinc finger structure and bind either DNA or 
RNA. The gene disrupted on chromosome 15 is the retinoic acid receptor a  
(R A R a) gene. This translocation has the effect of generating a fusion gene 
encoding a protein containing the C-terminus of the retinoic acid receptor a  
(containing the DNA and ligand binding domains) and the N-terminus of the 
product of the PML gene. This leukaemia can be successfully treated with all trans- 
retinoic acid, presumably by overcoming the block to differentiation (which is 
observed when blast cells from these patients are treated in vitro, Breitman et al., 
1981). However, much higher than physiological levels are necessary to induce 
differentiation and remission in these patients. As the leukaemic cells still retain a 
normal copy of both RARa and the PML genes, the differentiation block must act 
in a dominant negative fashion.
How the PML-RAR fusion protein blocks differentiation is unclear, 
however it has the ability to activate transcription of gene expression via the retinoic 
acid receptor binding site (Pandolf et al., 1991; de The et al., 1991; Kastner et al., 
1992). This trans-activation is variable depending on the cells used and the response 
element itself. The finding by Pandolfi et al., (1991) that the gene had dual activity, 
viz ligand independent repression and ligand dependent activation, would explain 
the differentiation block and the response to retinoic acid, although a number of 
other mechanisms are possible and further analysis will be instructive. Interestingly, 
transfection of a construct containing this fusion gene into the monocytic cell line 
U937 blocked differentiation of this cell line and reduced apoptotic death in the 
presence of low serum (Grignani etal., 1993).
A similar example is provided by the thyroid hormone receptor family. The
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acute erythroblastosis virus (AEV) induces rapid erythroleukaemia in chickens. This 
virus contains the oncogene v-erbA, the cellular homologue c-erbA  encodes the 
thyroid hormone receptor (Sap et al., 1986; Weinberger et al., 1986). The thyroid 
hormone receptor binds DNA constitutively but activates transcription only in the 
presence of ligand. The viral form however binds DNA but fails to activate 
transcription even in the presence of high levels of ligand. This dominant repressor 
effect is believed to block differentiation (Zenke et al., 1990; Damm et al., 1993).
The AEV also contains a second oncogene, v-erbB, the viral counterpart of 
the epidermal growth factor receptor. Mutant viruses lacking v-erbB activity show 
no transforming activity, but mutant viruses defective in the v-erbA  gene can 
transform erythroblasts. These transformed cells spontaneously differentiate at a 
high level underlining the co-operation of these two oncogenes, with v-erbB  
exerting its effects on growth and v-erbA in blocking differentiation.
The myelodysplastic syndromes may be a case where a lesion has occurred 
only in a gene(s) affecting normal differentiation without generating a proliferative 
advantage. The peripheral blood of these patients is characterised by low levels of 
leukocytes, however the marrow has normal or slightly elevated levels of precursor 
cells. The molecular mechanisms generating these conditions are unknown although 
oncogene abnormalities such as activating mutations of ras and p53 have been 
reported (Bos 1989). Treatment of these patients with CSFs has successfully 
increased the number of circulating white blood cells, but interestingly, 
examination of the bone marrow show that this treatment produces some of the 
features of acute leukaemia in a number of patients. This phenotype is lost when the 
CSF is withdrawn, suggesting that to generate acute leukaemia a change which can 
functionally substitute for the presence of exogenous growth factor is necessary in 
these cells (Ganser et al., 1990).
A recent report identified a fusion protein generated by the t(3:21) found in 
some therapy-related myelodysplastic syndromes, acute myeloid leukaemia and the 
blast crisis of CML. This translocation fuses the AML1 gene (which has homology
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to the Drosophila segmentation transcription factor runt) to the gene encoding the 
ribosomal protein L22. The mechanism of action of the fusion protein expressed in 
the cells is unknown. However, it may act in a dominant negative manner to block 
the normal activity of the AML1 transcription factor as the truncated AML1 gene 
generated by the translocation is postulated not to contain the the sequences 
encoding the transactivation domain. As this translocation is found in both acute 
myeloid leukaemia and in the blast crisis but not in the chronic phase of CML, 
studies of the mechanism of action of this protein may shed light on the process of 
maturation arrest.
Other nuclear acting oncogenes can also block differentiation, these include 
EVI-1 and Myb. These fail to confer growth factor independence onto factor- 
dependent cell lines and do not increase their proliferation rates (reviewed in Ihle 
and Askew 1986).
1.3 (v ) Apoptosis and leukaemia
The bcl-2 gene is associated with the t( 14:18) chromosomal translocation 
present in 85% of follicular lymphomas (Fukuhara et al., 1979). The sequence of 
the gene suggests that bcl-2 may encode a GTP-binding protein. This rearrangement 
joins the bcl-2 gene at its 3' untranslated region to an immunoglobulin heavy chain J 
segment, resulting in deregulated expression of bcl-2 (Tsujimoto et al., 1985; 
Bakhshi et al., 1985; Cleary and Sklar 1985)
Bcl-2 appears to act in a novel fashion in that it can promote cell survival 
without stimulating proliferation in growth factor dependent cell lines deprived of 
cytokines (Nunez et al., 1990). Transgenic mice with constructs similar to the 
fusion generated by the t(14:18) translocation recreate the pathology seen in 
follicular lymphoma (McDonnell et al., 1989). These transgenic animals develop 
lymph node and splenic enlargement as a result of a polyclonal expansion of mature 
B cells resting in GO. As in the human disease 10% of these animals go on to
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develop clonal large cell lymphomas. Around half of these lymphomas have 
acquired translocations activating the c-myc gene. (McDonnell and Korsmeyer 
1991). Transgenic mice containing c-myc and bcl-2 under the control of a B-cell 
specific promoter die at 5-6 weeks of age as a result of malignant lymphoma 
(Strasser et al., 1990). The ability of bcl-2 to act as an oncogene by preventing cell 
death is a novel mechanism. The extended lifespan of this population of cells will 
give it an increased chance of acquiring other mutations necessary for full 
transformation. The cooperativity between c-myc and bcl-2 is interesting in the light 
of the role of c-Myc in mediating apoptosis.
The ability of c-Myc to mediate apoptosis has been demonstrated in IL-3 
dependent cell lines. Constitutive expression of c-myc in these cells when deprived 
of IL-3 drives cells into the cell cycle and increases apoptotic cell death (Askew et 
al., 1991). Similarly activation of Myc in quiescent fibroblasts results in apoptosis. 
However expression of bcl-2 specifically abrogates apoptosis without affecting the 
mitogenic function of c-Myc (Fanidi et al., 1992). It has been suggested that two 
signals are necessary: c-Myc mediates a proliferative and an apoptotic signal and a 
second signal is necessary to suppress the apoptosis. This suggests that activation 
of Myc in non-transformed cells would lead to apoptosis and activation of Bcl-2 or 
a tyrosine kinase oncogene would allow this apoptosis to be suppressed.
1.4 Lineage commitment
1.4 (i) Lineage infidelity
The classical representation of haemopoiesis depicts a hierarchical structure 
with cells increasingly restricted in lineage 'choices' as they mature, eventually 
becoming committed to a single lineage. This scheme of haemopoiesis would 
predict that markers normally restricted to different lineages would not be co­
expressed on a single cell. However analysis of leukaemic phenotypes has revealed
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a number of examples of this co-expression of 'lineage specific' markers. 
M cCulloch has argued that this 'lineage infidelity' is the result of abnormal gene 
expression as a consequence of leukaemic transformation (McCulloch 1987). An 
alternative explanation is that these leukaemic cells are maturation arrested at an 
early stage of differentiation prior to lineage commitment. If the latter explanation is 
correct then what does this co-expression of normally lineage restricted markers 
suggest about the process of lineage commitment in normal haemopoiesis?
A number of these documented cases of lineage infidelity can be discounted 
on technical grounds (Greaves 1986), however some are genuine and merit further 
analysis. For example, expression of terminal deoxynucleotidyl transferase (which 
is normally restricted to immature lymphocytes) has been found in leukaemic 
m yeloblasts (Bollum 1982; Jani et a l., 1983) and T-cell receptor gene 
rearrangements have been detected in inappropriate lymphoid or myeloid leukaemic 
cells (Furley et al., 1986).
Greaves has suggested that rather than aberrant gene expression, the co­
expression of markers of different lineages occurs in normal haemopoiesis during a 
period of 'lineage promiscuity' before a cell becomes committed to a particular 
lineage. If a leukaemia arose in a pre-commitment phase of haemopoiesis and was 
subject to a relatively stringent maturation arrest, then this would present itself as 
lineage infidelity. Limited or selective promiscuity could occur with respect to genes 
that are the first to be expressed in a lineage and whose activity is perhaps 
functionally involved in commitment. Candidates for these genes would include the 
haemopoietic receptors which could serve to 'advertise' lineage options and the 
genes necessary for successful recombination of T-cell receptor / immunoglobulin 
genes, where successful recombination may commit a precursor to a particular 
lineage.
Does lineage infidelity follow this prediction in that early markers of a 
lineage are more likely to be involved in lineage infidelity? This prediction is borne 
out by the analysis of rearrangements of the immunoglobulin genes. A large number
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of reports have identified recombination of the heavy chain genes in non pre-B cell 
leukaemias, however to date no reports of recombination of the light chain genes 
have been reported in these leukaemias (Korsmeyer et al., 1981; Rovigatti et al., 
1984; Ha et al., 1986). This is instructive as rearrangement of the heavy chain 
genes occurs earlier in pre B-cell development than recombination of the light chain 
genes (Korsmeyer et al., 1981).
An early haemopoietic marker is terminal deoxynucleotidyl transferase 
(TdT). TdT is expressed in leukaemia and normal pre-B and pre-T cells but not in 
mature lymphocytes and is involved in the generation of diversity of T-cell receptor 
and immunoglobulin genes (Siu et al., 1984). Despite the lineage-restricted nature 
of this marker, it is found in 5-10% of acute myeloid leukaemias (Jani et al., 1983; 
Coleman and Hutton 1982). In a number of cases it has been unambiguously 
demonstrated that TdT and myeloperoxidase (a myeloid marker) coexist in the same 
cell (Lanham et al., 1984). Interestingly, although TdT has been identified in the 
blast crisis of CML, no TdT has been identified in the chronic phase granulocytes, 
despite the origin of this leukaemia in the pluripotent stem cell compartment 
(Coleman and Hutton, 1982; Bradstock et al., 1981 ; Hoffbrand et al., 1977). This 
suggests that the progressive differentiation of these leukaemic cells allows these 
markers to be switched off after irreversible lineage commitment.
1.4 (ii) Models of lineage commitment
Two basic models have been proposed to explain the renewal, 
differentiation commitment in stem cells. In perhaps the favoured model, lineage's 
are restricted in a stochastic or deterministic fashion, forming pluri, oligo, bi- 
potent and ultimately committed cells. This process is proposed to occur at the 
genetic level and is independent of the influence of external factors (Till et al., 1978; 
Ogawa et al., 1983). The alternative model proposes that progenitor cells are 
intrinsically flexible and external factors such as growth factors, stromal elements
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or the haemopoietic micro-environment determine the pathway of differentiation 
(Trentin 1971; Dexter 1982).
The lineage promiscuity model explains lineage infidelity by the co­
expression of markers which may be functionally involved in the choice of lineage. 
This is clearly a deterministic model of lineage commitment. Obvious candidates for 
lineage promiscuity are the haemopoietic growth factor receptors, which could be 
co-expressed on progenitor cells and serve to 'advertise' available lineage choices, 
which would be determined by the relative levels of haemopoietic growth factors. 
Many of the haemopoietic growth factors and their cognate receptors have been 
cloned and characterised. This has allowed experimental analysis to determine if 
these factors are involved in the process of lineage determination.
Lineage switching of 'committed' bone marrow cells has been observed on 
the introduction and expression of certain growth factors, receptors or oncogenes. 
Two examples demonstrate that lymphoid cells can differentiate into macrophages 
given the appropriate signals. Pre-B cells from transgenic mice containing a c-myc 
gene under the control of a B-cell specific promoter become macrophage like after 
the introduction of v-ra/(Klinken et al., 1988). Similarly, infection of normal bone 
marrow with a retrovirus expressing both v-myc and v-raf generates both pre-B and 
macrophage clones derived from the same progenitor cell (Principato et al., 1990). 
As \ - r a f  activates c-fms (M-CSF receptor) it is possible that this receptor is 
responsible for this lineage switch. This possibility is borne out by the introduction 
of c-fm s into the murine bone marrow culture. These cultures switch from 
lymphoid to macrophage in the presence of M-CSF, but this lineage switch is over­
ridden by the addition of IL-7 to the culture (Borzillo etal., 1990).
A similar deterministic function for colony stimulating factors (CSF) in 
lineage commitment has been suggested using the mulipotent murine line FDC-P 
mix (Spooncer et al., 1986). These cells depend on exogenous IL-3 for survival 
and proliferation, but can be induced to differentiate by reducing IL-3 levels and 
adding an appropriate growth factor. Single FDC-P mix cells infected with
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retroviral vectors expressing GM-CSF are induced to differentiate to granulocytes 
and macrophage, suggesting GM-CSF induces the differentiation by an instructive 
mechanism (Just et al., 1991).
A difficulty with many of these studies is that they are carried out in the 
presence of haemopoietic growth factors. These factors act as survival and 
mitogenic factors in addition to any role they may have in lineage determination. 
Uncoupling of these processes is difficult as the cells require these factors to remain 
viable, and much evidence suggests that rather than acting by determining lineage 
choice, these expand a compartment of committed cells expressing the appropriate 
receptor. Evidence that the differentiation pathway is determined intrinsically rather 
than via the receptor is that non-haemopoietic receptors can induce proliferation and 
differentiation when expressed in haemopoietic cells in presence of the appropriate 
ligand. This differentiation is these experiments is clearly cell-specific rather than 
determined by the receptors (Pierce et al., 1988; Wang et al., 1989). Similarly 
alterations in cell physiology indicating different signalling pathways for different 
haemopoietic receptors has not been observed, suggesting these receptors mediate 
common signals. These results suggest that rather than determining lineage 
commitment these haemopoietic growth factors act via expanding a compartment of 
committed cells via a proliferation signal which is coupled with a signal to 
differentiate along a lineage which has been predetermined.
An uncoupling of the survival signal from the mitogenic signalling of the 
CSFs has been achieved by generating cell FDC-P cell lines which constitutively 
express bcl-2. Expression of this gene has been demonstrated to delay apoptosis in 
factor dependent cell lines on withdrawal of growth factor (Nunez et al., 1990). 
When IL-3 was withdrawn from these cells lines, they showed continued survival 
in both serum-containing and serum-free conditions. This survival was 
accompanied by multi-lineage differentiation, which was not the result of autocrine 
production of haemopoietic growth factors. These results suggest that the lineage 
determination can be intrinsically determined without the influence of external
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factors (Fairbaim et al., 1993). Although these results suggest that external factors 
are not obligatory for lineage determination, this does not mean that they are unable 
to influence this lineage choice.
1.5 Human myeloid cell lines
Much of the work on myeloid differentiation has been undertaken using cell 
lines established from patients with either acute myeloid leukaemia or in blast crisis 
of CML. These cell lines are maturation arrested at different stages of differentiation 
and many can be induced to differentiate with the addition of a variety of 
physiological and non-physiological agents (reviewed in Hozumi 1985). These 
lines have been used as model of haematopoeitic differentiation, however they 
share abnormalities (both cytogenic and molecular) characteristic of the leukaemia 
from which they were derived as well as other changes which are presumably 
necessary for growth in vitro. The genetic changes necessary for leukaemic cells to 
become immortalised are unknown, making the generation of leukaemic cell lines a 
difficult and essentially fortuitous process (Koeffler 1984).
A large number of cell lines have been established which have a phenotype 
representative of normal haemopoietic counterparts. For example KG1 was 
established from a patient with erythroleukaemia (Koeffler and Golde 1978). This 
cell line is myeloblastic in nature and can be induced to differentiate towards 
macrophage by a number of agents. The K562 cell line was established from a 
patient in blast crisis of CML (Lozzio and Lozzio 1975). These cells are arrested at 
an early myeloblast / erythroblast stage, and can differentiate towards erythrocytes 
when cultured with hemin or butyrate (Miller et al., 1984). Many other cell lines 
have been established representative of different stages of haemopoietic 
differentiation e.g. megakaryoblastic CMK (Sato et al., 1987), monoblastic U937 
and THP-1 (Sundstrom  and N ilsson 1976; Tsuchiya et al., 1980), 
myelomonoblastic ML1, ML2 and ML3 (Takeda and Minowada 1982) and
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eosinophil precursor like cell lines EoL-1 and EoL-3 (Saito et al., 1985 ). Of 
particular importance to this study is the promyelocytic cell line HL60, and this is 
discussed in more detail in section 1.5 (i).
1.5 ( i ) HL60 as a model system for human myelopoiesis
This cell line was derived from a patient with acute non-lymphocytic 
leukaemia. It is an immortal, factor-independent cell line with distinct myeloid 
characteristics (Collins et al., 1978; Gallagher et al., 1979). The cell line is 
composed predominantly of cells which have the morphological and biochemical 
characteristics of promyelocytes. Most cultures particularly those which are passage 
60 or less show spontaneous differentiation with around 5% of cells showing 
features of more mature myeloid cells such as myelocytes, metamyelocytes and 
PMN (Collins et al., 1977). The ability of this cell line to differentiate in response to 
a range of inducing agents down a number of different pathways has made this cell 
line a particularly useful model for human myeloid differentiation. The ability of 
HL60 cells to proliferate continuously in vitro is in contrast to the properties of 
fresh leukaemia cells, which undergo a limited number of cell divisions before 
growth arrest and cell death. What genetic changes the HL60 cell line has 
undergone to become immortalised are unknown, although autocrine factors have 
been purified from the HL60 conditioned medium (Brennan et al., 1981; Perkins et 
al., 1984).
HL60 cells show many karyotypical abnormalities, a number of which 
have been described including monosomy, polysomy and a number of 
chromosomal translocations (Wolman et al., 1985; Donti et al., 1988). A number of 
specific lesions have been identified, which may have played a role in generating 
the original leukaemic phenotype and/or the immortalisation in vitro. The HL60 cell 
line lacks a functional p53 gene: the cells are monosomic for chromosome 17 
(Gallagher et al., 1977) and the other allele contains a deletion (Wolf and Rotter
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1985). The N-ras gene contains an activating codon 61 mutation (Bos et al., 1984) 
and this is responsible for the transforming activity of HL60 DNA in an NIH3T3 
transformation assay (Murray et al., 1983). Other acute myeloid leukaemias exhibit 
N -ras mutations (Bos et al., 1985; Needleman et al., 1986), but the functional 
significance of the preferential activation of mutations in N-ras rather than other 
members of the ras family in myeloid leukaemias is unknown.
The c-myc gene is amplified in the HL60 cell line as well as in the primary 
leukaemic cells (Collins and Groudine et al., 1982). The loss of expression of this 
gene is a rapid event following induced differentiation of HL60. The use of 
antisense oligonucleotides to c-myc results in the partial differentiation of HL60 
cultures, suggesting that the amplification and consequent high levels of c-Myc 
blocks differentiation in this cell line (Yokoyama and Imamoto 1987; Holt et al., 
1988;Wickstrom et al., 1988).
1.5 (ii) HL60 differentiation
The HL60 cell is morphologically myeloblastic/promyelocytic in nature, 
with a characteristic large rounded nucleus containing 2-4 distinct nucleoli, and a 
basophilic cytoplasm with azurophilic granules. The cell line also carries a number 
of markers chararcteristic of promyelocytes, including myeloperoxidase, acid 
phosphatase and receptors for lactoferrin, insulin and complement (reviewed in 
Collins 1987). The well-characterised nature of this cell line along with its ability to 
differentiate to either monocytes/macrophage like cells or granulocytes and ease of 
handling makes it a useful model of human myelopoiesis.
A variety of compounds induce granulocytic differentiation including 
dimethylsulphoxide and retinoic acid. This is accompanied by a progressive 
decrease in cell size and condensation of the nuclear material with the appearance of 
kidney-shaped or lobed nuclei characteristic of banded and segmented neutrophils. 
The ratio of nucleus to cytoplasm decreases and the cytoplasm becomes more
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diffuse. A large number of biochemical changes can detected, including decreased 
myeloperoxidase activity and the appearance in the culture of cells capable of 
reducing nitroblue tetrazolium (a marker of mature neutrophils). A number of 
features of this differentiation program illustrate that it is incomplete or defective. 
For example most cultures induced to differentiate to granulocyte-like cells consist 
primarily of metamyelocytes and banded neutrophils rather than fully differentiated 
multi-lobulated PMN. In addition, these differentiated cells lack lactoferrin 
suggesting that they are deficient in secondary granules (Newburgher et al., 1979; 
Olsson and Olofsson 1981).
In contrast treatment of HL60 cells with TPA (which induces monocytic 
differentiation) leads to the cells clumping and adhering to the tissue culture surface 
within 24hrs. These cells spread out and acquire a spindle like morphology with 
prominent pseudopodia. There is a decrease in myeloperoxidase activity and the 
appearance of non-specific esterase activity (a monocyte/macrophage marker). 
These differentiated cells also show functional changes with both HL60 
granulocytes and monocytes/macrophage capable of phagocytosis (Collins et al., 
1978; Polansky et al., 1985).
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Chapter 2: The regulation of transcription
2.1 The role of chromatin in eukaryotic gene control
Although many discussions on the control of transcriptional initiation centre 
on the binding of transcription factors to their appropriate sites as assayed by DNA- 
protein interactions in vitro, clearly the in vivo situation is more complex as 
chromatin, and not naked DNA, is the template for transcription.
The basic unit of chromatin is the nucleosomal core or histone octamer 
around which 166bp of DNA are wound approximately 1.8 times to form the 
'beads on a string' lOnm fiber. This fiber undergoes further condensation mediated 
by the histone HI binding in the nucleosomal linker to form the 30nm fiber. How 
this fiber is folded into higher order condensed structures (such as heterochromatin 
or fully condensed chromosomes) or the molecular organisation of such structures 
is not well understood.
Transcriptionally active chromatin in contrast to the bulk of chromatin is 
generally more unwound than that of transcriptionally silent chromatin. Classically 
this has been assayed by sensitivity to nuclease digestion (Wu et al., 1979a and b). 
This approach has revealed that the chromatin surrounding transcriptionally active 
(or inducible genes) is more sensitive to nuclease digestion (usually over many 
kilobases) than that of bulk chromatin. As well as increased sensitivity over a large 
domain, the chromatin surrounding active genes is normally characterised by the 
presence of a number of small sites (50-400bp) which show extreme sensitivity to 
nucleases. These are termed DNAse hypersensitive sites (DHS). These appear to be 
gaps in the nucleosomal array, however whether the nucleosome is totally 
displaced or just less stringently bound to DNA is not clear. Evidence of the latter is 
that cross-linking studies have demonstrated the DHS generated by the 
glucocorticoid receptor binding at the mouse mammary tumour virus (MMTV) LTR 
can still be cross-linked to nucleosomal histones (Bresnick et al., 1992).
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These DHS have been demonstrated to be bound by non-nucleosomal 
proteins both in vitro and in vivo by a number of studies, and are necessary for the 
transcriptional control of a number of genes (for review see Gross and Garrard 
1988). That areas of DNA important for transcriptional control (i.e. the binding of 
transcription factors) are often DHS in active genes suggests that nucleosomes may 
play a role as general repressor of transcription. However it could be argued that the 
DHS are of no functional importance and are simply displaced as a result of 
transcription factor binding. That nucleosomes act as general repressors has been 
investigated both biochemically and genetically, and the evidence is discussed in 
the following section 2.1 (i).
2.1 (i) Nucleosomes as general repressors of transcription
The study of several genes has demonstrated that nucleosome positioning 
can have important functional consequences for gene control. The yeast acid 
phosphatase PH 05 gene is inducible in low phosphate media and has a number of 
functionally important upstream activating sequences (UAS). The positions of the 
nucleosomes over the promoter and upstream have been precisely mapped (Aimer 
and Horz 1986). One of these UAS is within a DHS present in both inducing and 
non-inducing conditions. In low phosphate media the product of the PH 04 gene 
binds to this UAS which leads to the displacement of four nucleosomes revealing a 
PH 04 binding site and the TATA box (Aimer et al., 1986; Aimer and Horz 1986). 
Another transcription factor PH 02 can also bind to a site between the two PH 04 
binding sites; however, in vivo footprinting revealed that this protein could only 
recognise this site in nucleosomal but not non-nucleosomal DNA. Hence PH 02 
may facilitate the displacement of this nucleosome, as over-expression of PH 04 at 
high levels in high phosphate media leads to the loss of this nucleosome only in the 
presence of PH02. However over-expression of PH 02 has no effect on chromatin 
structure (Fascher 1990).
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Another example of nucleosome positioning repressing transcription by 
preventing access of transcription factors to their control sequences is the 
glucocorticoid mediated transcription from the MMTV promoter. In this case the 
glucocorticoid receptor (GR) binds its recognition sequence within a nucleosome 
displacing it and allowing access to another transcription factor binding site (which 
is bound by NF1) site and the TATA box (Richard-foy and Hager 1987; Archer et 
al 1992). The NF1 protein is unable to bind to nucleosomal DNA despite being able 
to bind to this sequence in naked DNA with high affinity. Similarly the enhancer of 
the rat tyrosine aminotransferase gene can be bound and activated by the GR when 
bound by nucleosomes (Riek et al., 1991). This example illustrates that some 
transcription factors can recognise sites within a nucleosomal array and that others 
can only bind to DNA when exposed in a DHS.
These examples suggest that setting up a positioned nucleosomal array in 
which some gaps are present (such as in the PH05 gene) may have important 
regulatory consequences. However what determines the precise positioning of 
nucleosomes is an important question. Nuclesomes show some sequence specificity 
in vitro, and artificial sequences that have lObp periodicity which are predicted to 
bend easily show 100-fold more specificity for nucleosomes than bulk DNA 
(Shader and Crother 1989). However this level of affinity is unlikely to account for 
the positioning affects seen in vivo. Another explanation proposed is that higher 
order folding of chromatin modulates the placing of nucleosomes (Thoma 1988). 
Many DHS have been demonstrated to be bound by non-histone proteins 
suggesting that DNA binding proteins may bind certain sequences and act as an 
anchor around which nucleosomes are placed. These proteins could bind to the 
DNA during replication or directly to the nuclesomal array and displace 
nucleosomes as is the case with the GR.
The above examples suggest that the precise positioning of nucleosomes 
has im portant regulatory functions. The use of genetic approaches have 
conclusively demonstrated that the nucleosomes themselves are negative regulators
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of transcription. The construction of yeast strains in which expression of the histone 
H4 gene has been brought under the control of an inducible promoter has 
demonstrated that altering histone stoichiometry can alone induce the expression of 
a number of genes including PH 05, CUP1 and HIS3 (Han et al., 1988; Durin et 
al., 1992).
Biochemical evidence that nucleosomes can repress gene expression comes 
from the reconstitution of transcription in vitro. A number of studies have 
demonstrated that the preassembly of nucleosomes onto transcriptional templates 
drastically inhibits transcriptional initiation (reviewed by Workman et al., 1992). 
Addition of the basal transcription factor TFIID prior to nucleosomal assembly 
relieves this repression (Workman and Roeder 1987). Using the adenovirus major 
late (Ad ML) promoter as a model it was demonstrated that inclusion of USF 
transcription factor as well as TFIID further increased transcription in vitro. It was 
suggested that this transcription factor was acting via stabilising/facilating TFIID 
binding as both factors had to be present prior to nucleosome assembly to function. 
In contrast to these results, in experiments with GAL4 derivatives, addition of 
TFIID after nucleosome assembly was still effective in stimulating transcriptional 
initiation. The transactivation domain was necessary for this activity (Workman et 
al., 1991). These results suggest that there may be two different modes of 
transcriptional activation, one may be to facilitate/stabilise preiniatiation complex 
formation without a direct role in the destabilising of nucleosomes. Strong evidence 
for this mode of transcriptional activation is that many transcription factors (albeit 
with much reduced efficiencies) can function in vitro on naked DNA templates 
(Chasman et al., 1989; Carey et al., 1990). The other mode of transcriptional 
activation is the destabilisation of nucleosome-DNA interactions allowing binding of 
basal and/or other transcriptional activators which can recognise nucleosomal DNA 
(cf. activation of the MMTV promoter). Both of these functions are likely to be 
important; for example, with naked DNA templates Spl and GAL4-VP16 
stimulated in vitro transcription 30-fold and 8-fold respectively. However with
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chromatin templates containing histone HI transcriptional activation mediated by 
these factors was 90 and 200 fold higher. This is the result of both true activation 
and the relief of chromatin mediated repression (Layboum and Kadonaga 1991).
Genetic analysis of the regulation of specific genes has identified mutants 
which have a global effect on the regulation of a number of genes. These mutations 
must be in genes encoding the general transcription machinery or be involved in 
modulating chromatin structure. Studies on the SUC2 gene in yeast (an invertase 
necessary for sucrose fermentation) revealed three mutants which also affected the 
expression a number of other genes. The mutants sw il, swi2 and swi3 are involved 
in the regulation of SUC2 expression, but do not appear to exert their effects 
through UAS of this gene (Peterson and Herskowitz 1992). Isolation of suppressor 
mutations suggested that these genes are involved in the modulation of chromatin 
structure. With one suppressor mutation in a gene with homology to HMG-1 
(implicated in mediating chromatin structure, Kruger and Herskowitz 1991), and 
the others affecting histone stoichiometry (Winston and Carlson et al., 1992).
2.1 (ii) Characteristics of active versus silent chromatin
Active chromatin as well as being in a more decondensed state (or DNAse 1 
sensitive) than bulk chromatin, it also has a number of other features; it is depleted 
of (or contains more loosely bound) histone H I, the DNA is undermethylated and 
contains higher levels of acetylated histones.
Histone HI
This histone binds the internucleosomal linker and is necessary for the 
formation of higher order chromatin structure. Purification of transcriptionally 
active chromatin from Xenopus oocytes has been found to be depleted of histone 
H I (Wolffe 1990; Garrard 1989). This is consistent with the ability of histone HI 
to inhibit in vitro transcription on reconstituted chromatin templates (Layboume and
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Kadonaga 1991). However, other studies have shown that both inactive and active 
chromosomal regions in chicken erythrocytes are associated with HI and H5 (a 
tissue specific histone H I), but the internucleosomal linkers of the inactive genes 
are less sensitive to nuclease digestion suggesting an altered binding (Weintraub 
1984). The role of histone HI in organising DNA into higher order structures 
would suggest that there must be some decondensation to allow the transcriptional 
machinery access to the transcriptional control sequences.
Methylation
The correlation between transcriptional inactivity and methylation has been 
noted in many studies. The methylation patterns are clonally inherited and have been 
suggested to form the basis of a stable regulatory system (Riggs 1975). Although 
many studies have suggested a role for methylation in the repression of transcription 
most of the data has been correlative. This and the lack of appreciable methylation in 
either Drosophila or Caenorhabdits elegans genome (Urieli-Shovel 1982; Simpson 
1986) cast doubt on the importance of methylation. However that methylation plays 
a crucial role in higher eukaryotes has been demonstrated by the generation of 
homozygous null mice for methlytransferase. These mice did not survive past mid­
gestation and were stunted and delayed in development (Li et al., 1992). Although 
clearly demonstrating the importance of methylation in higher eukaryotes these 
knockouts did not shed light on the role of methylation. Recent work has 
demonstrated that methylation plays a direct role in the repression of transcription. 
There appears to be two mechanisms for the repression of promoters by 
methylation, one of which is the methylation of transcription factor binding sites. A 
number of transcription factors fail to bind to their sequences when the latter are 
methylated (reviewed in Tate and Bird 1993). However, this cannot be the only 
mechanism of inhibition as the y-globin promoter is repressed by methylation but 
mutagenesis studies demonstrated that the methylation does not have to be at any 
particular site (Murray and Grosveld 1987).
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The second type of repression may be mediated by proteins which 
specifically bind methylated DNA, and a number of proteins with this property have 
been characterised. The methyl CpG binding protein MeCPl can bind to sequences 
containing multiple symmetrically methylated CpGs. This protein can repress the 
transcription of methylated promoters in vitro. Embryonic stem cells have low 
levels of M eCPl, and methylation fails to inactivate promoters in these cells (Boyes 
and Bird 1991). Repression by this protein depends on both the density of 
methylation and the strength of the promoter. A study by Boyes and Bird (1992) 
demonstrated that repression of a weakly methylated promoter could be relieved by 
addition of an SV40 enhancer but not that of a heavily methylated promoter. A 
second protein MeCP2 has been cloned which can bind to a single symmetrically 
methylated CpG pair and can repress transcription in a similar manner. These 
proteins may act via direct interference or perhaps by mediating a change in 
chromatin structure.
Another protein was identified as binding to a methylated CpG in the 
vitellogenin gene which inhibited in vitro transcription (Jost et al., 1991). 
Purification of this protein suggests that it is histone H I, although its binding 
properties and molecular weight are not the same as those previously noted (Jost et 
al., 1991). Evidence has suggested histone HI may have a preference for 
methylated DNA. This work demonstrated that methylated plasmid DNA incubated 
with histone HI is less sensitive to nucleases than its unmethylated counterpart 
(Higurashi and Cole 1992). As methylated DNA is enriched in histone HI in vivo , 
it may play a role in remodelling of chromatin (Ball et al., 1983).
There appear to be two classes of promoter with respect to methylation: 
those which are constitutively non-methylated and CpG rich (CpG islands) and 
those which are CpG poor and methylated in most tissues, often corresponding to 
tissue-specific genes (Bird et al., 1986). In cultured cell lines many CpG islands 
become methylated e.g. in NIH 3T3 and L cells, 50% of CpG islands tested were 
methylated. However, these CpG islands are not methylated in vivo even at
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transcriptionally silent promoters, suggesting that non-essential genes can be 
switched off in tissue culture by this mechanism (Antequera et al., 1990). An 
example is the CpG island at the myoD promoter which is methylated in vitro in 
10T1/2 cells. Treatment of these cells with 5-azacytidine relieves this methylation- 
mediated repression and the cells differentiate to muscle cells. This is in contrast to 
the in vivo situation where this CpG island is unmethylated in all tissues (Jones et 
al., 1990).
Histone acetylation
The amino terminal ends of the of the core histones all contain lysine 
residues which are reversibly methylated during the cell cycle. Treatment of cells 
with the deacetylating agent sodium butyrate leads to a partial unfolding of the 
interphase chromosomes (Annunziato et al., 1988). This and the observation that 
active chromatin is selectively enriched for acetylated histones has suggested that 
acetylation may play a role in regulation of chromatin structure (Allegra et al., 1987; 
Risdale et al., 1987). That acetylation is not simply a consequence of transcription 
has been demonstrated in Tetrahymena using indirect immunofluorescence with 
antibodies for acetylated lysine residues which reveals that acetylation of histone H4 
precedes transcription (Pfeffer et al., 1989).
Genetic evidence has suggested that histone tails play a role in mediating 
transcription factor access to DNA. Mutation in the H4 tails can prevent the 
activation of some genes (Durrin et al., 1991) and the repression of others (Kayne 
et al., 1988, Johnson et al., 1990). Acetylation has also been implicated in the 
positioning of nucleosomes; the yeast repressor a2  positions nucleosomes when 
binding an operator in a minichromosome, however when the histone H4 tails are 
mutated, the location and/or stability of the nucleosomes is altered (Roth et al., 
1992).
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2.2 Transcriptional control sequences
An important difference between prokaryotic and eukaryotic gene control is 
the existence of three RNA polymerases in eukaryotes. Each of these polymerases 
transcribes a specific subset of genes: RNA polymerase I transcribes the genes 
encoding the ribosomal RNAs 28S, 18S and 5.8S, RNA polymerase III transcribes 
the genes encoding tRNAs and small nuclear RNAs whereas RNA polymerase II 
transcribes the protein-coding genes and some small nuclear RNAs. The cis-acting 
sequences responsible for mediating the control of the class II genes are discussed 
below. These are simplistically classified into promoters and enhancers, the 
promoter is close to the site of transcriptional initiation, and enhancers are 
characterised by their ability to influence transcription up to many kilobases away 
from the promoter.
2.2 (i) Promoters: The TATA box and initiator elements
A characteristic of the promoters of many class II genes (those genes 
transcribed by RNA polymerase II) is the presence of a TATA box, which is 
usually centred around -28 with respect to the transcriptional start site. In fact, 
comparison of 168 class II promoters for sequence homology revealed that this was 
the only well conserved element, although this element itself appears to be absent 
from many class II genes. Mutational analysis have demonstrated the importance of 
this element in basal transcription (Grosveld et al., 1982), controlling the specificity 
of transcriptional initiation, mediating the activity of some upstream activating 
sequences and determining the direction of transcription (O'Shea-Greenfield et al., 
1992a and b).
In higher eukaryotes the TATA box directs the formation of the preinitiation 
complex, in which RNA polymerase II is poised to begin transcription at a distance 
from the TATA box of 25 to 30 nucleotides (reviewed in Sawadogo and Sentenac
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1990). The first step in this process is the binding of transcription factor II D 
(TFIID) to the TATA box, this is followed by the incorporation of TFIIB, TFIIF 
RNA polymerase II and TFIIE. As TFIID binds the TATA box in sequence specific 
manner, and as the preinitiaton complex forms in a directional manner (Sawadogo 
and Roeder 1985; Nakajima et al., 1988; Buratowski et al., 1989) it is conceptually 
easy to imagine how this sequence could determine the transcription start site by 
precisely positioning RNA polymerase in the preinitiation complex.
Many genes which lack a TATA box are characterised by multiple 
transcriptional start sites lending support to its role in determining the site of 
transcriptional initiation. However this is not the only element important in the 
determination of transcriptional initiation. Studies with a number of genes e.g. 
SV40 (Ayer and Dynan 1988), terminal deoxynucleotidyl transferase (Smale and 
Baltimore 1989) and dihydrofolate reductase (Mean and Farnham 1990) have 
identified elements which overlap the transcriptional start site and can influence its 
placement. These elements have been termed initiator elements or Inrs. The 
mechanism of action of these elements in unknown, however proteins which bind 
to these sequences have been identified (Seto et al., 1991). These elements have 
been identified in both TATA containing and TATA-less promoters, and some 
workers have attempted to assess the relative contributions of the TATA box and Inr 
elements (O'Shea-Greenfield et al., 1992). This study varied the position of a 
TATA box and the TdT Inr element and suggested that both could direct placement 
of the start site and act cooperatively together, however the TATA box appeared to 
be the dominant element in determining the start site during both basal and activated 
transcription.
Transcriptional initiation determination is more complex than the above 
description would suggest, with the TATA box as the primary determinant and the 
Inr elements playing a subsidiary role, as the TATA box does not always occur 
approximately 25-30 bp upstream of the CAP site. For example the Adenovirus 
IVa2 gene contains a functional TATA box downstream of the CAP site (Carcamo
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et al 1990) and mutations in the promoter of the CYC-1 gene of Saccharomyces 
cerevisiae which contains three functional TATA boxes does not alter the start sites 
as would be predicted by the simple model discussed above (Han et al., 1985). 
Another case where elements other than the TATA box may be important in 
determining the transcriptional start site and direction is where the TATA box is 
symmetrical, it may be that other factors such as chromatin structure may be 
important in this process in vivo.
Possibly all genes (including class I and III) require functional TATA 
binding protein (TBP) to allow transcriptional initiation to occur as this factor has 
been demonstrated to be necessary for a number of class II genes that lack an 
apparent TATA box as well as a number of class I and III genes (reviewed in White 
and Jackson 1992). It is not clear whether any class II genes lack a TATA box in 
the functional sense, as the SV40 ML promoter contains an element at -30 with no 
apparent homology to the TATA consensus but with similar properties. TBP can 
bind to this sequence, albeit with an affinity one sixth that of the Ad ML promoters 
TATA box. Mutational analysis of this element reveals that similarly to the TATA 
box; it can direct RNA polymerase II to initiate transcription approximately 30bp 
downstream of its location, inactivation leads to increased heterogeneity in the site 
of transcriptional initiation and point mutational analysis revealed that the affinity of 
TBP for this element correlated with the efficiency of transcription. All five other 
TATA-less promoters tested in this study bound the TBP at a site around -30, 
suggesting that many TATA-less promoters differ from TATA containing promoters 
only in the affinity of their -30 regions for binding of this basal transcription factor 
(Wiley et al., 1992).
2.2 (ii) Transcriptional activating sequences
As well as these basal elements, a number of other cL-acting sequences 
have been identified in functional studies, which can mediate elevated levels of
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transcription either constitutively, in a tissue-specific or developmental-specific 
manner or in response to a signal such as a cytokine or growth factor. These 
elements function by binding sequence-specific transcription factors which elevate 
or repress the activity of the promoter. These elements are many and varied and a 
small number are discussed below to illustrate important principles.
The CCAAT box
A common motif found in a number of promoters is termed the CCAAT 
box, an element which is found at variable distances and orientations with respect 
to the CAP site. A promoter may contain one or several of these elements e.g. the 
protein disulphide isomerase gene contains six CCAAT boxes located between -108 
and -378 (Tasanen et al., 1992).
In common with many transcriptional control elements the CCAAT box is 
capable of binding a range of different sequence-specific transcription factors. The 
first two CCAAT binding proteins to be identified were the CCAAT/enhancer 
binding protein C/EBP (Johnson et al., 1987) and CCAAT transcription factor 
CTF/NF1 (Jones et al., 1985). Both of these transcription factors are capable of 
interacting with the CCAAT box of the of the HSV tk promoter, however they have 
distinct properties and are members of unrelated transcription factor families. The 
C/EBP factor is heat stable and can also bind to the related sequence GCAAT with 
high affinity, in contrast CTF/NF1 is heat labile and fails to bind to this sequence 
(M cKnight and Tjian 1986). There is a large family of C/EBP factors, each 
member can bind to this sequence, and a number of other factors can bind to this 
and related sequences (Dorn et al., 1987).
The octamer element
Another common element is the octamer sequence which in common with 
the CCAAT box, can bind a range of different transcription factors. This element 
was originally identified in the histone H2B promoters and the immunoglobulin IgH
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and IgK promoters. These sequences are necessary for the lymphoid-specific 
expression of these genes (Wirth et al., 1987; Falkner and Zachua 1984). Although 
these elements are important in the tissue-specific activity of a number of promoters 
and enhancers, this sequence also confers cell-cycle regulated expression on the 
histone H4 and H2B promoters (La Bella et al., 1988; Fletcher et al., 1987).
The GC box
The GC rich TATA less' promoters of a number of growth related genes 
often contain a number of 'GC boxes' within the first few hundred base pairs from 
the site of transcriptional initiation e.g. H -ras (Ishii et al., 1986) and c-myb 
(D vorak et al., 1989), as well as a number of housekeeping genes such as 
hypoxanthine phosphoribosyl transferase (Kim et al., 1986) and dihydrofolate 
reductase (Swick et al., 1989). Several genes contain a single GC box upstream of 
a TATA box such as the adenovirus E1B (Schmidt et al., 1989) and the NF1 
(Ammendola et al., 1990) promoters.
Although many of these elements function by binding the ubiquitous 
transcription factor Spl, some sites may be targets for other transcription factors. 
For example, studies of the P450I Al gene revealed the presence of a single GC 
box in the promoter termed basic transcription element. This element was capable of 
binding both Spl and another transcription factor termed basic transcription element 
binding protein (BTEB). This transcription factor repressed this promoter but was 
capable of transactivating promoters with multiple GC boxes, whereas Spl can 
activate promoters with a single GC box. (Imataka et al., 1992). These transcription 
factors were found to be present in all cells tested but varied independently in level, 
suggesting that the activation of promoters containing GC boxes will be dependent 
on the relative affinities of individual GC boxes for different factors, the relative 
levels of these factors and the regulatory context of the element in a promoter.
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2.2 (iii) Modularity of promoters
In the preceding discussion the elements are described in isolation. 
However, promoters consist of multiple elements (or modules), each of which has 
intrinsic activity but all are necessary for the wild type activity of the promoter. For 
example HSV tk promoter contains two Spl sites which surround a CCAAT box. 
All of these three elements are required for maximal activity, however each has 
intrinsic activity (Jones et al., 1985).
The existence of multiple elements has important functional consequences. 
Firstly, with multiple elements a promoter can be controlled differently in a number 
of situations e.g. basal and induced activity of cytokine genes in macrophages 
(Grove and Plumb 1993). Another important consequence of multiple elements is 
that of synergy. This is defined as when a promoters activity resulting from a 
number of control elements is greater than the sum of the individual activities. This 
is an important mechanism of control as this allows a gene to be finely tuned, 
needing a whole range of transcription factors present and active to allow maximum 
transcription.
The most straight forward mechanism of synergy is that of co-operative 
binding. This has been demonstrated to occur in a number of cases. For example, 
two tandemly linked progesterone / glucocorticoid response elements (PRE/GRE) 
were placed upstream of a heterologous promoter. These elements conferred a 
synergistic response in the presence of the activated receptors. DNA binding studies 
in vitro demonstrated that the presence of one progesterone receptor increased the 
affinity of binding at the second site one-hundred fold (Tsai et al., 1989). Although 
several cases of co-operative binding have been documented to-date, it appears that 
co-operative binding is the exception rather than the rule and that other mechanisms 
are necessary to explain transcriptional synergy. For example, a similar study of 
two oestrogen response elements could find no evidence of co-operative binding 
despite their synergistic activation of a minimal promoter (Mathurose et al., 1990).
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Other mechanisms are likely to involve the interaction of transcription factors with 
components of the preinitiation complex with multiple interactions stabilising the 
complex.
The third important consequence of the modularity of promoters is that the 
activity of an element is dependent on its context within the promoter. An interesting 
example of this is provided by the oesteocalcin gene. The promoter of this gene 
contains a vitamin D response element which overlaps with a consensus API site. 
Activation of this gene can be achieved by treatment with vitamin D, however 
transfection of the cell lines with expression vectors containing c-fos and c-jun 
reduced basal and abolished induced transcription (Schule et al., 1990a and b). This 
is in contrast to the effect of an API site in most promoters which is to induce 
transcription under these conditions, illustrating the importance of the context of a 
sequence in determining its activity (Angel et al., 1987). Similarly the rat a l  
glycoprotein gene contains two C/EBP binding sites in its promoter. The distal 
element overlaps that of a glucocorticoid response element, and acts in an 
antagonistic manner in the presence of glucocorticoids. This same element 
contributes positively to the promoters activity in the absence of glucocorticoids. 
This example illustrates that the same element can mediate different activities under 
different conditions (Nishio et al., 1993).
Clearly the activity of a promoter is determined by a number of elements, 
both positive and negative which act together to confer a specific spatial and 
temporal gene expression pattern on a gene. However, promoters are not the sole 
determinants of transcription control. Sequences removed from the immediate 
promoter region can have profound effects on transcription: these are termed 
enhancers.
2.2 (iv) Enhancers
Sequences further from the site of transcriptional initiation than the promoter
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can exert effects on the initiation of transcription. These sequences are termed the 
enhancers, and are usually larger in size than the promoter elements usually ranging 
from 40-700 bp in length. These enhancers may be positive or negative (termed 
silencers) in action, may be tissue-specific (for example the B-cell specific 
immunoglobulin H chain enhancer, Mercola et al., 1983), inducible (e.g. rat 
aminotransferase Reik et al., 1991) or constitutive in nature (e.g. SV40 enhancer, 
Ondek et a l., 1988). Enhancers are characterised by their distance and orientation 
independent nature and have been found to activate transcription despite being 
located many kilobases upstream from the CAP site (Pinket et a l., 1987), 
downstream from the polyadenylation site (Campo et al., 1983), within introns 
(e.g. Huang et al., 1993), and even within the protein coding regions of genes 
(e.g. the Hepatitis B enhancer, Tognoni et al., 1985).
The mechanism of enhancer activity is not fully understood, but is thought 
in many cases to involve the looping out of the intervening DNA between the 
promoter and the enhancer, allowing interaction of the proteins binding these e x ­
acting sequences and components of the preinitiation complex (Ptashne et al., 
1986). The transcription factor Spl, which binds both promoter and enhancer 
elements, has been demonstrated to form higher order structures, looping out DNA 
between GC boxes via direct protein-protein interactions (Su et al., 1991), 
illustrating that DNA looping can be mediated by sequence-specific transcription 
factors.
The distinction between promoter and enhancer elements is not clear, as 
many elements are found in both enhancers and promoters. The octamer motif 
originally defined in promoters (Harvey et al., 1982) is also an important 
component in many enhancers e.g. the SV40 enhancer (Nomiyama et al., 1987). 
Multimers of promoter sequences can have enhancer activity when placed upstream 
of a heterologous promoter (Ondek et al., 1987), illustrating the functional 
similarity of these sequences. Both promoters and enhancers exert their effect via 
the binding of fra«.s-acting sequence-specific DNA-binding proteins. These proteins
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are discussed in the section 2.3.
2.2 (v) Position effects and higher order chromatin structure
If enhancers are position and orientation independent (section 2.2 (iv) why 
don't they promisciously activate many surrounding promoters in vivo? In contrast 
to yeast where the UAS are usually relatively close to their promoter, higher 
eukaryotes often have enhancers which can act at long distances from the promoter. 
For example Drosophila Ubx gene can be activated by an enhancer 35kb away 
(Qian et al., 1991). In addition enhancers have been documented to activate more 
than one promoter (eg.the Drosophila yolk protein genes YP1 and YP2 are activated 
by the same enhancer in fat bodies and a distinct enhancer directs expression in the 
ovary; Logan 1989). That enhancers have the ability to act promiscuously has been 
clearly demonstrated by their ability to activate heterologous enhancers in artificial 
constructs (e.g. Huang et al., 1993; Ondek et al., 1987) and the success of 
'enhancer trap' experiments in Drosophila (Bellen et al., 1989).
One mechanism which may limit the activity of enhancers may involve 
higher order chromatin structure. The DNA of higher eukaryotes is organised into a 
number of discrete domains. The physical compaction may also serve to organise 
DNA into functional units of transcription, outside which the enhancers can have no 
activity. This is supported by nuclease studies which reveal that active genes are 
within a sensitive region usually 10-100 kb in length. The organisation of these 
domains is unclear but it has been suggested that they form anchored loops attached 
to the nuclear scaffold (reviewed Gasser and Laemmli 1987).
Presumably these domains must have boundaries and might have a 
specialised structure. One candidate for these boundary sequences are the matrix 
attachment or scaffold attachment regions (MAR/SAR). These sequences are 
defined biochemically as regions of DNA which are bound to the nuclear matrix 
after extraction of bulk chromosomal protein (Mirkovitch et al., 1984). These sites
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have been mapped to regions surrounding a number of genes (Gasser and Lammli 
1987; Garrard 1990). These elements and a number of other interesting potential 
boundary elements have been tested in functional assays.
Stable transfections and transgenic mice have been used as a functional 
assay to test sequences for the ability to determine position independent expression 
(PIE). Clearly elements other than those which act only as a boundary are necessary 
to determine PIE, however these elements should insulate a gene from the 
repressive effects of the surrounding sequences.
The chicken lysozyme gene is flanked at the 5' and 3’ boundaries of 
DNAsel sensitivity by regions previously designated SARs. These elements ('A' 
elements) when flanking a reporter construct had no effect in transient transfections, 
but increased transcription 10-fold in stable transfectants (Stief et al., 1989). 
Similarly, transgenic mice containing the lysozyyme promoter and enhancer 
elements flanked by these A elements showed that the expression level was 
correlated with the copy number of transgenes (Bonifer et al., 1990).
Studies of the D rosophila hsp70 genes have defined elements termed 
specialised chromatin structures (scs) which flank one of these genes and appear to 
demarcate boundaries of chromatin perturbation within this heatshock puff in 
salivary gland polytene chromosomes (Udvardy et al., 1985). Both of these 
elements are characterised by a set of nuclease hypersensitive regions surrounding a
protected region of 200-350 bp. These elements can insulate the Drosophila reporter 
gene white (whose expression results in the development of white eyes) from 
positive and negative euchromatic effects when they flank this gene, irrespective of 
the site of insertion of these constructs (Kellum and Schedl 1991). This element 
could also block the activity of an enhancer when placed between it and the 
promoter, however an MAR could not block transcription in this assay, although 
the lysozyme A elements could block enhancer activity suggesting that these 
boundary elements may have separable functions (Kellum and Schedl 1992).
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2.3 Transcriptional regulatory proteins
In addition to the general transcription factors and RNA polymerase II, 
transcription is controlled by sequence-specific transcription factors. These factors 
are often composed of modules or domains with discrete functions. Many 
transcription factors have separable DNA binding and transcriptional activating 
domains; for example the yeast transcription factor GAL4 can be experimentally 
split into functional DNA binding and transcriptional activation domains (Brent 
1985; Keegan et al., 1986). A large number of transcription factors have been 
identified, and many belong to families which share sequence similarity over a 
domain which mediates DNA binding or dimerisation. A number of these motifs are 
discussed in section 2.3 (i).
2.3 (i) DNA binding and dimerisation domains
Helix-turn-helix
This motif was first identified in prokaryotic transcription factors (Cl, CRO, 
CAP). These proteins bind DNA as a dimer and consequently the binding sites 
show dyad symmetry. Their structures were determined and these proteins 
recognised DNA sequences via an a-helix inserted into the major groove. Binding 
of the factor as a dimer places the recognition helices in an anti-parallel organisation 
such that each is aligned to half of the dyad symmetric site.
A specific conserved constellation of amino acids allowed identification of 
eukaryotic helix-turn-helix (HTH) like proteins, initially the yeast M A T al and 
M A T a 2 , and subsequently extended to the D rosoph ila  homeotic genes 
antennapedia, fushi tarzu and ultrabithorax (Matthews et al., 1982; Scott and 
W einer 1984; Sheperd et al., 1984). These genes which are involved in 
segmentation in Drosophila share extreme sequence relatedness across a 60 amino- 
acid domain - the homeobox. These transcription factors are also found in
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mammalian cells, and bind to a sequence containing an AT-rich core. These 
proteins play a key role in embryogenesis and development.
Zinc fingers
This common motif was first discovered in transcription factor IIIA 
(TFIIIA) which binds to the internal promoter of the 5S rRNA genes. Cloning and 
sequencing revealed the presence of a repetitive motif cys-N2-cys-N12-his-N2-his. 
This motif was repeated nine times (Shastry et al., 1982). Each of these repeats 
binds a zinc ion via a tetrahedral coordination of the cysteine and histidine residues. 
The intervening amino-acids loop out to form a "finger". This type of zinc finger 
motif is termed the C2 H 2  motif and this sub-family includes the Spl and TFIIIA
transcription factors (Kadonaga et al., 1987).
A related motif is termed the Cx zinc finger. This is typified by clusters of 4- 
6 cysteines often separated by 2 or 4 amino acids. These motifs occur in 25-30 
amino-acid clusters that tend to be repeated. Members of this group include the 
hormone receptors, GAL4 and EF-1 (Ham and Parker 1989; Johnston 1987; 
Sargant et al., 1990). As for the HTH proteins, the zinc fingers serve to present an 
a-helix which provides the binding specificity of the finger. This is a common 
feature of sequence-specific DNA-binding proteins.
Leucine zippers
The leucine zipper is a motif found in a number of transcription factors. The 
motif was first discovered in the CCAAT/enhancer binding protein or C/EBP 
(Landschulz et al., 1988). This motif has now been found in a number of other 
proteins e.g. Myc, GCN4, ATF, Fos and Jun. The family is separated into two 
groups: the basic-leucine zipper (bZIP) which includes C/EBP and Fos, and other 
transcription factors which contain another dimerisation/DNA binding motif; these 
are the helix-loop-helix leucine zipper proteins which include Myc and Max 
(Blackwood and Eisenman 1991). The leucine zipper mediates dimerisation via a
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coiled coil arrangement of parallel a-helices, in which a leucine occurs at every 
seventh residue. This dimerisation brings together the preceding basic regions 
necessary for sequence-specific binding (O'Shea et a l,  1989). The dimerisation is 
specific and the leucine zipper mediates this control (Kouzarides and Ziff 1989).
Helix-loop-helix
This sequence was first identified as a region of homology between the 
products of the c-myc, myoD  and the Drosophila achaete-scute complex genes 
(Lassar et al., 1989; Villares et al., 1987). This motif has also been identified in the 
products of a number of Drosophila cell type determination genes e.g. daughterless, 
hairy as well as in the immunoglobulin enhancer binding proteins E12 and E47 
(Murre et al., 1989).
Although there is no structural data the protein has been divided into two 
domains, the helix-loop-helix (HLH) and an adjacent basic region (Tapscott et al., 
1988). The HLH domain contains two stretches of amino acids capable of forming 
am phipathic a -h e lic e s  (Murre et al., 1989). The HLH domain has been 
demonstrated to be capable of mediating protein dimerisation (Murre et al., 1989; 
Murre et al., 1989b). The basic HLH structure is critical for the myogenic activity 
of MyoD and the transforming activity of Myc (Tapscott et al., 1988; Weintraub 
1991; Stone et al., 1987). The activity of these proteins is critically controlled by the 
choice of dimerisation partner. This is discussed in more detail in section 2.4
Other classes of DNA-binding domains
A variety of other domains exist (eg Ets and POU (Le Prince et al., 1983; 
Herr et al., 1988) and new domains are being defined in the light of newly cloned 
transcription factors. A large number of the known factors fall into one of the above 
families, suggesting that a limited number of domains have been utilised by 
evolution to solve the problem of sequence-specific DNA-binding.
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2.3 (ii) Transcriptional activating domains
The ability to experimently swap domains of transcription factors to generate 
chimeric proteins has suggested that in many cases the binding to DNA many serve 
a neutral function in terms of transcriptional activity (Brent 1985; Keegan et al.,
1986). In other words, the DNA-binding domain serves only to bring the activating 
domain into the region involved in the initiation of transcription.
In contrast to the conserved nature of DNA binding motifs, transcriptional 
activation domains appear to have little underlying structure in common. Three 
types of activating domain have been classified:
(i) Acidic activating domains - composed of stretches of negatively charged 
amino acids which may be able to form amphipathic a-helices , with negatively 
charged groups on one surface of the helix and hydrophobic groups on the other 
(Hope and Struhl 1986; Hope et al., 1988).
(ii) Glutamine-rich domains are found in a number of transcription factors 
such as S pl, OTF-2 , AP2 and SRF (Clerc et al., 1988; Williams et al., 1988; 
Norman et al., 1988).
(iii) Proline domains are found in CTF and NF-1 transcription factors 
(Mermod et al., 1989).
A protein may have more than one activating domain e.g. Spl contains four 
activating functions (Pascal and Tjian 1991). Some activating regions may require 
to be induced; e.g., the human oestrogen receptor has two transcriptional activating 
functions, one is constitutive and the other is induced by ligand binding (Tasset et 
al., 1990).
Experimental evidence is available implicating a number of targets of 
transactivation domains. A number of mechanisms can be envisioned to explain 
how transcription factors mediate transactivation. Most transcription factors 
function via stabilising/facilitating preinitiation complex formation. Transcription 
factors have been demonstrated to interact with the basal transcription machinery
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including TATA-binding protein (TBP), TAFs (TBP-associated factors) and 
TFIIB (Lin et al., 1991; Ing et al., 1992; Zhou et al., 1992). The existence of a 
large number of TAFs or coactivators suggests that there may be a number of 
possible sites of interaction with transactivation domains of transcription factors. As 
mentioned in section 2.1, transcriptional activation can also be mediated by 
destabilisation of chromatin structure; other mechanisms may include protein- 
protein interactions which may allow enhancer binding proteins to be brought into 
close proximity. Evidence for the latter mechanism is that one of the four Spl 
transactivation domain can mediate DNA looping in vitro (Su et al., 1991).
2.3 (iii) Dimerisation and the control of transcription factor activity
The majority of known transcription factors bind DNA as multi-protein 
complexes that frequently take the form of dimers. Many transcription factors are 
members of a family of related proteins which may have the ability to homodimerise 
and/or heterodimerise. This ability to dimerise is often an absolute requirement for 
transcription factor activity. This dimerisation is not promiscuous as even proteins 
which dimerise through the same class of domain cannot always form heterodimers. 
For example, although the C/EBP transcription factors and Fos and Jun are 
members of the bZIP super family, the C/EBP factors are unable to dimerise with 
either Fos or Jun.
Why is dimerisation so common within transcription factor families? A 
number of important regulatory consequences can be envisioned as a result of 
dimerisation and these are discussed.
DNA binding
The most obvious functional consequence of dimerisation is the alteration of 
DNA binding specificity. The widespread use of dimerisation provides an 
explanation as to why so many recognition sequences show dyad symmetry.
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Homodimers would be expected to bind to sites showing dyad symmetry, whereas 
the recognition sites of heterodimers may be composite elements. An example of 
altered binding specificity depending on the choice of dimerisation partner is 
provided by c-Jun. This protein binds preferentially to an API site when dimerised 
with itself or another member of the Fos/Jun family. Jun is also capable of 
dimerising with an ATF family member, and this heterodimer recognises the related 
cAMP element in preference to the API site (Ivashkiv et al., 1990; Benbrook and 
Jones 1990). In addition to altering the sequence specificity of transcription factors, 
dimerisation can also alter the affinity of a factor for its binding site. The API 
family provides an example of this type of regulation: Jun-Jun homodimers bind 
the API site with an affinity 500-fold less than Fos-Jun heterodimers, although this 
is a consequence of the greater stability of the Fos-Jun heterodimers (Cohen and 
Curran 1990). Similarly, heterodimers of MyoD and the E12/E47 proteins bind the 
kE2 site of the immunoglobulin k  gene with a higher affinity than homodimers 
(Murre et al., 1989).
Negative regulation of transcription factor activity
A number of dominant negative regulators of transcription factor activity 
have been characterised. These factors seem to play a central role in transcriptional 
control particularly during differentiation.
The basic helix-loop-helix gene myoD  can confer a muscle-specific 
phenotype on heterologous cells when its expression is driven by a viral LTR (see 
section 2.5). The levels of this factor do not however change during myogenesis 
and the regulation seems to be exerted by a protein termed Id. This protein lacks a 
basic domain and forms inactive heterodimers with E12/E47 and to a lesser extent 
MyoD (Benezera et a l, 1990). During myogenic differentiation the levels of Id fall, 
allowing the formation of functional MyoD-E12/E47 dimers which then activate a 
battery of muscle-specific genes. Id is not limited to muscle cells with Id or Id-like 
genes expressed in a range of tissues, including oesteoblasts, haemopoietic cells
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and neuronal precursors, as well as displaying a broad pattern of expression during 
embryogenesis (Kawaguchi et al., 1992; Duncan et al., 1992; Wang et al., 1992). 
Evidence that it plays a similar role in other systems is that over-expression in 
myeloid cells blocks differentiation (Kreider et al., 1992).
These negative regulators are not restricted to the bHLH family of 
transcription factors, for example the C/EBP family contains a member CHOP-10 
which does not contain a DNA-binding domain and can inhibit C/EBP activity on 
co-transfection (Ron and Habener 1992).
Regulation of transactivation capacity
An interesting example of the control of transcriptional activation properties 
via the choice of dimerisation partner is provided by the Myc/Max proteins. Max is 
present constitutively and readily forms homodimers which bind to E-box 
sequences (Blackwood and Eisenman 1991). These homodimers however fail to 
transactivate gene expression. As a result of a proliferation signal Myc is induced, 
this protein is unable to form homodimers but forms heterodimers with Max which 
transactivate gene expression via binding to E-box sequences (Amati et al., 1992).
Other regulatory possibilities resulting from dimerisation include the ability 
to respond to different signal transduction pathways. For example C/EBP(3 is IL-6 
responsive, and heterodimer dimerisation with this factor can confer IL-6 induction 
on the heterodimer (Poli et al., 1990).
2.3 (iv) The regulation of transcription factor activity by 
phosphorylation
There are four main levels at which phosphorylation can affect transcription 
factor activity.
1) Control of subcellular location.
2) Alteration of DNA binding activity.
i
48
3) Alteration of transactivation properties.
4) Choice of dimerisation partner.
The yeast transcription factor SW15 is required for cell-cycle regulated 
expression of the HO site-specific endonuclease. This transcription factor 
translocates to the nucleus during G1 of the cell cycle. The inactive cytoplasmic 
form is phosphorylated at three cdc2 consensus sites near or within the basic 
nuclear localisation signal (Moll et al., 1991). Mutation of these three serine 
residues to alanine results in a constitutively active nuclear SW15 protein. The 
regulation is presumably mediated by cdc2 kinase or a similar cell cycle regulated 
kinase in vivo.
Other examples include the Rel family of transcription factors. NFkB when 
inactive is held in the cytoplasm by interaction as a result of dimerisation with IkB. 
In vitro phosphorylation of IkB by protein kinase A and C (PKA and PKC) results 
in activation of NFkB (Shirakawa and Mizel 1989; Ghosh and Baltimore 1990).
Phosphorylation of c-Myb by casein kinase II (CKII) in vitro results in a 
decrease in DNA binding, which is reversed by phosphatase treatment (Luscher et 
al., 1990). Since these CKII sites are phosphorylated in vivo they may regulate 
DNA binding activity in vivo. This postulate is supported by the inability of CKII to 
inhibit v-Myb activity as a result of loss of these sites which is generated by a 
truncation necessary for the oncogenic activity of this protein (Luscher et al., 1990). 
Another example is provided by the serum response factor (SRF), which binds to 
the serum response element in the c-fos promoter. In A431 cells this activity is 
partly inducible by epidermal growth factor (Prywes and Roeder 1986). 
Phosphorylation of recombinant SRF by CKII at one or more of a number of 
serines close to the DNA binding domain can stimulate DNA binding (Janknecht et 
al., 1992). Whether this has a role in vivo is unclear, but microinjection of CKII 
into the cytoplasm led to an increase in SRF phosphorylation and c-fos transcription 
(Gauthier-Roviere et al., 1991)
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In most cases phosphorylation effects on transactivation are of positive 
control. The cAMP response element binding protein (CREB) mediates 
transcriptional activation of cAMP responsive genes upon phosphorylation by 
protein kinase A (PKA) (Gonzalez et al., 1989). Most experiments rule out an effect 
of PKA on either DNA binding or dimerisation (Yamamoto et al., 1989). The target 
of PKA phosphorylation of CREB is serine 133 and mutation of this residue 
abolishes transactivation activity (Gonzalez and Montmimy 1989).
The yeast transcription factor ADR1, which increases the expression of the 
ADH2 gene via an upstream activating sequence, provides an example of negative 
regulation of transactivation by phosphorylation. Catabolite repression of ADR1 
activity requires PKA and appears to be due to direct phosphorylation of ser-230 
(Cherry et al., 1989). Equivalent ADR1 DNA binding activities are detected in 
repressed and non-repressed cells and a constitutively active mutant has an altered 
PKA consensus for phosphorylation suggesting the inhibition is at the level of 
transactivation (Taylor and Young 1990).
There is no direct evidence for the control of dim erisation by 
phosphorylation, however as the choice of dimerisation partner has profound 
functional consequences, this seems an attractive level to control transcription 
factor activity. Under certain conditions C/EBPp is phosphorylated in vivo at a 
serine residue within the leucine zipper domain. This phosphorylation does not alter 
the DNA binding properties but increases the transactivation activity of this factor, 
suggesting that this phosphorylation may alter affinity for different heteromeric 
partners although other mechanisms could explain these results (Wegner et al.,
1992).
Phosphorylation can alter the activity of a single transcription factor both 
positively and negatively, the best example being provided by c-Jun. 
Phosphorylation at one set of sites negatively regulates DNA binding, whereas 
phosphorylation at another set of sites increases transactivation (reviewed in Hunter 
and Karim 1992). A single exogenous signal can regulate phosphorylation at a
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number of sites coordinately, for example TPA can induce dephosphorylation of 
the inhibitory sites in c-Jun and induce phosphorylation of the stimulatory sites 
(Pulverer et al., 1992).
The role of phosphatases is also likely to be of key importance in the 
regulation of transcription factor activity, e.g. it has been demonstrated that 
transcriptional attenuation following cAMP induction requires protein phosphatase 1 
mediated dephosphorylation of CREB at serine 133 (Hagiwara et al., 1992).
The importance of phosphorylation is underlined by the fact that almost 
every transcription factor studied is a phosphoprotein. However, in most cases the 
functional consequences of this phosphorylation is unknown.
2.4 Tissue-specific gene expression
A number of tissue-specific genes have been characterised in some detail for 
a range of different lineages. These studies have characterised both the ds-acting 
elements which confer this tissue specificity and the factors which bind them to 
mediate it. Liver-specific gene regulation has been studied in some detail and has 
provided a number of insights into the mechanisms controlling tissue-specific gene 
expression.
The serum albumin gene is expressed exclusively in the liver and its 
regulatory elements have been dissected in detail. The promoter of this gene 
contains five ds-acting motifs in addition to the TATA box. These functionally 
defined elements have been well conserved throughout mammalian evolution. Each 
of these elements binds transcription factors present in liver nuclei (HNF1, NFY, 
C/EBP, DBP and an NF1-related protein). With the exception of the CCAAT 
motif, each of these sequences contributes to the hepatocyte specificity of the 
promoter (Maire et al., 1989; Cereghini et al., 1987; Gorski et al., 1986). This 
modular organisation is typical of promoters of other liver-specific genes, with a 
number of elements having intrinsic activity. In addition, many of the genes also
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contain elements which bind ubiquitous factors. These elements do not contribute to 
tissue specificity, but can increase the level of transcription.
Enhancers as well as promoters are important in the control of liver-specific 
gene expression. The serum albumin gene in addition to its tissue-specific promoter 
also has a liver-specific enhancer. This enhancer is located lOkb upstream and 
transgenic mice revealed that this element mediates expression exclusively in the 
liver (Pinkert et al., 1987) and contains three functionally defined elements, binding 
NF1, C/EBP and HNF3 family members (Herbst et al., 1989; Jackson et al., 
1993). Similarly the liver-specific a-1 microglobulin/bikunin gene displays a 
modular structure. This enhancer contains six functional elements which bind 
members of the HNF1, HNF3 and HNF4 families of transcription factors. In 
contrast to the serum albumin gene the tissue-specificity seems to be conferred by 
the enhancer alone (Rouet et al., 1992).
The simplest explanation of how transcription factors control tissue- 
specificity of gene expression would be that specific regulatory elements are bound 
by transcription factors which are restricted to a particular cell lineage. However, to 
date no transcription factor has been discovered whose expression is restricted 
solely to the liver. It seems that liver-specific promoters and enhancers are bound by 
a range of factors which are enriched in liver cells compared to many other tissues. 
A number of transcription factor families have been identified which are important 
in transcriptional regulation in liver cells. These include C/EBP, hepatocyte nuclear 
factors 1, 3 and 4 (reviewed in Lai and Darnell 1991). These factors are expressed 
at high levels in the liver, but not exclusively, e.g. H N F la  is expressed in the 
liver and has been demonstrated to bind to the 5' region of a number of liver- 
specific genes and activate their transcription in co-transfection assays e.g. serum 
albumin (Schorpp et al., 1988; Cereghini et al., 1988), aldolase B (Tsutsumi et al.,
1989). However, H N F la  is also expressed in kidney and lung, although kidney 
and liver express a number of genes in common e.g. a l  antitrypsin which contains 
an HNF1 site within its promoter (Baumhueter et al., 1988). Clearly single
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elements are not tissue-specific, rather the combination of a number of cis-acting 
sequences within a promoter or an enhancer together confer tissue specificity on a 
gene.
Further complexity is emerging in the regulation of tissue-specific gene 
expression, with the discovery of tissue-specific co-activators. The H N F la  
homeodomain protein can dimerise with itself or H N F lp , but maximal 
transactivation requires a novel cofactor termed dimerisation cofactor of HNF1 
(DcoH) which does not bind DNA. This factor shows a tissue-specific distribution 
with levels high in the liver, and can increase transcription up to 200-fold. The 
mechanism of action is unclear but this factor cannot bind DNA, rather it acts via 
binding HNF1 and stabilising dimers (Mendel et al., 1991).
A similar example of a co-activator playing a role in tissue-specificity is 
provided by B-cell specific activation via octamer elements. These motifs have been 
demonstrated to be important in mediating the B-cell specific expression of the 
immunoglobulin genes and paradoxically the cell cycle regulated expression of the 
histone H2B genes. Until recently it was presumed that these two effects were 
mediated by separate octamer binding proteins, i.e. the tissue-restricted Oct-2 was 
responsible for the immunoglobulin gene expression and the ubiquitous Oct-1 
responsible for H2B gene expression. Recent work has implicated a novel B-cell 
specific co-factor OCA-B in the tissue-specific activity of octamer elements. This 
factor was isolated by testing fractions from B-cells for the ability to restore IgH 
chain transcription in vitro upon a HeLa extract. This factor can activate the IgH 
promoter in conjunction with either Oct-1 or Oct-2 (Luo et al., 1992).
Interestingly, this co-activator had no effect on the octamer/Oct-1 dependent 
transcription of the histone H2B promoter. The reason for the promoter-specific 
effect of this factor is unclear, but may be a result of the short and highly conserved 
spacing between the octamer and TATA elements in H2B promoters (Harvey et al., 
1982). This shorter spacing may obviate the need for a co-activator, further 
illustrating the importance of the context of an element in determining activity.
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2.5 Transcription factors and the control of differentiation
The myoD  gene provides a paradigm for the role of transcription factors in 
development and differentiation. This gene is capable of activating previously silent 
muscle-specific genes when introduced into a large variety of cell types under the 
control of a viral LTR. MyoD  is a member of a family of muscle-specific HLH 
proteins (myogenin, myf5, mrf-4-herculin) which all seem to play a similar role in 
activating muscle-specific genes (and each other). A positive feedback mechanism is 
generated by the ability of MyoD to activate both its own expression and the other 
members of the myoD gene family which leads to muscle differentiation.
MyoD dimerises with the ubiquitous HLH proteins E12 and E47 to form 
active heterodimers. The levels of these three HLH proteins remain steady during 
differentiation. The control seems to be exerted by the negative regulator Id (see 
section 2.4 (ii). This protein readily forms dimers with E l2 and E47 which are 
unable to bind DNA (Id lacks a basic domain). The level of this repressor falls 
during myogenic differentiation (Benezera et al., 1990), allowing the formation of 
MyoD-E12/47 heterodimers which mediate the muscle-specific differentiation 
program.
Clearly those cells which contain MyoD are committed to muscle 
differentiation. This begs the question: how is the decision to continue to proliferate 
or to differentiate controlled? Id is expressed at high levels in proliferating cells and 
is down regulated on withdrawal of serum. Hence in conditions favouring 
proliferation the levels of Id are high and this prevents the E l2/47 proteins from 
dimerising with MyoD. This is supported by the fact that the majority of the E 12 
and E47 proteins are complexed in inactive heterodimers with Id in proliferating 
myoblasts (Jen et al., 1992). However proliferation signals regulating Id levels do 
not alone control the differentiation program. In contrast to serum, which inhibits 
the DNA-binding activities of MyoD and Myogenin and induces Id expession, 
TGF(3 inhibits the myogenic activity of these factors without affecting their ability to
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bind to DNA, hence excluding a role for Id in TGF(3 mediated repression of 
differentiation (Brennan et al., 1991).
Recent work has provided strong evidence for the role of the product of the 
retinoblastoma susceptibility gene (pRb) in muscle cell commitment and 
differentiation (Gu et al., 1993a). This work demonstrated that pRb was required 
for the growth arrest and differentiation often observed when the myoD  gene is 
introduced into a number of cell types. Two oesteosarcomas cell lines Saos-2 and 
USOS were used as experimental system. These cell lines are phenotypically similar 
but Saos-2 lacks a functional pRb gene. Expression vectors containing myoD in the 
sense or antisense orientation were introduced into these cell lines. The inclusion of 
the myoD in the expressing vector reduced the number of colonies produced in the 
USOS (pRb+) by 50% in comparison to the numbers generated using the antisense 
construct. Introduction of these constructs into Saos-2 (pRb- cell line) showed no 
reduction in colony formation. Stably transfected Saos-2 cell lines expressing myoD 
were retransfected with Rb; this resulted in the cessation of proliferation and the 
expression of the muscle-specific myosin heavy chain. Hence Rb is required for 
both growth arrest and muscle-specific differentiation.
MyoD and pRB interact directly both in vitro and in vivo; however, at least 
in vitro, MyoD could only bind to the underphosphorylated form of pRb. As pRb 
remains in this underphosphorylated form in differentiating cells (even in response 
to growth factors) suggesting that MyoD may lock pRb in this growth factor 
unresponsive state. The correlation of differentiation with the inability to 
rephosphorylate pRb is seen in other terminally differentiating systems including 
HL60 cells (Whyte and Eisenman 1992; Mihara et al., 1989). The key role of pRb 
in inhibiting proliferation was demonstrated by the ability of differentiated muscle 
cells containing a ts SV40 large T antigen to re-enter the cell cycle when large T was 
activated (and thus inactivating the pRb protein). The pRb protein also seems to 
stabilise the MyoD-E protein heterodimers, as when pRb is removed from muscle 
cell extracts E-box activity is diminished or abolished. This suggests that pRb aids
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in myogenesis by increasing the number of functional myogenic heterodimers.
The question remains, why does the 'free' MyoD in myoblasts not interact 
with pRb in G1 (when pRb is underphosphorylated) and commit cells to 
differentiation? An intriguing possibility is suggested by the demonstration that c- 
Jun can bind MyoD (Bengal et al., 1992). This results in mutual inactivation of API 
and MyoD activity. A further link demonstrating the antagonistic action of MyoD on 
API is that MyoD has been demonstrated to down regulate the c -fos promoter 
(Trouche et al., 1993). Serum and TGFp (which does not increase Id expression) 
increase the levels of Fos and Jun; these oncogenes in either viral or cellular form 
can block differentiation when over-expressed in myoblasts (Brennan et al., 1991; 
Lassar et al., 1989). This along with the evidence that the level of MyoD (or other 
m yogenic transcrip tion  factors) is im portan t in determ ining  the 
proliferation/differentiation choice suggests that the relative levels of these factors 
will determine the choice of proliferation or differentiation. This dual role of pRb in 
cell-cycle control and muscle-specific differentiation provides a molecular 
mechanism for the incompatibility of proliferation and terminal differentiation. As 
differentiation in this system requires pRb in an underphosphorylated form to 
interact with MyoD, whereas hyperphosphorylated pRb is necessary for cell cycle 
progression. It is interesting to note that induction of differentiation of HL60 cells 
results in a rapid induction of the product of the waf-1 gene (Hongping et al., 1994; 
Steinman et al., 1994). This gene encodes a cyclin-dependent kinase inhibitor 
whose activation results in the prevention of pRb phosphorylation (Xiong et al., 
1993; Harper et al., 1993; El-Deiry et al., 1993), and may be an important mediator 
of differentiation in a number of systems.
The CCAAT / enhancer binding protein a  is expressed in a number of 
tissues, including lung, liver, adipose, gut and placenta at varying levels. Several 
lines of evidence suggested C/EBPa may have an important role in terminally 
differentiated tissues. In adult liver C/EBPa is restricted to the nuclei of mature 
hepatocytes (Birkenmeier et al., 1989), whereas proliferating hepatoma cells
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contain very low levels (Friedman et al., 1989). Similarly, cultured 3T3-L1 
adipoblasts do not express C /EBPa when proliferating, but exhibit marked 
induction when stimulated to differentiate (Birkenmeier et al., 1989; Christy et al.,
1989). This correlation suggested that C/EBPa may have a role in differentiation, 
by switching on a differentiation program and/or being involved in the maintenance 
of a terminally differentiated phenotype. Evidence for the latter is that C/EBPa is 
involved in the regulation of a number of genes expressed only in specific 
terminally differentiated tissues, as well as being implicated in many others. These 
include the hepatocyte-specific serum albumin gene (Friedman et al., 1989) and the 
adipocyte-specific 422(aP2) and GLUT4 (Christy et al., 1989; Kaestner et al.,
1990).
C /EB Pa also appears to be a key mediator of terminal differentiation in 
adipocyte tissue and perhaps in a number of other tissues also. 3T3-L1 
preadipocytes with appropriate hormonal stimulation can differentiate into cells with 
morphological and biochemical characteristics of normal adipocytes (Green and 
Kehinde 1974, 1975 and 1976). Using this as a model system a number of workers 
have demonstrated that C/EBPa antisense constructs inhibit the differentiation of 
these cells as measured by the lack of expression of a number of adipocyte-specific 
genes and the accumulation of cytoplasmic triglyceride (Lin and Lane 1992; 
Samuelson et al., 1991). Conversely the activation a conditional fusion protein 
C/EBPa-oestrogen receptor with estradiol led to a direct cessation of growth which 
was dependent on the C/EBPa portion of the protein for activity. When abetted by 
the effects of three adipogenic hormones this chimeric protein could promote 
terminal differentiation (Umek et al., 1991).
c-Myc is tightly correlated with proliferation and constitutive expression of 
the gene in a number of tissues can block differentiation. This includes adipogenesis 
in which constitutive expression of c-myc prevent 3T3-L1 adipoblasts from 
differentiating. This enforced expression of c-myc prevented the normal induction 
of C/EBPa in response to differentiation signals. Transfection of these cells with
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C/EBPa-expressing constructs led to a reduction in both the number of neomycin 
resistant colonies formed (in comparison to the number generated with an antisense 
construct) and an increase in the number of cells containing lipid droplets in their 
cytoplasm (Freytag and Geddes 1991). This suggests that c-Myc negatively 
regulates the expression of the C /EBPa gene and as a result inhibits the 
differentiation of these cells.
As C/EBPa is present in a number of terminally differentiated tissues, most 
notably the liver, it seems likely that it may play a similar role in a number of 
tissues i.e. growth arrest and the promotion of a predetermined differentiation 
program. This is supported by the ability of the C/EBP-ER fusion protein to 
produce growth arrest in a number of different cell lines including the pluripotent 10 
t1/2 cells.
There are a number of similarities between C /EBPa and MyoD. Both 
produce growth arrest when expressed at high enough levels to overcome 
proliferative signals (Umek et a l., 1991; Sorrentino et al., 1990) and both are 
involved in the expression of genes necessary for a specialised phenotype. 
However, unlike MyoD, C/EBPa cannot confer a specific differentiation program 
when over expressed in heterologous cell lines. This is not suprising as C/EBPa is 
expressed in a number of different tissues, but may act as a switch between 
proliferation and differentiation depending on the relative strengths of proliferation 
and differentiation signals, and as an auxiliary factor in a predetermined 
differentiation pathway.
Although the above provides an attractive model for the control of 
differentiation it is an over simplification. A range of different C/EBP family 
members exist, which are coexpressed at varying levels in different tissues. These 
family members can heterodimerise in all intra-familiar combinations tested (Poli et 
al., 1990; William et al., 1991; Cao et al., 1991). Interestingly a C/EBP family 
member has been cloned (CHOP-10) which has two prolines in the highly 
conserved basic domain. This protein is capable of acting as a dominant negative
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inhibitor of C/EBP activity as measured by transient transfection studies (Ron and 
Habneur 1992). This gene is induced in parallel with C/EBPa during adipogenesis 
however there is still a large increase in C/EBP activity in these terminally 
differentiated cells. Whether CHOP-10 is simply a negative regulator of C/EBP 
activity in terminal differentiation is not known. Similarity between the mouse 
CHOP-10 and the hamster GADD 153 gene suggests they may act in a functionally 
similar manner. The GADD 153 gene is induced on DNA damage and is associated 
with growth arrest of the cells, suggesting that perhaps CHOP-10 has a role in the 
C/EBPa mediated growth arrest (Bartlett et al., 1992).
The pattern of C/EBPa expression, high in terminally differentiated tissues 
and low in proliferating cells is not absolute, the reciprocal pattern is true in the 
myeloid system with C/EBPa and C/EBP5 being highest in immature proliferating 
cells and C/EBPp highest in the terminally differentiated cells (Scott et al., 1992). 
It may be that the varying isoforms from tissue to tissue are involved in defining a 
specific pattern of gene control and perhaps a differentiation program unique to that 
tissue (the role of C/EBP in myeloid gene control is discussed in section 3.).
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Chapter 3: The transcriptional control of myelopoiesis
Gene regulation during myeloid differentiation
During haemopoiesis, pluripotent stem cells differentiate to generate 
precursor cells committed to a particular lineage, which eventually mature into 
functional, morphologically distinct end cells. This process requires the co-ordinate 
regulation of a number of genes which can be into a number of groups: the 
ubiquitous 'housekeeping' genes, those necessary for proliferation, differentiation 
or survival and those encoding proteins specifically required for the function or 
maintenance of the fully differentiated cell.
The existence of a large number of myeloid cell lines (c.f. section 1.5), a 
number of which can be induced to differentiate in vitro, has provided a useful 
homogenous source for the cloning of myeloid-specific genes and systems in which 
to study their regulation. Studies of this kind have been undertaken to identify ex ­
acting sequences which confer both myeloid and differentiation-stage-specific 
expression on genes, and to characterise the trans-acting factors which bind at these 
sites. Although a large number of studies have identified genes which are expressed 
exclusively in myeloid cells or in a differentiation-stage specific-manner, detailed 
studies identifying the transcriptional control elements are available only for a small 
number of genes.
The chicken lysozyme gene is constitutively expressed in macrophages 
(Hauser et al., 1981). The actively transcribed gene is located in a 20kb DNAsel 
sensitive region. This region is flanked by the so called 'A' elements (discussed in 
section 2.1 iii), which together with the -6Kb enhancer can confer high level 
position independent gene expression on reporter constructs. This enhancer is 
hypersensitive in cells actively transcribing the lysozyme gene (or have this 
potential). Deletion analysis has narrowed this enhancer down to 157bp, and this is 
sufficient to confer tissue-specific activity. Footprinting studies identified at least six
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elements which bound transcription factors, however nuclear extracts from non- 
myeloid cells also contained factors which bound at a number of sites. Surprisingly 
overlapping oligonucleotides containing at least two of these sites all contributed to 
the specificity of the enhancer when cloned upstream of the HSV tk promoter. 
These elements show sequence similarity to A PI, NF1 and octamer binding 
sequences although no attempt to identify the interacting proteins was reported in 
the study (Grewal et al., 1992).
In contrast, the mouse genome contains two lysozyme genes, the M and P 
genes expressed in myeloid and paneth cells respectively. The two genes are the 
result of a duplication event, and the downstream M gene contains only 1.7Kb of 
5' flanking sequence (Cross and Renkawitz 1990). Analysis by nuclease sensitivity 
of the surounding chromatin revealed a complex pattern of hypersensitive sites 
occurring at different stages of differentiation in myeloid cell lines Whereas no 
nuclease sensitivity was found in non-myeloid cells. (Mollers et al., 1992). The 5' 
flanking region of this gene was not sufficient to confer activity on a heterologous 
promoter. However, a 3' region (unique to the M gene) encompassing a cluster of 
hypersensitive sites could confer strong enhancer activity on this construct in all cell 
lines tested. Further investigation revealed that this region was under methylated in 
expressing cells. Methylation of a single CpG residue in the enhancer core was only 
observed in non-expressing cells, and this residue was demethylated when FDC-P 
A4 cells were induced to differentiate in vitro. Binding of a nuclear factor to this site 
was inhibited by methylation, as was enhancer function. Demethylation was found 
to parallel or just follow the establishment of a hypersensitive site at this sequence. 
Treatment of immature myeloid cells with 5-azacytidine resulted in demethylation at 
this site accompanied by the activation of this gene; however this treatment failed to 
elicit a response in fibroblasts indicating the importance of other sequences in 
contributing to the tissue specificity of this gene (Klages et al., 1992).
The CD1 lb gene encodes a subunit of the complement receptor type 3. The 
expression of this gene is limited to myelomonocytic cells and the rate of
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transcription of this gene increases markedly during differentiation of myeloid cell 
lines towards monocytes/granulocytes (Pahl et al., 1992). Although sequences 
further upstream contribute to the activity of the promoter, the first 92bp are 
sufficient to direct tissue-specific expression of a reporter gene. The transcription 
factor PU.I which has a limited tissue distribution, binds to a sequence around -20 
in vitro. Mutation of this site reduced activity in U937 cells 3 to 4-fold, but had no 
activity in the epithelial cell line HeLa (Pahl et al., 1993). An Spl site was also 
present in this fragment and in vivo footprinting of this site established that it was 
bound only in expressing cells. Mutations at this site reduced activity 18-fold, 
suggesting that PU.I may facilitate the binding of Spl in myeloid cells in vivo. A 
similar case of PU.I acting as a recruiting factor is seen at the immunoglobulin k  3' 
enhancer (Pongubala et al., 1993). These studies implicated Spl and PU.I in the 
tissue-specific activity of the CD1 lb promoter; however, those sequences which 
confer elevated expression on this gene as a result of differentiation were not 
identified although Spl was eliminated by mutational analysis.
These examples are of genes expressed in both monocytic and granulocytic 
lineages. Only one gene which is expressed exclusively in granulocytes has been 
studied in detail; this is the chicken mim-1 gene. This gene was originally isolated 
by differential hybridisation of ts v-myb transformed cells at permissive and non- 
permissive temperatures (Ness et al., 1989). This gene encodes a secretable protein 
stored in the granules of both normal and v-mj/?-transformed promyelocytes. The 
promoter contains three sites which can bind v-Myb in vitro and the endogenous 
gene can be transactivated in HD11 chicken macrophage by E26 v-Myb, but not in 
non-myeloid cell lines. Transactivation studies have implicated Ets-2 in activating 
this gene synergistically with c-Myb, although whether the endogenous gene 
would be activated is unclear. Interestingly, only the E26 v-Myb (which is the 
product of a myb-ets fusion gene) and not the AMV v-Myb (which is not) could 
activate the endogenous gene in these cells.
Two other studies have demonstrated that C/EBP transcription factors can
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synergistically activate the mim-1 gene in conjunction with c-Myb. Two potential 
sites have been identified which bind the chicken homologue of C/EBP(3 in vitro 
(Ness et al., 1993). Mutation of one of these sites prevents transactivation by c- 
Myb. More surprisingly, expression of C/EBP transcription factors in fibroblasts 
could confer c-Myb inducibility upon the endogenous mim-1 gene. C /EBPa or 
C/EBP5 but not C/EBP(3 could also confer c-Myb inducibility on the lysozyme gene 
in these cells, suggesting that the C/EBP transcription factors may be important 
mediators of myeloid-specific gene expression (Ness et al., 1993; Burk et al.,
1993).
The chicken C/EBPp (NF-M) is also involved in the regulation of the 
chicken myelomonocytic growth factor. However, Myb is not required for the 
activity of this gene, but the myeloid-specific promoter contains two binding sites 
for this factor which act synergistically with a kinase inducible element which binds 
an API-like transcription factor (Stemeck et al., 1992).
3.2 Transcription factors involved in myelopoiesis
The previous section discussed the regulation of genes which are myeloid- 
specific and/or are regulated in a differentiation-specific manner. What are the 
transcription factors responsible for this expression ? To date no transcription factor 
has been identified which can confer a myeloid-specific phenotype when expressed 
in heterologous cell types, nor has any factor been isolated which is strictly limited 
to the myeloid compartment. Despite this lack of obvious candidates for mediating 
myeloid-specific expression a number of transcription factors which have limited 
distribution patterns have been implicated in determining specific phenotypes within 
the myeloid lineages. Three families of transcription factors which are of particular 
relevance to this work are discussed in more detail in sections 3.3, 3.4 and 3.5. A 
number of other transcription factors merit a brief mention.
A key role for the helix-loop-helix proteins in granulocytic differentiation
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has been illustrated by the ability of Id to block differentiation of the mouse myeloid 
progenitor 32D cell line when treated with G-CSF (Kreider et al., 1992). This result 
implies the existence of HLH proteins in these cells which must become active to 
promote differentiation. The identification of the HLH proteins present in these cells 
will be particularly instructive given the role of cell-specific HLH proteins in other 
differentiating systems. The importance of these HLH proteins in other 
haemopoietic compartments is illustrated by the involvement of a number of these 
genes in lymphoid leukaemias (reviewed in Green and Begley 1992). A role for the 
API transcription factor in monocytic differentiation has been suggested by a 
number of studies, although exactly which members of the Fos/Jun family are 
active in this complex in myeloid cells is unknown. The introduction and expression 
of c-fos and c-jun  into M l myeloblasts results in increased spontaneous 
differentiation (Lord et al., 1993). Similarly, Egr has been implicated in inducing 
differentiation along the monocytic pathway (Nguyen et al., 1993).
3.3 The Myb family of transcription factors
The c-myb proto-oncogene is the cellular homologue of the transforming 
gene of the avian myeloblastosis and the E26 (myb-ets fusion) viruses (Klempnauer 
etal., 1982). The involvement of these viruses in transforming haemopoietic cells, 
and the high levels of c-Myb present in immature progenitors suggests that this 
protein may play a key role in the control of haematopoiesis (Westin et al., 1982). 
This has been conclusively demonstrated using knockout mice, nullizygous for c- 
myb. These mice develop normally for 14 days then display a severe impairment of 
both erythropoieisis and myelopoiesis. Interestingly embryonic haematopoiesis in 
the yolk sac is apparently normal suggesting that other members of the Myb family 
may carry out overlapping functions (Mucenski et al., 1991).
As well as c-myb, there have been two other cellular myb-related genes 
identified to-date, A -myb and B-myb (Normura et al., 1988). In addition several
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Myb related proteins have been described in species as diverse as Drosophila, yeast 
and Zea mays, with the DNA binding domain displaying the most homology 
(Peters et al., 1987; Tice-Baldwin et a i, 1989; Paz-Ares et al., 1987). All of these 
Myb related proteins are sequence-specific DNA binding proteins. The A- and B- 
Myb proteins have a wider tissue distribution than c-Myb which is limited to the 
haematopoetic system. A-myb is highly expressed in the kidney, colon and 
lymphoid tissue, whereas B-myb was expressed in all cell lines tested (Normura et 
a l,  1988).
3.3 (i) Functional domains of c-Myb
The c-Myb protein can be divided into three functional domains: the DNA- 
binding domain, the transactivation domain and the negative regulatory domain. 
The DNA-binding domain is the most conserved region of the protein and consists 
of three imperfect repeats of 50-52 amino acids; however, only two of these 
repeats are necessary for DNA binding. Sequence comparison suggests that each 
repeat may consist of three a-helices with homology to the HTH motif (Frampton 
et al., 1989). Both mutational analysis and Raman spectroscopic analysis support 
this model structure (Frampton et al., 1991; Grabrielsen et al., 1991; Saikumar et 
al., 1990; Kanei-Ishii et al., 1990).
The transactivation domains have been functionally mapped for both c-Myb 
and v-Myb. This has identified a 50-residue domain, located C-terminal to the 
DNA-binding domain (Klempauer et al., 1989; Sakura et al., 1989; Ibanez and 
Lipsick, 1990). This transactivation domain is hydrophilic and slightly acidic, 
although it is not clear whether this is necessary for its activity (Weston and 
Bishop, 1989).
The presence of a negative regulatory domain is suggested by mutational 
analysis which has demonstrated that deletion of the N-terminus of c-Myb increases 
its transactivation up to 10-fold. Studies mapping this negative regulatory domain
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have produced conflicting results. Dubendorf and co-workers demonstrated that 
two separate negative domains need to be deleted before transactivation by c-Myb 
increases (Dubendorf et al., 1992). One of these domains was capable of inhibiting 
transcriptional activation in trans by Myb, Myb-VP16 or LEXA-Myb proteins. 
This inhibition is presumably mediated by protein-protein interactions and does not 
require DNA binding. A similar study identified a leucine zipper sequence in one of 
the negative regulatory domains. Disruption of this leucine zipper increases both 
transactivation and transforming activities of c-myb. This result suggests a protein 
interacts with c-Myb to repress its activity, and this leucine zipper could mediate 
this interaction with other as yet unidentified protein(s) (Kanei-Ishii et al., 1992). A 
study has obtained partial sequence of two proteins which interact with this leucine 
zipper, although the effect of these interactions are unknown (Favier and Gonda
1994).
3.3 (ii) Genes regulated by c-Myb
There have been several attempts to identify c-Myb and v-Myb regulated 
genes; however, there is compelling evidence only for one target. This is the 
chicken mim-1 gene which is directly regulated by both v-Myb and c-Myb. The 
promoter of this gene contains three Myb binding sites (Ness et al., 1989). Other 
potential targets include the c-myb and c-myc genes as their promoters contain 
potential Myb binding sites and synthetic reporter constructs can be transactivated 
by c-Myb (Evans et al., 1990; Zobel et al., 1991; Nicholaides et al., 1991). In 
transfection assays, c-Myb can activate gene expression without binding to DNA, 
as is the case for the activation of the hsp70 gene (Klempnauer et al., 1989; Kanei- 
Ishii etal., 1994). Presumably this action is mediated by binding negatively acting 
transcription factors, or perhaps by a 'squelching' mechanism titrating out a subset 
of co-activators necessary for transactivation by a number of transcription factors 
(reviewed Gill et al., 1992).
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3.3 (iii) Regulation of c-Myb activity
Alternative splicing of c-myb has been documentented in both human and 
murine cells, with a larger message generated by the inclusion of an extra exon 
located between exons 9 and 10 (Ramsey etal., 1989; Dudek and Reddy 1989). In 
addition another spliced variant has been identified in human cells which included a 
cryptic exon located between exons 10 and 11. The messages generated by the 
alternative splicing events are similar in both human and mouse cells, the proteins 
generated are very different. In the murine cells the spliced variant generates a 
larger form of c-Myb (Ramsey et al., 1989), whereas the human variants are 
predicted to generate 3' truncated proteins as a result of the inclusion of a stop 
codon in these exons (Sheng-Ong et al., 1990). The functional consequences of 
these variants are unknown but the human proteins have similar 3' truncations as 
the viral Mybs.
Phosphorylation may also be an important mediator of Myb activity as 
specific interaction with a Myb binding site in vitro is abolished when c-Myb is 
phosphorylated at an authentic in vivo phosphorylation site (Luscher et al., 1990). 
This site is lost in most oncogenic variants suggesting that this may uncouple Myb 
from its normal regulation.
3.3 (iv) C-Myb : role in proliferation and differentiation
Antisense and knockout experiments have demonstrated the importance of c- 
Myb in normal haematopoiesis. The importance of c-Myb in proliferation can be 
demonstrated with antisense oligonucleotides which inhibit growth of cell lines 
(Calabretta etal., 1991; Venturelli et al., 1990). Evidence suggesting that c-Myb is 
involved in differentiation includes the of ability c-Myb to block differentiation 
when over-expressed in MEL cells (Clarke et al., 1988), whereas an alternatively
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spliced variant enhances differentiation (Weber et al., 1990). These experiments 
suggest that Myb may have a role in the regulation of differentiation, however it is 
difficult determine if these are a direct effect on differentiation rather than a 
consequence of stimulating or inhibiting proliferation. A number of lines of 
evidence suggests that Myb in addition to stimulating proliferation has a role in 
differentiation.
The most straightforward evidence that Myb is involved in determining a 
specific differentiation program is that it has been demonstrated to regulate the mim- 
1 gene. It is extremely unlikely that this gene is involved in the control of 
proliferation, rather it seems to be a tissue-specific protein, necessary for the 
function of the neutrophil. Perhaps the most convincing evidence that this gene has 
a central role in haemopoietic differentiation is provided by studies with the viral 
forms of this protein. Avian macrophages can be transformed with either v-myc or 
v-myb, however only v-myb confers an immature phenotype on the transformed 
cells. Superinfection of v-myc transformed macrophage with a v-rayfr-eostrogen 
receptor construct confers an immature promyelocyte-like phenotype on the cells in 
the presence of estradiol, illustrating the dominance of Myb in this system in 
conferring a specific differentiation phenotype on these cells (Ness et al., 1987; 
Burk et al., 1991).
In normal myelopoiesis, c-Myb may maintain an early granulocyte gene 
expression program. Cells in which c-Myb is down regulated would enter a default 
pathway and become monocytic. Supporting evidence of this model is that c-myb 
and mim-1 are co-expressed in normal promyelocytes and transformation of v-myc 
transformed macrophages with c-myb can transactivate mim-1 (Nakano et al., 
1992). The E26-transformed cells resemble myeloblasts and express m im -1, 
whereas AMV-transformed cells resemble monoblasts and do not express mim-1. 
The AMV v-myb gene contains a number of point mutations relative to both c-myb 
and E26 v-myb. Back mutation of any one of three mutations in the DNA binding 
domain restores the ability to activate mim-1 expression, and back mutation of two
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of these mutations causes the transformed cells to resemble promyelocytes and 
cause promyelocytic leukaemia (Introna et al., 1990). These results suggest that 
Myb in addition to promoting proliferation has a separable role in conferring a 
specific differentiation phenotype. Further evidence that Myb is necessary to 
promote granulocytic differentiation has came from antisense studies using HL60 
cells. Treatment of these cells with antisense c-myb oligonucleotides prevents 
induced granulocytic differentiation; these cells, however, still have the capability 
to respond to monocytic inducers. This experiment suggests that these cells require 
'c-Myb conditioned’ proliferation to complete a granulocytic differentiation program 
(Ferrari et al., 1992).
An obvious question is how can Myb confer a specific differentiation 
program during myelopoiesis when it is expressed throughout the haemopoietic 
system ? Clearly no protein acts in isolation and it may be that other factors are 
necessary which act in concert with Myb to determine a specific differentiation 
phenotype. There is emerging evidence of the co-operation of C/EBP proteins and 
Myb in determining the expression of myeloid-specific genes. It has been suggested 
that C/EBP factors are restricted to the myeloid compartment within haemopoietic 
tissues (Scott et al., 1992; Katz et al., 1993), and hence this is the only tissue in 
which both Myb and C/EBP factors are co-expressed, and together may determine 
a specific gene expression pattern in these cells (Ness et al., 1993). The role of 
C/EBP in myelopoiesis is discussed in section 3.4. An intriguing question which 
remains to be answered is does Myb play a similar role in other lineages in 
conjunction with other as yet unidentified factors?
3.3 (v) B-Myb
It has been suggested that B-myb may functionally substitute for c-myb 
outside the haemopoietic system as it is ubiquitously expressed. Although it is 
possible that they have some overlapping functions, B-Myb has a number of
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distinct properties. The human B-Myb been demonstrated to bind to a number of 
c-Myb binding sites in vitro, but can also bind to other sites which have little or no 
affinity for c-Myb (Mizuguchi et al., 1990). These workers demonstrated that this 
protein could transactivate gene expression through these sites. In contrast the 
chicken and mouse B-Myb have been shown to act as repressors of transcription 
(Foos et al., 1992; Watson et al., 1993); the chicken B-Myb failed to transactivate 
the mim-1 gene and the Mouse B-Myb failed to transactivate a Myb responsive 
promoter, and could repress c-Myb mediated transactivation of this construct. 
Fusion studies with the GAL4 DNA-binding domain and fragments of B-Myb 
failed to detect a transactivation domain. However the same study reported that both 
c-Myb and B-Myb could weakly transactivate the DNA polymerase a  promoter 
(Watson et al., 1993)
Antisense experiments with B-myb in HL60 and U937 cells resulted in 
inhibition of proliferation in the absence of differentiation, either spontaneous or 
induced (Arsura et al., 1992). This is in contrast to the results obtained when HL60 
cells were treated with antisense c-myb oligonucleotides. These cells retained the 
capacity for monocytic differentiation, suggesting these proteins have different 
roles.
3.4 The C/EBP family of transcription factors
The first member of the family to be identified was a heat stable DNA- 
binding protein present in rat liver nuclei (Johnson et al., 1987). This protein was 
cloned and termed C/EBP (and subsequently C/EBPa) - CCAAT/enhancer binding 
protein due to its ability to bind both the CCAAT homology and the enhancer core 
homology (Landschulz et al., 1988). A number of C/EBP family members have 
subsequently been cloned (Roman et al., 1990; Descombes et al., 1990; Chang et 
al., 1990; Ron and Habener 1992), revealing a highly conserved leucine zipper 
and basic DNA-binding domain. This places the C/EBP family in the bZIP family
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o f transcription factors (other members include Fos, Jun, GCN4)
3.4 (i) DNA binding
A characteristic feature of the C/EBP family members is the degenerate 
nature of the sequences to which they bind. Although originally described as 
CCAAT binding protein, substitution of the first C for a G increases the affinity of 
C/EBP for this sequence ten-fold (McKnight and Tjian 1986). It has also been 
reported that C/EBPa can bind to a number of cAMP response elements (Bakker 
and Parker 1991), perhaps due to the similarity of the cAMP response element to 
the enhancer core homology. As these factors bind DNA as dimers and show 
conservation in the DNA binding domain, we would perhaps expect their binding 
sites to show dyad symmetry. However, although some sites show symmetry, 
many are asymmetric yet can still bind homodimers.
Comparison of C/EBPa binding to symmetric and asymmetric sites revealed 
that both sides of the asymmetric site made contacts which stabilised complex 
formation. This was despite only two of the seven nucleotides of the left matching 
those on the right. The contacts essential for C/EBP binding have two-fold 
symmetry and major groove contacts extend over a full turn of the helix for both 
asymmetric and symmetric sites (Nye and Graves 1990).
3.4 (ii) Functional domains
As mentioned previously the C/EBP family are bZIP transcription factors 
and this DNA-binding domain has been well studied. The transactivation domains 
have been mapped for C/EBPa. Two domains are required for the transactivation of 
the serum albumin gene, one of which is NH2 -terminal and the other centrally 
located. These transactivation domains do not show any homology to the acidic, 
proline or glutamine rich domains previously identified (Friedman and McKnight
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1991). Another report identifies three functional domains in the NH2 -terminus, 
two transactivation domains sandwiching an 'attenuator' domain. This attenuator 
dampens down the transactivation mediated by these domains in a number of 
sequence contexts. Whether this domain serves to reduce the activity of these 
transactivation domains (which are extremely powerful in GAL4 fusion-reporter 
experiments) constitutively or can be regulated in vivo is unknown (Pei and Shih
1991).
3.4 (iii) The control of C/EBP activity
As many tissues co-express a number of family members, choice of 
dimerisation partner may have important functional consequences. As all cloned 
C/EBP factors contain a highly conserved leucine zipper this suggests that they be 
able to form heterodimers. Indeed, all family members tested have shown that they 
can dimerise in all intra-familiar combinations (Poli et al., 1990; William et al., 
1991; Cao et al., 1991). In most cases this heterodimerisation does not result in 
any apparent changes in DNA sequence specificity; however, dimers between 
C/EBPa and C/EBPy have a higher affinity for the serum albumin promoter site D 
than either homodimer (Roman et al., 1990). Another consequence of choice of 
dimerisation partner is differential transactivation properties. This was noted in a 
study with cotransfection with a synthetic C/EBP-responsive promoter and C/EBPa 
and C/EBPp expression vectors. C/EBPa had higher constitutive activity than 
C/EBPp. C/EBPa/p heterodimer had dimished constitutive activity, but C/EBPP is 
IL-6 responsive and the heterodimer showed similar levels of induction as 
C /EB Pp/p homodimer (Poli et al., 1990). This may function by altering the 
subcellular location of the heterodimer as C/EBPP is largely cytoplasmic in PC 12 
cells but on stimulation with cAMP localises to the nucleus as well as showing 
increased DNA binding (Metz and Ziff 1991).
A common theme in transcriptional control is the presence of
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heterodimerisation partners which are dominant negative regulators of transcription 
factor activity (c.f. section 2.3 (iii)). These transcription factors act by sequestering 
the positive activators into a heterodimer which fails to bind DNA (e.g. MyoD and 
Id). Examples of dominantly negative C/EBP family members have been isolated. 
CHOP is a developmentally regulated transcription factor which is present in a 
number of terminally differentiated cell types, and is capable of dimerising with 
C/EBPa and C/EBPp. The basic region adjacent to the leucine zipper contains two 
prolines and heterodimers which include this transcription factor are unable to bind 
DNA in vitro (Ron and Habener 1992). Interestingly there are two proteins 
generated from the C/EBPp gene, C/EBPp and LIP. The two proteins are 
generated by different choice of translational start sites. LIP does not contain a 
transactivation domain and can repress C/EBPp activity in a cotransfection assay. 
Interestingly these two isoforms are regulated during hepatic differentiation 
(Descombes and Schibler 1991), and have opposing effects as C/EBPp (but not 
LIP) able to exert a growth arrest in hepatoma cells (Buck et al., 1994).
Phosphorylation is an important mediator of transcription factor control, 
linking signal transduction pathways to gene regulation. The phosphorylation of the 
C/EBP family members has not been intensively studied, however some 
information is available. C/EBPa phosphorlation by PKC can reduce DNA binding 
in vitro, however whether this site has a role in vivo is not known (Mahoney et al.,
1992). The affinity of C/EBPp and C/EBP5 for DNA can be reduced by PKA or 
PKC mediated phosphorylation at sites which are phophorylated in vivo (Trautwein 
etal., 1994; Ray and Ray 1994)
C/EB Pp is phosphorylated in pituitary cells in response to increased 
intracelluar calcium concentrations as a consequence of activation of a calmodulin- 
dependent protein kinase. A reporter gene containing C/EBP binding sites was 
rendered calcium-responsive in these cells. The phosphorylation site is at a serine 
residue within the leucine zipper, suggesting that this may be important in the 
choice of dimerisation partner (Wegner et al., 1992). Phosphorylation also mediates
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the translocation to the nucleus of C/EBPp in response to elevation of cAMP in 
PC 12 cells, this translocation does not require protein synthesis and correlates with 
increased phoshorylation of C/EBPP (Metz and Ziff 1991).
3.4 (iv) The role of C/EBP family in myeloid differentiation
Given the important role of the C/EBP family in differentiation in other 
systems, what role does this family play within the myeloid lineage? The 
expression pattern of the isoforms in myeloid cells differs from that of adipose and 
hepatic tissue, with an increase in C/EBPp rather than C/EBPa as cells become 
terminally differentiated (Scott et al., 1992). As discussed in section 3.1, the chick 
homologue of C/EBPp (Katz et al., 1993) and c-Myb are involved in the regulation 
of the mim-1 gene (Ness et al., 1993; Burk et al., 1993). Surprisingly, when 
expressed in fibroblasts these transcription factors could activate the endogenous 
mim-1 and the myeloid-specific lysozyme genes (Ness et al., 1993). In the chick 
haemopoietic system, C/EBPp is restricted to the myeloid compartment, and it has 
been suggested that together c-Myb and C/EBPp may produce a myeloid-specific 
phenotype. The importance of C/EBPp in myelopoiesis is underlined by its 
involvement in the regulation of the chick cMGF gene (Katz et al., 1993; Sterneck 
et al., 1992) which is distantly related to the mammalian G-CSF and IL-6 genes 
(Leutz et al., 1984; 1989). It is also of interest to note that those cells which v-Myb 
can transform express C/EBPp.
Clearly this family of transcription factors plays a key role in myelopoiesis, 
which merits further study. The question of how close the mammalian system 
reflects the avian remains unanswered, as although the presence of C/EBP proteins 
have been reported to be limited to the myeloid compartment within the 
haemopoietic system (Scott et al., 1992), the expression of C/EBPp is much more 
widespread in mammalian tissues than in the chicken (Katz et al., 1993).
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3.5 The Ets family of transcription factors
The first member of the Ets family to be identified was \-ets  in the chicken 
E26 transforming retrovirus as a fusion product with the Myb transcription factor 
(Nunn et al., 1983). This Myb-Ets fusion is the result of an aberrant splicing event 
between the a cryptic splice donor site in c-myb exon VI and the splice acceptor site 
of exon I of the c-ets-1 proto-oncogene (Leprince et al., 1988). Since this gene was 
discovered, a large and expanding family of Ets proteins has emerged. Family 
members have been cloned from species as diverse as Drosophila to human and all 
members encode sequence-specific transcription factors.
3.5 (i) Functional domains of the Ets proteins
Sequence comparison of family members revealed a number of conserved 
regions, most notably the presence of a unique DNA binding domain. This domain 
has limited homology to the DNA binding domain of c-Myb, which has 9 
tryptophan residues repeated at 18-19 amino acid intervals around a predicted a- 
helical structure (Karim et al., 1990). The Ets domain contains a single triplet of 
tryptophan residues with 17-18 amino acid spacing. All family members identified 
todate contain this triplet, with the exception of Spi-1 (PU.l) and Spi-B which have 
replaced the third tryptophan with a tyrosine residue (Ray et al., 1992).
The minimal DNA-binding domain of the chicken c-Ets-1 has been mapped 
by deletion analysis, this domain includes the Ets domain and surprisingly C- 
terminal sequences outside the Ets domain. These sequences may be important in 
mediating the specificity of DNA binding as these amino acids are conserved 
between Ets-1 and Ets-2, both of which can bind to the PEA3 motif with high 
affinity, whereas v-Ets which has lost these sequences cannot. However neither of 
these proteins can bind to the Ets binding site in the m bl promoter with high 
affinity, both PUT and v-Ets can. Deletion of these COOH terminal amino acids
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increases the specific binding by 20 to 50 fold at this site (Hagman and Grosschedl
1992). However, a conflicting result (Lim etal., 1992), demonstrated that c-Ets-1 
was unable to bind a PEA3 site efficiently, but v-Ets could. Deletion of an 
inhibitory domain increased binding of c-Ets to this site.
Domain swap experiments involving p68 c-ets-1 have identified three 
transactivation domains RI, II & III. When fused to a lexA DNA-binding domain 
both RI and RIII can transactivate, but RII has no activity alone. RII however has a 
negative effect on the transactivation by RI and a positive effect on that of RIII 
(Schneikert et al., 1992). Interestingly the RII region of the protein maps to a 
sequence which has limited homology to the helix-loop-helix motif, and this region 
is conserved in a number of the Ets proteins (Pongubala et al., 1992) although the 
functional significance of this homology is not clear. The transactivation domains of 
the PU.l protein have also been mapped, and contain a glutamine rich and an acidic 
rich region which may be important in this activity (Pongubala et al., 1992).
The Ets proteins also contain a nuclear localisation signal similar to that of 
the SV40 large T antigen, this region has been demonstrated to be sufficient to 
localise c-ets-1 to the nucleus (McCleod et al., 1992). A number of family members 
also contain a PEST sequence; these sequences are rich in proline, glutamine, 
serine and threonine and are thought to be a target for proteases. Cleavage at the 
PEST sequence could lead to the separation of the DNA-binding domain from the 
rest of the protein. In PU.l, the PEST sequence is involved in protein-protein 
interactions with other transcription factors and dimerisation may prevent access of 
proteases to this sequence which may have important regulatory consequences 
(Pongubala et al., 1992).
3.5 (ii) The regulation of Ets protein activity
The control of Ets protein activity is mediated at a number of levels. 
Different Ets family members show very different expression patterns. For example
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ets-1 is preferentially expressed in adult lymphoid tissues, with high levels also in 
the spleen and lung whereas expression of PU.l is limited to macrophage and B 
cells. In contrast ets-2 is expressed in almost every tissue (Seth et al., 1990; Bhat et 
al., 1987; Klemsz et al., 1990). The expression can also be varied under different 
conditions; for example in T cells Ets-1 is at high levels in quiescent cells and 
decreases following T-cell activation, whereas Ets-2 levels follow the reciprocal 
pattern (Bhat et al., 1990).
Tissue specificity is also generated by alternative splicing. Both chicken and 
human c-ets-1 are alternatively spliced in a tissue-specific manner (LePrince et al., 
1988; Koizumi et al., 1990); exons IV and VII, containing a negative regulatory 
region (which affects DNA binding), is spliced out in endothelial cells but not in T- 
cells. Interestingly Ets-2 also contains this domain but PU.l lacks it.
The Ets family members are also regulated post-translationally with 
phosphorylation being an important mediator of activity. Phosphorylaton of both 
Ets-1 and Ets-2 as a consequence of T-cell activity results in the loss of non-specific 
DNA binding activity of Ets-1 and stabilisation of Ets-2 half-life (Pognec et al., 
1988; Fujiwara et al., 1988, 1990). TCF, an Ets family member is phosphorylated 
by MAP kinase in response to serum stimulation, which allows it to complex with 
the serum response factor over the serum response element (Gille et al., 1992). 
Similarly activation of the oncogene-responsive element of the polyoma virus 
enhancer by TPA or non-nuclear oncogenes requires Raf-1 which is upstream of 
MAP kinase (Kryiakis et al., 1992), which could phosphorylate Ets proteins to 
activate this element.
3.5 (iii) DNA binding
All of the Ets family of transcription factors bind to sites containing a core 
GGAA/T, however the surrounding sequence mediates the specificity of binding. 
Many of these Ets binding sites can be bound by a number of different Ets proteins;
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for example the PEA3 element can be bound by Ets-1, Ets-2, Elk-1 and PEA3 and 
each of these proteins can transactivate DNA through this element (Wasylyk et al., 
1990; Rao and Reddy 1992; Xin et al., 1992). In vitro the Ets proteins bind DNA 
in the absence of other proteins and appear to bind as monomers. In vivo the 
situation is more complex, with protein-protein interations playing a key role in 
mediating binding specificity and transactivation properties.
The oncogene-response region of the polyoma virus enhancer can be 
activated by TPA or non-nuclear oncogenes. This element contains a PEA3 site 
which can bind Ets-1 or Ets-2 in response to these signals. This PEA3 site is 
juxtaposed to an API site and these show synergistic activity. Mutation in either of 
these sites reduces activity, but not to the level of only having a single element 
present suggesting that protein-protein interactions may involved in co-operative 
binding/transactivation (Wasylyk et al., 1989; 1990). Adjacent AP1/PEA3 sites are 
found in several promoters of oncogene responsive genes e.g. collagenase, c -fos 
suggesting that this may be a common mechanism of activation. Another case of an 
Ets family member interacting with another protein allowing it to activate 
transcription is exemplified by the immunoglobulin K 3' enhancer. In this case 
PUT recruits another factor to an adjacent site by protein-protein interactions 
(Pongubala et al., 1993).
Two Ets family members SAP-1 and elk-1 exhibit the p62/TCF activity 
(Hipskind et al., 1991; Dalton and Triesman 1992). This activity cannot recognise 
the serum response element (SRE) of the c-fos promoter alone. However, when 
the SRE is bound by the serum response factor it can bind to this complex and make 
sequence-specific contacts with the adjacent sequence (Rao and Reddy 1992). In the 
absence of any other proteins Elk-1 can also bind to the E74 sequence and act as a 
transcriptional activator. This illustrates the importance of the context of the Ets 
binding site and the interactions with other transcription factors in mediating DNA 
binding specificity and transcritpional activation.
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3.5 (iv) Target genes for Ets family members
A large number of genes have been found to contain Ets binding sites in 
their promoters (Ho et al., 1990) including oncogene responsive genes, a 
significant number of lymphoid-specific genes e.g. T-cell receptor a  gene and 
genes involved in the degradation of the extracellular matrix e.g. stromelysin 1 , 
collagenase (Wasylyk et al., 1992) and genes involved in tissue-specific expression 
(Pahl et al., 1993). A number of these genes have been demonstrated to be 
transactivated by a specific family member. These include PU.l, which has been 
demonstrated to be important in the myeloid-specific expression of the CD1 lb gene 
and Ets-1 which has been implicated in the megakaryocyte-specific expression 
(Lemarchandel et al., 1993). Given the restricted expression pattern of these two 
genes, they may play an important role in the tissue-specific expression of a number 
of genes.
3.5 (v) The Ets proteins and cancer
The insertional activation of fli-1  and spi-1 in viral induced murine 
leukaemias and the role of the v-ets gene in conferring the ability to transform 
immature erythroid progenitors on the E26 virus is clear evidence of their 
importance in tumourigenesis. A number of common translocations found in human 
leukaemias are potentially involved in activating expression of a number of ets 
genes (reviewed in Papas etal., 1990). The only conclusively demonstrated case of 
activation/alteration of ets genes playing a role in human tumours is in Ewings 
sarcoma. This is characterised by a translocation which results in a fusion protein 
containing the DNA binding domain of Fli-1 linked to a putative RNA binding 
protein, although the mechanism of this fusion proteins action is unknown (Delattre 
et al., 1992)
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3.6 Structure and expression of the human defensin genes
The chromosomal location of the human defensins has been mapped to 8p23 
(Sparkes et al., 1989). Fine mapping has not been undertaken for the human 
genes, however the rabbit genes have been studied in more detail. This has 
revealled the MCP1 and MCP2 genes are contained within a 13kb stretch of DNA 
(Lehrer et al., 1989). The genes encoding HNP1 and HNP3 genes have been 
cloned and analysed, revealing that individuals contained different copy numbers of 
HNP1 and HNP3 encoding genes. The results from a limited family study 
suggested that individuals contain four defensin genes, two per chromosome 8 , 
which are tightly linked (Lamb 1990). No information is available as to the copy 
number or chromosomal organisation of the gene encoding HNP4.
The expression of the defensin genes occurs predominantly in the myelocyte, 
with transcription coinciding with the production of prim ary granules. 
Consequently the defensin genes are expressed in both normal and leukaemic bone 
marrow, but only in the peripheral blood of chronic myeloid leukaemia patients and 
ocassionally in the peripheral blood of acute non-lymphocytic leukaemia. The 
expression of the defensin genes being coincident with the present of myelocytes in 
the samples (Wiedemann et al., 1983; Daher et al., 1988). Low levels of expression 
have also been reported in the promyelocyte cell line HL60, and levels are 
increased when the cells are induced to differentiate towards granulocytes (Daher et 
al., 1988).
There have also been reports of defensin expression in cells other than 
immature granulocytes. In rabbit two defensins MCP 1 and MCP 2 are found in 
adult alveolar macrophage, and the levels of these two proteins can be increased by 
challenging the rabbit with Freunds adjuvant (Ganz et al., 1989). A survey of 
tumour tissue and surrounding normal tissue revealed occasional defensin mRNA in 
lung and intestine (Daher et al., 1988). Whether this is the result of infiltration of 
phagocytes stimulated to produce defensin mRNA is unknown.
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3.7 Purpose of the project
As discussed in section 3, relatively few genes which are transcriptionally 
regulated during myelopoiesis have been analysed in detail. Similarly little 
information is available with regard to the transcription factors which control the 
differentiation program during myelopoiesis, or confer a myeloid phenotype.
Transcription factors have been demonstrated to play a central role in the 
control of differentiation in a number of systems, such as MyoD in myopoiesis 
(section 2.7). In addition to being key regulators of differentiation, the alteration of 
the normal properties of transcription factors is an important target in 
leukaemogenesis . This can be either a result of deregulated expression (for 
example as generated by the translocation activating c-myc in Burkitts lymphoma or 
TAL/SCL activation in T-cell ALL (Rabbitts and Boehm 1991; Baer 1993) or 
alteration of the properies of the transcription factor (most notably, as generated by 
the RARa gene rearrangements seen in APL, section 1.3 iv). As the alteration of 
the properties of transcription factors involved in normal proliferation/differentiation 
seems to be a key event in leukaemic transformation, the identiifcation of the 
transcription factors which control these processes is an important step in the 
understanding of how this process can be deregulated in leukaemia.
An approach to understanding the control of differentiation, is to analysis 
the regulation of genes which are expressed in a differentiation-specific manner. As 
described in section 3.6, the expression of the defensin genes is restricted to a very 
limited 'window' during myelopoiesis, namely the myelocyte. This allows a 
unique opportunity to study both how the differentiation stage-specific and myeloid- 
specific expression of these genes is mediated. Identification of the ds-acting  
sequences which are necessary for this control, and analysis of the transcription 
factors which mediate these activities will be instructive in understanding the control 
of normal myelopoiesis and how this may be altered to generate maturation arrest
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and leukaemia.
The aims of this work were to identify those c/s-acting sequences which 
control the differentiation stage-specific and myeloid-specific expression of these 
genes and to characterise and identify the fruws-acting factors which bind these 
elements.
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Part 2: Materials and Methods
Chapter 4: Methods
4.1 Cell culture
4.1 (i) Cell culture conditions
Cells were obtained from Beatson Institute stocks, which were regularly 
tested for the presence of mycoplasma using the Hoechst 33258 staining method 
(Chen 1977).
Most cells were maintained in special liquid medium (Gibco BRL) 
supplemented with 10% Foetal calf serum and 2mM glutamine, gassed to 5% CO2 
and incubated at 37°C. Where appropriate, cells were maintained in RPMI-1640 
(Northumbria Biologicals Ltd), supplemented with 0.2% sodium bicarbonate, 
2mM sodium pyruvate, and 10% foetal calf serum.
Cells cultures were routinely passaged every 2-3 days to maintain cells in a 
continuously growing state. Monitoring of cell numbers was carried out using a 
Coulter counter (Coulter Electronics Ltd., Bedfordshire UK) or a haemocytometer. 
Frozen stocks were stored in liquid nitrogen in 10% DM SO.
4.1 (ii) Induction of differentiation
The exact protocol depended on the cell line to be induced and the agent to 
be used. Typically the cells were split the day prior to the induction. If the agent 
prevented further cell division i.e. TPA treatment of HL60 cells, then the cells were 
split to 0.5x1 O^/ml on the previous day. If the agent did not block cell division 
then consideration of the number of divisions that would take place during the 
experiment was necessary.
Dimethyl sulphoxide; HL60 cells were treated with DMSO to give a final 
concentration of 1.5 % (v/v) in the medium.
Retinoic acid; Stock solution was made up fresh for each induction at 10"2 M, and 
stored at -20°C in the dark. HL60 cells were treated with retinoic acid to give a final
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concentration of 10“6 M. This was added fresh every day of the induction period. 
The induction was carried out in the dark.
TPA; HL60 cells were treated with TPA (dissolved in acetone) to give a final 
concentration of 1.6 xlO '7M.
4.1 (iii) Cell staining - May-Grunwald and Giemsa staining
Cells were spun onto glass slides using a Shannon cytocentrifuge at 2000g 
for 5 minutes and air dried. The cells were then fixed in 70% methanol. May- 
Grunwald stain was prepared by diluting 2 volumes of stain in 3 volumes of 
Sorensen's buffer pH 6.85 (0.066M disodium orthophosphate, 0.066M potassium 
dihydrogen orthophosphate) and filtering through Whatman 3MM paper. Giemsa 
stain was also diluted in Sorensen's buffer (1 volume stain: 9 volumes buffer) and 
filtered. The slides were stained for 5 minutes in May-Grunwald and then for 10 
minutes in Giemsa. They were then washed in double-distilled water, air dried 
mounted in DPX mountant (BDH), and examined by light microscopy.
4.1 (iv) Nitroblue tetrazolium
1x10^ cells were harvested by centrifugation in an MSE Centaur bench 
centrifuge at 2000g for 5 minutes at room temperature. The supernatant was 
discarded and the pellet was resuspended in lOmM tetradecanoyl phorbol acetate 
(Sigma) containing 0.2% (w/v) nitroblue tetrazolium in PBS. The cell suspension 
was incubated at 37°C for 25 minutes. 0.5ml of the cell suspension was removed 
and the cells centrifuged onto a clean glass slide using a Shannon cytocentifuge. 
The slide was then stained as described in the previous section.
4.1 (v) Preparation of white blood cells from buffy coats
Buffy coats were supplied by the West of Scotland Blood Transfusion 
Service. To the buffy coat, 5 volumes of erythrocyte lysis buffer (0.83% NH4 CI 
(w/v), 0.037g/l NA2EDTA, lg/1 KHCO3) was added and incubated on ice for 10
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minutes. This was then centrifuged 15()()g/5 minutes/4°C in a Beckman J6 B, the 
supernatant was removed and the pellet was resuspended in PBS. The procedure 
was repeated until all the red colouring in the pellet was lost. The pellet was then 
washed in PBS.
4.2 Recombinant DNA techniques
4.2 (i) Host strains
E.coli. XL1 (Bullock et al., 1987) were obtained from Institute stocks, and 
were grown in L-broth at 37°C with good aeration, ampicillin (lOOpg/ml) and 
tetracyclin (12.5pg/ml) were used when appropriate.
4.2 (ii) Generation of competent cells
4ml of an overnight culture of XL1 was inoculated in 500ml of L-broth and 
grown at 37°C with good aeration until the absorbance at 550nm had reached 
between 0.4 and 0.6 (lcm  light path, L-broth blank). The cells were collected by 
centrifugation in a Beckman J 6 B at 3000g/10 minutes/4°C. The pellet was 
resuspended in 250ml lOOmM M gCb and repelleted. The supernatant was 
discarded and the pellet resuspended in 250ml of lOOmM CaCl2 , incubated on ice 
for 40 minutes and respun. The pellet was resuspended in 15ml of lOOmM 
CaCl2/ 2 0 % glycerol. Aliquots were flash frozen in liquid nitrogen and stored at 
-70°C.
4.2 (iii) Transformation of bacterial cells
Competent cells were thawed slowly on ice, and 100|il placed into pre­
chilled 15ml falcon 2059 tubes. Plasmid or ligation mix was pipetted into the cells, 
mixed by gently tapping the tube and incubated on ice for 30 minutes. The cells 
were heat shocked at 42°C for 2 minutes, lm l of L-broth was then added and 
incubated for 1 hr at 37°C in a New Brunswick G25 shaker at 225rpm. 100-200pl 
was then spread onto 1.5% (w/v) agar L-broth plates supplemented with the
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appropriate antibiotic. The plates were then allowed to dry and then inverted and 
placed in a 37°C incubator overnight.
4.2 (iv) Glycerol stocks
E.coli. host strains or hosts bearing useful plasmids were stored as glycerol 
stocks for future retrieval. Stationary cultures in L-broth were mixed with an equal 
volume of glycerol and stored at -20°C.
4.3 Preparation of plasmid DNA
4.3 (i) Minipreparation of plasmid DNA
Colonies were picked from agar plates using a sterile toothpick and used to 
inoculate 10ml of L-broth (with appropriate antibiotics), and incubated overnight at 
37°C with good aeration. Cells from 1.5ml of this culture were pelleted in a 
microfuge, and resuspended in lOOpl of solution A (50mM glucose, 25mM tris.Cl 
pH 8 , lOmM EDTA, 4mg/ml lysozyme) and stored on ice for 5 minutes. 200|il of 
alkaline lysis buffer (1% SDS, 0.2M NaOH) was added, mixed gently and 
incubated on ice for 5 minutes. 150|dl of 3M NaAc (pH 5.2) was added, the 
solution was vortexed and microfuged at 12000g/5minutes/4°C. 380pl of the 
supernatant was removed and a phenol/chloroform extraction was performed. 
Plasmid was then precipitated by the addition of 800jll1 of ethanol, incubated at 
room temperature for 2 minutes, then pelleted in a microfuge at 1 2 0 0 0 g/1 0  
minutes/4°C. The pellet was resuspended in 50pl of TE containing 10|ig/ml of 
RNAseA.
4.3 (ii) Large scale plasmid preparation
lm l of an overnight culture was inoculated into 250ml of LB medium 
containing the appropriate antibiotics and grown overnight in an orbital shaker at 
37°C. The culture was harvested by centrifugation in a Beckmann J6 B at 30()0g/10
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minutes/4°C. The supernatant was discarded and a Quiagen (Quiagen Inc.) large 
scale plasmid preparation was carried out as recommended by the manufacturer.
4.4 Quantification of nucleic acids
Nucleic acids were quantified by measuring absorbance at 260nm in a 
Beckman DU 650 spectrophotometer.
4.5 Restriction digests and gel electrophoresis
4.5 (i) Restriction digests
For plasmid DNA, typically 5 units of enzyme/qg of DNA was added in 
the appropriate buffer and incubated for lhour. Restriction digestion of genomic 
DNA was carried out using the desired enzyme at a concentration of 10 units of 
enzyme/(ig of DNA and incubated for 12 hours. Spermidine pH 7 was included to a 
final concentration of 3mM. At the completion of the digest, the reaction was 
stopped by the addition of EDTA pH 8 to 20mM.
4.5 (ii) Agarose gel electrophoresis
An agarose solution was made using lxTBE buffer (89mM Tris base, 
89mM boric acid, 2mM EDTA, pH 8.0) and an appropriate amount of agarose 
(dependent on the size of the DNA molecules to be separated, see Sambrook et al., 
1989). This was heated in a microwave and then ethidium bromide was added to a 
final concentration of 0.5pg/ml and the solution was poured into a horizontal gel 
mould when hand hot. The DNA samples were mixed with one-tenth volume of gel 
loading buffer (50% glycerol, 1% bromophenol blue, lOmM sodium phosphate 
pH 7) and applied to the wells using a micropipette. Gels were run at 10-100 volts 
depending on the size of the gel tank and the time available. Markers were run 
simultaneously and were usually lambda 'phage DNA digested with Hindlll for the 
sizing of large fragments and 8X174 DNA digested with HaelU for sizing of small 
fragments (Promega). The DNA was then visualised by UV fluorescence on a
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Chromato-Vue transilluminator, then photographed through a red number 9 Kodak 
Wratten gelatin filter.
4.5 (iii) Non-denaturing polyacrylamide gel electrophoresis (PAGE)
A 30% stock acrylam ide solution was made up containing 
l%N,N'methylbisacrylamide. This stock solution was used to cast vertical gels of 
various concentrations, depending on the size of the fragments to be resolved. The 
gel contained TBE, the concentration of which was varied depending on the 
concentration of acrylamide used in the gel (see Sambrook et al., 1989 for details). 
The gel was set by the addition of 250|il of 10% ammonium persulphate (APS) 
and lOOpl of TEMED per 5()mls of gel solution. The gel was run in a vertical tank 
at a constant current of 25mA, and the DNA was visualised by staining with a 
solution of 0.5|ig/ml ethidium bromide and UV illumination.
4.5 (iv) Denaturing polyacrylamide gel electrophoresis
These gels were cast on glass plates (20cm x 45 cm) which had been 
cleaned and siliconised. The plates were separated by 0.5mm spacers and the 
polyacrylamide gels were made up as described by Sambrook et al., (1989); 6 % 
acrylamide, 0.2% bis-acrylamide, 1 X TBE, 8 M urea, 0.08% APS and 0.05% 
TEMED. Running conditions were usually 1600V, 50W. At the end of the run, 
the glass plates were separated and a sheet of Whatman 3MM paper was placed on 
top of the gel. The gel sticks to the Whatman paper and can be peeled from the 
plate. It was covered with Saran-wrap, dried on a commercial gel drier at 80°C for 
2 hours before autoradiography.
4.5 (v) Purification of DNA fragments from agarose gels
The fragment was excised from the gel using a scalpel. This gel fragment 
was placed into a pre-prepared eppendorf column and microfuged at 5000g for 5 
minutes. The resultant liquid was subject to phenol/chloroform extractions,
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precipitated and resuspended in an appropriate volume. The columns were prepared 
by placing a 0.5ml eppendorf tube inside a 1.5ml screw cap eppendorf tube. A hole 
was pierced in the base of the 0.5ml tube and this was filled with polyallomer wool. 
The agarose fragment was placed on top of the wool. The liquid is recovered after 
centrifugation and is found in the bottom of the screw cap eppendorf tube.
4.6 Subcloning of DNA
4.6 (i) Generation of vectors for cloning fragments
Plasmids were digested with the appropriate restriction enzyme, included in 
the reaction was lp.1 of calf intestinal alkaline phosphatase (CIAP, Boehringer 
Mannheim). For the generation of blunt-ended vectors, the reaction was transferred 
to a 56°C water bath and incubated for a further 30 minutes with the addition of 
another lpl of CIAP. EDTA (pH8 ) and SDS were added to a final concentration of 
5mM and 0.5% respectively. Proteinase K was added to a concentration of 
100pg/ml and the reaction was incubated at 56WC for 30 minutes. The reaction was 
phenol/chloroform extracted, chloroform extracted and precipitated, the pellet was 
then resuspended in 100|il of EbO.
4.6 (ii) Preparation of inserts for cloning
Inserts were generated by either restriction enzyme digest of plasmid DNA 
or by PCR followed by digestion. These reactions were phenol/chloroform 
extracted, chloroform extracted and purified after agarose gel electrophoresis. The 
inserts were quantified after purification, by gel electrophoresis of a fraction of the 
insert and comparison with markerDNA of known concentration.
4.6 (iii) Ligation reactions
For each ligation the following controls were set up; vector alone, 
unphosphorylated vector and insert alone. To each reaction lOOng of vector was 
added, and usually a four-fold molar excess of insert. In addition, another three
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reactions were set up containing different amounts of insert, ranging from 
equimolar to a 10 fold molar excess of insert to vector. Water was then added to a 
final volume of 7(ll1. The reaction was heated to 45°C for 5minutes and then chilled 
on ice for 5 minutes. To each reaction, 2p.l of 5X T4 ligase buffer (supplied with 
the enzyme) and lq l of enzyme (NBL) was added. For 'sticky end' ligations, 0.1 
Weiss units was added, whereas 0.5 Weiss units were added for blunt end 
ligations. The reaction was incubated at 14°C for 4-16 hours, and typically 2p.l of 
the ligation mixture was used for transformation.
4.7 Synthesis of oligonucleotides.
Oligonucleotides were synthesized at the Beatson Institute on an Applied 
Biosystems model 381A DNA synthesizer according to the manufacturers 
instructions. 5' trityl groups were removed by the machine, and the DNA 
immobilized on a column. The DNA was eluted from the column in 29% (v/v) 
ammonia, by passing the ammonia continuously through the column for three 5- 
minute periods separated by 20 minute intervals. The resulting DNA-ammonia 
solution was sealed in a glass vial, incubated overnight at 55°C, then precipitated 
after additon of ammonium acetate to 0.3M with 3 volumes of ethanol. DNA was 
pelleted by centrifugation at 12000g in a Sorvall SS-34 rotor for 15 minutes, 
redissolved in 3 ml of aqueous 0.2 M sodium acetate, precipitated with 3 volumes 
of 100% ethanol, then pelleted by centrifugation. The DNA pellet was washed with 
70% (v/v) ethanol and dissolved in 1 ml of distilled water. After quantitation by 
spectrophotometry, oligonucleotides were stored at -20°C until required.
4.8 Polymerase chain reaction
4.8 (i) Design of PCR oligonucleotides.
In each case, two single-stranded oligonucleotide primers generally 20-40 
bases in length, were designed such that they were complementary to opposite 
strands and opposite ends of the DNA sequence of interest. Oligonucleotides
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contained a number of nonspecific nucleotides at their 5 ' ends followed by a 
restriction enzyme recognition sequence, allowing subcloning of the PCR- 
generated DNA fragment into the appropriate restriction sites of the chosen plasmid 
vector. The 3' end of oligos was either a G or a C base if possible, in order to 
enhance priming from the oligonucleotide.
4.8 (ii) PCR reactions.
The template for PCR reactions was linearized plasmid DNA, containing the 
sequence of interest at a concentration of lOOng/reaction, was combined in a PCR 
reaction tube with 25 pmols. of each PCR primer, lOpl of Taq polymerase buffer 
(provided with Taq enzyme by the manufacturers), 2|il from 5 mM stock solutions 
(in distilled water) of each of dATP, dTTP, dGTP and dCTP, 6 p.l of 25mM 
MgCl2 , 0.5pl of Taq polymerase and distilled water to a final volume of lOOp.1. The 
solution was overlayed with 50pl of parafin oil, then incubated in a PCR machine 
(Perkins-Elmer) for 25 of the following cycles: 1) 95°C for 1 minute; 2) 55°C for 1 
minute; 3) 72°C for 90 seconds. Reactions were incubated for 15 minutes at 72°C 
after the final cycle, then gradually cooled to 4°C. Each reaction was extracted with 
one volume of chloroform, ethanol precipitated, analysed by agarose gel 
electrophoresis and the relevant band purified, restriction digested and resuspended 
in distilled water.
4.9 Sequencing plasmid DNA
4pg of plasmid in a total volume of 20jnl of 0.2M NaOH was incubated at 
37°C for 30 minutes. The DNA was then precipitated by the addition of 8 |il 5M 
ammonium acetate pH 5.2 and lOOpl ethanol and incubated for 5 minutess on dry 
ice, then spun at 12000g/5 minutes/4°C in microfuge. The pellet was washed in 
70% ethanol and resuspended in 7|il H2O lpl of primer (3ng), 2ptl reaction buffer 
(USB sequenase kit) and incubated at 65°C for 2 minutes then slowly cooled to
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room temperature. The sequencing reactions were then carried out using a 
sequenase kit (USB) as recommended by the manufacturers.
4.10 Isolation of RNA
Preparation of total cytoplasmic RNA was prepared using the RNAzol B 
method (Biogenesis Ltd.). Cells were harvested in an MSE bench top centrifuge at 
150()g for 5 minutes. The cells were resuspended in RNAzol at 2ml per 10 cells 
and 200|il of chloroform. The samples were vortexed for 15 seconds, and 
incubated on ice for 5 minutes. The samples were then centrifuged at 12000g at 4°C 
for 15 minutes. The upper aqueous phase was transferred to a fresh tube, 
precipitated with a half volume of isopropanol at 4°C for 15 minutes and 
centrifuged at 12()()()g for 15 minutes at 4°C. The pellet was washed with 70% 
ethanol and resuspended in Diethylpyrocarbonate (DEPC) treated water.
4.11 Northern blot analysis
4.11 (i) Agarose electrophoretic separation of RNA
To 87ml of DEPC treated H2O, lg  of agarose and 10ml lOxMOPS (3-(N- 
morpholino)propanesulphonic acid, 50mM sodium acetate, lOmM EDTA pH 7) 
was added. This was dissolved by heating in a microwave, cooled to hand hot and 
then 5.1ml formaldehyde solution was added. The gel was then cast and run in 
IxMOPS buffer. Samples of RNA were dissolved in DEPC treated water and 10|il 
sample buffer (which was made up fresh before use; 0.75ml deionised formamide, 
0.15ml lOx MOPS, 0.24ml formaldehyde 0.1ml H2O, 0.1ml glycerol, 0.08% 
bromophenol blue) was added per 2pl of sample prior to electrophoresis. An RNA 
ladder (BRL) was run to provide markers on each gel.
4.11 (ii) Northern transfer of RNA
After electrophoresis the gel was soaked in distilled H2O for 1 hour. The 
blot was set up as described in Sambrook et al., (1989), and the RNA was
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transferred onto Hybond N+ nylon membrane (Amersham International) in 
lOxSSC overnight by capillary action. The RNA was fixed to the membrane using 
a UV Stratagene 1800 crosslinker.
4.12 Southern blot analysis
After electrophoretic separation of the digested DNA samples, the gel was 
soaked in 1.5M NaCl, 0.5M NaOH for 2x 20 minutes with gentle shaking, 
followed by soaking in 1M ammonium acetate, 0.02M NaOH for 2x 30 minutes. 
The blot was then set up as described in Sambrook et al., (1989) and transferred to 
Hybond N+ nylon membrane in 1M ammonium acetate, 0.02M NaOH overnight. 
The filter was then rinsed in 2xSSC and the DNA was crosslinked using a UV 
Stratagene 1800 crosslinker.
4.13 Random-primed radiolabelling of DNA probes.
All DNA probes used for hybridisation to Northern and Southern blots were
^9
labelled for 30 minutes at 37°C with [a -‘ Pj-dCTP, using a random-priming kit as 
recommended by the suppliers (Boehringer-Mannheim). After the labelling 
reaction, the probe was separated from unincorporated nucleotides on a Nick- 
column (Pharmacia) equilibriated with O.lx SSC, 0.1% (w/v) SDS. Radiolabelled 
probes were denatured by boiling for 5 minutes prior to use.
4.14 Hybridisation conditions
Hybridisations were carried out as recommended by the manufacturers of 
Hybond N+ (Amersham International), with the inclusion of 50% formamide for 
Northern blots which were carried out at 42°C whereas Southern blots were 
hybridised in the absence of formamide at 65°C. Pre-hybridisations were carried 
out for a minimum of 4 hours, and fresh hybridisation buffer was added containing 
denatured radiolabelled probe at 106CPM/ml and incubated for 16 hours. The filters 
were then washed as recommended by the manufacturers.
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4.15 DNAsel hypersensitivity analysis of chromatin structure
4.15 (i) Isolation of nuclei
The amount of starting material varied, but lxlO 8 cells was optimal. The 
cells were harvested by centrifugation in a Beckman J-6 B at 4000g/10 minutes/4°C, 
washed in PBS and re-centrifuged . The pellet was washed in 100ml TMS (0.25M 
sucrose, lOmM Tris, 5mM MgCl2 , 7mM p-mercaptoethanol) and respun, the 
resultant pellet was resuspended in TMS/0.25% triton and repelleted at 4000g/10 
minutes/4°C. The pellet was washed in 100ml TMS X 2 and resuspended in 5ml 
TMS (the integrity of nuclei was assessed by light microscopy).
4.15 (ii) DNAsel treatment and purification of DNA
The nuclei were split into a number of tubes each containing 0.5-lml nuclei, 
to each of these tubes was added lpl 1M MgCl2 and DNAsel (Lome Laboratories 
Ltd) between 0.1 and lOpg/ml final concentration. The samples were made up to 
lm l with TMS and incubated at 37°C for 5 minutes. The reactions were then 
stopped by the addition of 9ml of stop solution (lOmM Tris pH7.8, 0.5% SDS, 
5mM EDTA, 5()|ig/ml proteinase K). These reactions were then incubated at 37°C 
overnight with gentle agitation. The solution was then extracted sequentially, twice 
with 1 volume of phenol, once with 2 volumes of phenol/chloroform/IAA, and 
once with 1 volume of chloroform/IAA. Sodium chloride was added to a 
concentration of 0.2M, nucleic acids were ethanol precipitated overnight at -20°C, 
pelleted, dissolved in 2 ml of 5x TE [pH 8.0] buffer, and digested overnight at 4°C 
with lOOpg/ml of DNase-free RNaseA. Samples were then sequentially extracted 
with phenol/chloroform/IAA and chloroform/IAA, the nucleic acids were ethanol 
precipitated overnight, pelleted and resuspended in TE buffer.
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4.16 Nuclear protein preparations
4.16 (i) Protease inhibitors
All solutions used for the preparation of nuclear protein contained a cocktail 
of the following protease/phosphatase inhibitors which were added fresh to the 
solutions: 5()mM phenylmethyl-sulphonyl fluoride made up in isopropanol (l(X)x); 
5 ()mM benzamidine (lOOx); 1M sodium butyrate (lOOx); 200mM levamisole 
(lOOx); lOOmM sodium orthovanadate (2()()0x); leupeptin 1 mg/ml (lOOOx); 
aprotinin lmg/ml (l(X)Ox); bestatin lmg/ml (l(X)Ox); pepstatin A lmg/ml in ethanol 
(lOOOx); 14.4M (3-mercaptoethanol (2000x). All inhibitors were obtained from 
Sigma.
4.16 (ii) Minipreparation of nuclear extracts
Typically lxlO 7 cells were used as starting material, although as few as 
5x1 cells could be used. All centrifugations of less than 30 seconds were carried 
out at room temperature in a microfuge; between the steps samples were placed on 
ice. Adherent cells were harvested by scraping into 1.5ml of ice cold PBS, 
suspension cells were pelleted and resuspended in 1.5ml PBS. Cells were 
microfuged for 10 seconds and resuspended in 400|il buffer A (lOmM Hepes-KOH 
pH7.9, 1.5mM MgCl2 , lOmM KC1, 0.5mM DTT) by flicking the tube. The cells 
were allowed to swell on ice for 10 minutes, and then vortexed for 10 seconds. 
Samples were then microfuged for 10 seconds and the pellet was resuspended in 
100p.l of buffer B (20mM Hepes-KOH pH7.9, 25% glycerol, 420mM NaCl, 
1.5mM MgCl2 , 0.2mM EDTA, 0.5mM DTT) and incubated on ice for 20 minutes. 
Cellular debris is removed by centrifugation 12000g/2 minutes/4°C and the 
supernatant is aliquoted and stored at -70°C. The yield was typically 50-75|ig/106 
cells (Andrews and Faller 1991)
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4.16 (iii) Large scale preparation
This preparation was typically carried out using a minimum of 5x l0 8 cells. 
Cells were harvested by centrifugation in a Beckman J-6 B at 4000g/5 minutes/4°C. 
The pellets were washed in PBS and respun. The pellets were pooled in a falcon 
tube in 50ml of PBS and respun at 4000g/15 minutes/4°C. The pellets were then 
washed in TMS and spun at 4000g/10 minutes/4°C. The supernatant was discarded 
and the packed cell volume was estimated. The pellet was then resuspended in 4x 
this volume of TMS/0.1% triton and incubated on ice for 10 minutes. This was then 
homogenised using Dounce B horaogeniser with 25 strokes. This solution was 
placed in falcon 2059 tubes and spun in a Sorvall HB-4 rotor at 3500g/10 
minutes/4°C. The pellet was resuspended in TMS/0.1% triton and respun. The 
pellet was then washed in TMS and repelleted. The pellet was then resuspended in 
TMS to a volume of 10ml. A total of 750pl of 5M NaCl was added slowly to nuclei 
stirring on ice. The suspension was incubated on ice for 30 minutes. This was then 
spun at 3500g/10 minutes/4°C in a Sorvall HB-4 rotor and the supernatant was 
stored on ice. The pellet was resuspended in 5ml TMS 375|il of 5M NaCl and 
stirred on ice for 15 minutes. This was then pelleted at 3500g/10 minutes/4°C and 
the two supernatants were pooled and spun at 100 OOOg in an ultracentrifuge for 60 
minutes at 4°C. The volume of the supernatant was accurately estimated and 
0.4533g of ammonium sulphate was added per ml of supernatant and the 
suspension was stirred on ice for 30 minutes. The precipitate was spun in a Sorvall 
HB-4 rotor at 12000g/15 minutes/4°C, and the pellet was resuspended in 
TMS/0.35M NaCl and dialysed over night against 1 litre storage buffer (20mM 
Hepes pH 7.8, 50mM NaCl, 5mM M gC h, O.lmM  EGTA, 5mM (3- 
mercaptoethanol, 20% glycerol). The extract was then aliquoted and stored at 
-70°C.
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4.17 Electrophoretic mobility shift assays
4.17 (i) Preparation of double stranded probes
10|ig of complementary oligonucleotides were mixed in lOOpl of TE. This 
was heated to 90°C and slowly cooled to room temperature. Oligonucleotides were 
labelled by one of two methods; oligonucleotides which were blunt ended were 
labelled with yATP using T4 polynucleotide kinase (NBL), those with a nucleotide 
overhang were labelled using klenow polymerase (NBL) with the appropriate 
radiolabelled dNTP(s ). Reactions were performed as described in Sambrook et al., 
(1989). Labelled oligonucleotides were purified after separation by PAGE. The 
labelled oligonucleotide was visualised by autoradiography, the band was cut out 
and eluted into lml of TE by incubation at 37°C for 12 hours.
4.17 (ii) Binding reaction
The appropriate volume of nuclear extract (typically containing lOjig) was 
incubated along with 6 pg poly (dl.dC), 5pl gel shift buffer (final concentration 
lOmM Hepes pH8 , 0.5mM EDTA, lOOmM NaCl, lOmM MgCl2, ImM DTT, 10% 
glycerol, 0.1 mg BSA), approximately 500pg labelled oligonucleotide probe and 
H20  to a total volume of 25|il. Reactions were incubated at room temperature for 
20 minutes before being loaded onto the gel. Where necessary, cold competitor was 
added prior to the addition of labelled probe and incubated on ice for 10 minutes. 
Samples were electrophoresed through 0.5xTBE, 6 % acrylamide gelss in 0.5xTBE 
running buffer (pre-run for 1 hr at 25mA) for approximately 3 hours at 25mA; the 
gel was then dried prior to autoradiography.
4.18 In vitro transcription and translation
The sequence to be transcribed was within the Bluescript plasmid, such that 
the T7 promoter was 5' of the gene. lOpg of the plasmid was linearised by 
restriction digestion of a unique 3 ' site, phenol/chloroform and chloroform 
extracted, precipitated and resuspended at in 2()pl of TE buffer. In vitro
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transcription was carried out with 1 pg of plasmid in 1 x transcription buffer (40mM 
Tris (pH 7.5), 6 mM MgCl2 , 2mM spermidine, lOmM NaCl) with 2.5mM NTPs, 
lOmM DTT, 40U of RNasin and 30U of T7 RNA polymerase in a final volume of 
20pl for 90 minutes at 37°C. 2pl of this reaction was then used to prime a rabbit 
reticulocyte translation reaction (Promega), which was carried out according to the 
manufacturers instructions. Aliquots from this reaction were then used in EMSA 
reactions.
4.19 DNAsel footprinting
4.19 (i) Generation of radiolabelled probes.
The region of to be footprinted was subcloned into bluescript. lOpg of 
DNA was cut with a restriction enzyme linearising the plasmid at one end of the 
sequence to be footprinted. After completion of the digest this reaction was 
phenol/chloroform extracted and precipitated. The resulting pellet was then 
resuspended in nick translation buffer (Sambrook et al., 1989) and the fragment 
was end labelled with the appropriate radionucleotide (e.g. HindlU  requires 
radioactive dATP as the first nucleotide to be ‘filled in’ is dATP) as described in 
section 4.15 (i). Unincorporated nucleotide was removed by precipitation. The 
pellet was then resuspended in H2O and digested with a restriction enzyme which 
cleaves the DNA at a second site which marks the end of the probe. These 
fragments were separated by agarose electrophoresis and the band of interest was 
visualised by autoradiography, purified and resuspended in H2O.
4.19 (ii) Footprint analysis
Each reaction contained lpl of probe (-20000 CPM), 6 pg of poly (dl.pdC) 
(Sigma), nuclear protein and storage buffer (50mM NaCl, 20mM Hepes (pH7.9), 
5mM MgCl2 , 0 .ImM EDTA, ImM DTT, 20% glycerol) to 100 pi. The reactions 
were incubated at 4°C for lhour and at room temperature for 20 minutes. In 
addition control reactions containing an equal amount of BSA instead of nuclear
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protein were included in each experiment. Reactions were set up in triplicate and a 
range of DNAsel treatments were given to test which was optimal. 1-lOp.l of a 
1/10 dilution of HPLC purified RNAse free DNAsel (2mg/ml stock, Worthington 
Ltd.) was added to the reactions which were incubated for 20 seconds at room 
temperature before the addition of lOOpl of stop solution made up fresh before use 
(1.5ml= 1.3ml lOOmM Tris (pH 8 ) lOmM EDTA, 70^1 10% SDS, 60^1 proteinase 
K (lOmg/ml), 38p.l 4M NaCl). These reactions were then incubated at 30°C for 30 
minutes and then 90°C for 3 minutes. The reactions were 2x phenol/chloroform and 
chloroform extracted, then precipitated by the addition of 10|il of 5M LiCl, 600|il 
of ethanol and incubation in dry ice for 15 minutes. The DNA was pelleted in a 
microfuge at 12000g/4°C for 10 minutes. The pellet was washed in ice cold 95% 
ethanol and air dried. This was then redissolved in 10(il of stop buffer (95% 
formamide, 0.1% xylene cyanol, 0.1% bromophenol blue). The samples were 
heated at 90°C for 3 minutes and frozen at -70°C. The samples could then be 
thawed at leisure and ran on a denaturing polyacrylamide gel (minimum of 5000 
CPM/lane).
4.19 (iii) Maxani and Gilbert sequencing reactions
Footprinting probes were sequenced using a kit from NEN according to the 
manufacturers instructions.
4.20 Transfection into mammalian cell lines
4.20 (i) Electroporation
The cell cultures were passaged the day prior to the transfection so the 
cultures were exponentially growing at the time of electroporation. Cells were 
harvested in a MSE bench top centrifuge at 18()()g for 5 minutes (lx lO 7 cells were 
used per transfection) the medium was removed and stored at 37°C. The cell pellet 
was resuspended in 0 .2 ml fresh medium and the cell suspension was added to a
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cuvette (BioRad) containing DNA in 50|il of TE. The cells were electroporated in a 
BioRad Gene Pulser at 250V, 960pF. lml of fresh medium was added to each 
cuvette and the cells were placed in tissue culture flasks containing 4ml of 
conditioned medium with penicillin and streptomycin. The cells were grown in a 
humid 5% CO2 incubator at 37°C and then medium was removed 18 hours after 
transfection for analysis.
4.20 (ii) Assay for secreted placental alkaline phosphatase (SPAP).
2 0 0 jil of cell growth medium was removed from transfected cells for use in 
the SPAP assay (Henthorn et al, 1988). Cell growth medium contains high levels 
of phosphatase activity, which is sensitive to heat-treatment; in contrast, SPAP is 
highly resistant to heat-treatment (Henthorn et al, 1988). Hence, cell growth 
medium from transfected cells was incubated at 65°C for 2 hours prior to use, then 
briefly microfuged, and lOOpl aliquots transferred to plastic cuvettes. DEA buffer 
(1M diethanolamine, 0.28M NaCl, 0.5 mM MgCl2, pH 9.85), and a lOOmM stock 
of p-nitrophenylphosphate (PNPP) in DEA buffer, were used immediately prior to 
the assay, to make a 5 mM stock of PNPP in DEA buffer. 1 ml of this solution 
was pipetted onto each heat-treated sample. Phosphatase treatment of PNPP 
produces p-nitrophenol, which has a yellow colour; thus reactions were incubated 
at 37°C until yellow colour was seen to develop. Colour development was assayed 
spectrophotometrically, by measuring absorbance at 405nm, using heat-treated 
medium from mock-transfected cells as a blank.
4.20 (iii) Assay for human growth hormone (hGH).
This assay is based on the work of Selden et al (1986) and uses the Allegro 
dual growth hormone-specific monoclonal antibody system as recommended by the 
supplier (Nichols Institute Diagnostics Ltd.). Briefly, hGH secreted by transfected 
cells into the cell growth medium is recognised by two anti-hGH protein murine
125
monoclonal antibodies, to different hGH protein epitopes, one of which is [ -I]-
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labelled and the other of which is biotinylated and linked to avidin-coated glass
beads. hGH present in the cell growth medium becomes sandwiched between the
125two antibodies, thus allowing linkage of [ ‘ -1] with the glass beads in amounts
proportional to the levels of hGH present in the sample of cell growth medium. The
125level of [ ~ -I] thus linked to the glass beads is monitored by its gamma-particle
emission, using a Beckmann gamma-counter. 200|il samples of medium were 
removed from transiently transfected cells, and 100 jil of each sample was assayed 
for human growth hormone (hGH) activity.
In all transient transfections, a positive control plasmid pHSVTKGH, in 
which a Herpes Simplex Virus (HSV) promoter drives hGH reporter gene 
expression, and a negative control plasmid pOGH, containing a promoterless hGH 
gene, were used in transfection (co-transfected with the chosen reference plasmid) 
of each of the transfected cell types. In a particular cell type, corrected transient 
transfection expression values for reporter plasmids and for the pTKGH positive 
control were obtained by first deducting background counts (usually -300  cpm), 
then measuring the reference plasmid gene activity in each transfectant, and 
adjusting the measured hGH activity for each transfectant accordingly. The adjusted 
hGH activity of the zero control plasmid (pOGH) was then deducted from the 
adjusted hGH values obtained for the other transfectants. Reporter gene activity 
was compared between cell types by assuming the HSV TK promoter is equally 
active in all cell types, and arbitrarily assigning the corrected hGH activity produced 
by the pHSVTKGH plasmid transfectants as 1 unit in all cell types. Reporter 
plasmid hGH activity in each cell type was then expressed as a multiple of the hGH 
activity of the pHSVTK plasmid.
4.21 Western blotting
4.21 (i) Preparation and quantification of samples
Samples were prepared by washing cells in PBS and then resuspending in 
sample buffer (0.0625M  Tris pH 6 .8 , 2% SDS, 10% glycerol, 5%
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mercaptoethanol). The samples were then boiled for 5 minutes and sonicated. 
Protein content was quantified using a BioRad protein assay kit as recommended by 
the manufacturer.
4.21 (ii) SDS-PAGE
Samples were electrophoresised in vertical polyacrylamide gels. These gels 
were composed of a stacking gel [20ml=3ml acrylamide stock (28.2% 
acylamide:().8 %bisacrylamide), 5ml buffer (0.5M Tris pH 6 .8 , 0.4% SDS), 14ml 
HoO, 60pl 10% APS, 20pl TEMED] and a running gel [40ml=13ml acrylamide 
stock, 9ml buffer (1.5M Tris pH8 .8 , 0.4% SDS), 200|ll APS, 20pl TEMED, H20  
to 40ml]. The running buffer was 25mM Tris pH 8.3, 192mM glycine, 0.1% 
SDS. Samples were ran along with pre-stained size markers.
4.21 (iii) Western blotting
After electrophoretic separation proteins were blotted onto nitrocellulose 
membranes (Schleicher and Schull BA85) using a Sartorious semi-dry blotting 
apparatus as follows. Twelve pieces of Whatman 3MM paper and one piece of 
membrane were cut to the size of the gel and equilibrated in transfer buffer (60mM 
Tris, 50mM glycine, 1.6mM SDS, 20% (v/v) methanol). The gel was rinsed in 
transfer buffer and placed upon 6  pieces of 3MM paper. The membrane was placed 
on the gel and topped with the remaining pieces of 3MM. Air bubbles were 
removed and transfer effected at full power for 15-40 minutes. The membrane was 
removed after the transfer was complete, and could be stored at 4°C if desired. The 
membrane was blocked for 30 minutes in blotto (2.5% non-fat milk powder, 0.1% 
NP40 in PBS) before incubation with antiserum in blotto (1:5000 dilution) for a 
minimum of 4 hours. The membrane was subsequently washed three times in blotto 
before incubation with anti-rabbit IgG conjugated to alkaline phosphatase (1:5000 
in blotto) for 2 hours at room temperature. The membrane was washed extensively 
in blotto and alkaline phosphatase buffer (lOOmM Tris pH 9.5, lOOmM NaCl,
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5 mM M gCl2 ) before development with chromogenic alkaline phosphatase 
substrate. This substrate was prepared by dissolving 16mg nitroblue tetrazolium 
and 8mg of 5-bromo-4-chloro-3-indolyl phosphate in 50ml of alkaline phosphate 
buffer. Substrate solution was added to the membrane and allowed to developed as 
long as necessary before termination by rinsing in water.
104
Chapter 5: Materials
5.1 Tissue culture media and supplies
Supplier: Beatson Institute central services 
Penicillin (7.5mg/ml)
Streptomycin (lOmg/ml)
Sterile PBS
Sterile glassware and pipettes 
Supplier: Fison Scientific equipment, Loughborough, Lies., England.
DMSO
Supplier: Gibco Europe Life Technologies Ltd., Paisley, Scotland.
Special liquid medium 
Foetal calf serum 
2(X)mM glutamine 
Sodium bicarbonate 
Supplier: Northumbria Biologicals Ltd., Cramlington, England.
RPM1-1640 medium 
Supplier: A/S Nunc, Roskilde, Denmark.
Tissue culture flasks 
Nunc tubes
5.2 Bacterial media
Components of media were purchased from BDH Chemicals Ltd., Poole, 
Dorset, England, unless otherwise stated.
Supplier: Beatson Institute central services
L-broth (prepared according to Sambrook et al., 1989)
Sterile glassware 
Supplier: Difco, Detroit, Michigan, USA 
Agar
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Bacto-tryptone
Supplier: Sigma chemical Co. Ltd., Poole, Dorset, England 
Ampicillin 
X-gal
5.3 Plasticware
Supplier: Becton Dickinson Labware, Plymouth, England.
Falcon tubes
Supplier: Bibby-Sterilin Ltd., Stone, Staffs., England.
All bacteriological dishes 
30ml universal tubes
5.4 Kits, columns and miscellaneous
Supplier: Boehringer Mannheim UK, Lewes, East Sussex, England.
Random-primed DNA labelling kit.
Supplier: United States Biochemical, Cleveland, Ohio, USA.
Sequenase version 2.0 kit.
Supplier: Promega, Madison, Wisconsin, USA.
Nuclease-treated rabbit reticulocyte lysate in vitro translation system 
Supplier: Nichols Institute Diagnostics Ltd., Saffron Walden, Essex, England.
Human growth hormone assay kit.
Supplier: NEN Research Products DuPont, Stevenage, Hertfordshire, England.
DNA sequencing system (Maxam & Gilbert).
Supplier: Perkin Elmer Cetus, Norwalk, CT 
GeneAmp PCR reagent kit.
Supplier: Pharmacia Ltd., Milton Keynes, Bucks, England.
Nick columns
106
5.5 Membranes, paper and X-ray film.
Supplier: Amersham International pic, Amersham, Bucks., England.
Hybond N+ nylon membrane 
Supplier: Bethesda Research Laboratories, Gibco Ltd., Paisley, Scotland.
Dialysis tubing
Supplier: Whatman International Ltd., Maidstone, Kent, England.
3MM filter paper 
Supplier: Eastman Kodak Co., Rochester, New York, USA.
X-ray film (X-OMAT AR)
Duplicating film (DUP-1)
Supplier: Presentation technology Ltd., Clydebank, Scotland.
AGFA Rapitone paper (Pl-2 and Pl-4)
5.6 Nucleotides, polynucleotides, RNA and DNA.
The following nucleotides were used to label DNA and were purchased 
from Amersham International pic, Amersham, Bucks., England:
[a -32Pl dCTP, dATP, dTTP, dGTP 3000 Ci/mmol.
|a - 35S| dATP 1000 Ci/mmol.
[y-3 2 P] dATP 50(X) Ci/mmol.
Unlabelled nucleotides were also supplied by Amersham.
Supplier: Pharmacia Ltd., Milton Keynes, Bucks, England.
Poly Idl-dC]
Supplier: Sigma chemical company Co. Ltd., Poole, Dorset, England 
Salmon sperm DNA 
Supplier: Bethesda Research Laboratories, Gibco Ltd., Paisley, Scotland.
DNA markers bacteriophage 0X174 DNA (Haelll-cut) and bacteriophage 1 
DNA (Hind Ill-cut).
RNA ladder 0.24-9.5kb.
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5.7 Enzym es
Supplier: Bethesda Research Laboratories, Gibco Ltd., Paisley, Scotland.
All enzymes not included in the following list.
Supplier: Boehringer Mannheim UK, Lewes, East Sussex, England.
Calf intestinal alkaline phosphatase (lU/p.1)
RNAseA
Supplier: Northumbria Biologicals Ltd., Cramlington, Northumberland, England. 
T4 polynucleotide kinase (l()U/p.l)
Klenow DNA polymerase (lU/p.1)
Supplier: Promega, Madison, Wisconsin, USA.
RNasin (20U/pl)
Supplier: Sigma Chemical Co. Ltd., Poole, Dorset, England.
Lysozyme
Supplier: Lome Laboratories Ltd., Twyford, Reading, England.
DNAsel (Molecular biology grade, RNase and protease free)
5.8 Chemicals
All other chemicals not listed above, were obtained (AnalaR grade) from 
BDH Chemicals Ltd., Poole, Dorset, England, with the following exceptions: 
Supplier: Sigma Chemical Co. Ltd., Poole, Dorset, England.
Bromophenol blue 
Diethylpyrocarbonate (DEPC)
Dithiothreitol 
Nitroblue tetrazolium 
MOPS 
TPA
Retinoic acid
Spermidine
TEMED
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Triton X-100 
Xylene Cyanol 
Supplier: James Burrough Ltd., Witham, Essex, England.
Ethanol.
Supplier: Rathburn Chemicals Ltd., Walkerbum, Scotland.
Water-saturated phenol.
Supplier: Pharmacia Ltd., Milton Keynes, Bucks, England.
Ficoll 400.
Supplier: Cinna/Biotecx Laboratories Inc., Houston, Texas, USA.
RNAzol B.
Supplier: Northumbria Biologicals Ltd., Cramlington, Northuberland, England.
Bovine Serum Albumin (20% w/v).
Supplier: Fisons Scientific Equitment, Loughborough, England.
Formaldehyde (38% w/v).
Supplier: Fluka Chemika-Biochemika AG, Buchs, Switzerland.
Formamide
5.9 W ater
Distilled water for buffers and general solutions was obtained from a 
Millipore MilliRO 15 system. Water for protein/enzyme work or recombinant DNA 
protocols was further purified on a Millipore MilliQ system to ISMQcm.
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PART 3: RESULTS
Chapter 6: Analysis of cell lines for the expression of the 
defensin genes
The defensin genes were previously found to be expressed in the HL60 cell 
line in this laboratory, but after initial experiments this expression was lost. A series 
of other haematopoietic cells were also screened to test for defensin expression, see 
table 6.1 (taken from R.Lamb PhD thesis). Although a large number of different 
myeloid cell lines were tested no expression could be detected, this included six 
different HL60 sublines.
Table 6.1: Cell lines screened for defensin gene expression
This result is perhaps not surprising given the defensin genes very narrow 
window of expression during differentiation, as only the HL60 cell lines are at a 
stage of granulocytic differentiation which would be expected to express the defensin 
genes (Wiedemann et a l ,  1989; Daher et al., 1989; Koeffler 1991). One possible 
approach was to try to induce expression of the defensin genes with a range of 
differentiation inducing agents. Cell lines which are arrested at an earlier stage of 
differentiation than promeylocyte/myelocyte may switch on the defensin genes as 
they differentiate through this intermediate stage. To test this possibility, human
HL60p25 KG1
HL60 B KG1A
HL60 T Daudi
HL60ICRF Raji
HL60 N CEM
K562
ML1
U937
MOLT-4 
Km 3
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myeloid cell lines were induced to differentiate and RNA was harvested at different 
time points and northern blot analysis was undertaken to probe for defensin mRNA.
6.1 Analysis of defensin expression during HL60 differentiation
The first experiments were to determine if the defensin genes were expressed 
in the HL60 cell line after treatment with differentiation inducers. Three different 
inductions of HL60 were undertaken, with the differentiation inducers TPA (induces 
macrophage differentiation), DMSO and retinoic acid (induce granulocytic 
differentiation). RNA was harvested from a number of time points (see figures 6.1 
and 6.2) and analysed by northern blot. In these experiments it is important to 
determine that the induction of differentiation was successful. To determine this, the 
differentiation status of the cells were assayed for the ability to reduce NBT, which 
is a marker of mature phagocytes and by morphological examination, as 
differentiation results in profound morphological change. For the TPA induction, 
90% of the cells became adherent by 24hrs. The uninduced cultures contained 2% 
NBT-positive cells, fully induced retinoic, DMSO and TPA treated cultures 
contained 72%, 85% and 40% respectively. The low proportion of NBT-positive 
cells in the TPA treated cells is a reflection of a poorer ability of these cells to reduce 
NBT in comparison to their normal counterparts, rather than a failure of this 
particular induction (Koeffler et al., 1981). These results indicated that the 
differentiation inductions were successful.
The results of the northern blot analysis using defensin cDNA as a probe can 
be seen for the DMSO, TPA and retinoic acid inductions in figures 6.1 and 6.2. For 
each of the inductions, no defensin mRNA could be detected, with the exception of 
the positive control which is RNA isolated from the peripheral leukocytes of a CML 
patient. To check for integrity and quantity of the RNA, the blots were reprobed with 
p2-microglobulin (panel I in each figure) which remains constant during myeloid 
differentiation. Clearly the defensin genes are not expressed at appreciable levels
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Figure 6.1A: Northern blot analysis of RNA extracted from an HL60 DMSO 
induced differentiation time course. Sample: 1, 5jig of CML RNA, all other lanes 
contain 15|ig of RNA extracted from HL60 harvested after treatment with DMSO (final 
conc.1.5%) for 2, 0 mins; 3, 30 min; 4, lhr; 5, 2hrs; 6, 8hrs; 7, 24hrs; 8, 
72hrs; 9, 120hrs.
The filter was probed with both a defensin cDNA (panel II) and a P2 -microglobulin 
cDNA (panel I). The bands generated are of estimated size of 1.1 and 0.75 kd in 
panels I and II respectively. The defensin probe was a full length HNP3 encoding 
cDNA (Lamb 1989), and the p2 -niicroglobulin probe was a 545bp Pstl fragment 
(Suggetal., 1981).
Figure 6.1B: Northern blot analysis of RNA extracted from an HL60 TPA induced 
differentiation time course. Sample: 1, 15jig of CML RNA, all other lanes contain 
lOjig of RNA extracted from HL60 harvested after treatment with TPA (final conc.10" 
^M) for :- 2, 0 mins; 3, 30 min; 4, lhr; 5, 2hrs; 6, 8hrs; 7, 24hrs; 8, 72hrs.
The filter was probed with both a defensin cDNA (panel II) and a p2 -microglobulin 
cDNA (panel I). The bands generated are of estimated size of 1.1 and 0.75 kd in 
panels I and n  respectively.
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Figure 6.2: Northern blot analysis of RNA harvested during an HL60 retinoic acid 
induced differentiation time course. Sample: 1, 15pg of CML RNA, all other lanes 
contain 15pg of RNA extracted from HL60 harvested after treatment with retinoic acid 
for:- 2, 0 mins; 3, 2hrs; 4, 8hrs; 5, 3 days; 6, 5 days.
The filter was probed with both a defensin cDNA (panel 11) and a fc-microglobulin 
cDNA (panel I). The bands generated are of estimated size of 1.1 and 0.75 kd in panels 1 
and II respectively.
during induced differentiation of HL60 cells utilising these agents.
6.2 Analysis of defensin expression during ML1 induced differentiation.
This cell line is arrested at the myelomonoblast stage of differentiation, and 
can be induced to differentiate (Takeda et al., 1982; Craig et al., 1984). This 
differentiation can generate cells with characteristics of granulocytes or macrophages 
depending on the agent used (Takeda et al., 1982). This cell line was induced with 
DMSO (which generates cells with granulocytic characteristics) and TPA (which 
generates monocytic like cells) and RNA was harvested at different time points. 
Differentiation was assessed by morphological examination and by NBT staining. 
This differentiation generated 25% and 55% NBT-positive cells after 7 days DMSO 
and 5 days TPA respectively which is similar to previously reported inductions of 
this cell line (Takeda et al., 1982). TPA treatment resulted in rapid morphological 
changes, with greater than 75% of the cells becoming adherent by 12hrs (figure 6.3 
A shows the morphological changes observed after 5 days culture with TPA).
To determine if the defensin genes were expressed during induced ML1 
differentiation, northern blot analysis was undertaken using defensin cDNA as a 
probe. The results can be seen for the DMSO and TPA inductions in figures 6.3 B 
and 6.3 C respectively. No expression of the defensin genes can be detected during 
either TPA or DMSO induced ML1 differentiation (panel II in figure 6.3). To check 
for integrity and quantity of the RNA, the blots were reprobed with p2- 
microglobulin (panel I in each figure).
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Figure 6.3 A: Figure illustrating the morphological changes which occur during TPA 
induced ML1 differentiation. Panel I shows uninduced cells, panel II shows a culture 
of cells after 5 days incubation in TPA.
Figure 6.3 B: Northern blot analysis of RNA extracted from an ML1 TPA induced 
differentiation time course. Sample: 1; 15|J.g of CML RNA, all other lanes contain 
15|ig of RNA extracted from ML1 cells harvested after treatment with TPA (5x10" 
l^M) for:- 2, 0 mins; 3, 2hrs; 4, 12hrs; 5, 24hrs; 6, 72hrs; 7, 168hrs.
The filter was probed with both a defensin cDNA (panel II) and a P2 -microglobulin 
cDNA (panel I). The bands generated are of estimated size of 1.1 and 0.75 kd in 
panels I and II respectively.
Figure 6.3 C: Northern blot analysis of RNA extracted from an ML1 DMSO 
induced differentiation time course. Sample: 1, 15fig of CML RNA, all other lanes 
contain 15|ig of RNA extracted from ML1 cells harvested after treatment with DMSO 
(final concentration 1.6%) for:- 2, 0 mins; 3, 2hrs; 4, 8hrs; 5, 12hrs; 6, 24hrs; 7, 
72hrs; 8, 120 hrs; 9, 168hrs.
The filter was probed with both a defensin cDNA (panel II) and a P2 -microglobulin 
cDNA (panel I). The bands generated are of estimated size of 1.1 and 0.75 kd in 
panels I and II respectively.
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6.3 Analysis of defensin expression during KG1 differentiation
This cell line is thought to represent a more primitive cell (myeloblast) than 
ML1 with 98% of the cells myeloblast-like and 2% intermediate to late stage 
granulocytes and rare macrophages. This cell line can proliferate in response to IL-3 
and GM-CSF but these agents do not induce differentiation (Koeffler and Golde 
1978). KG1 cultures however, can be induced to differentiate to macrophage like 
cells by the addition of TPA. This generates cells which become adherent, develop 
pseudopodia, phagocytic activity, non-specific acid and esterase activity, and 
expression of lysosomal enzymes and Fc receptors (Koeffler et al., 1978b, 1981). 
Although the induction of differentiation results in macrophage-like cells, it is 
possible that these cells express some genes which are a component of the 
granulocytic program, given that the uninduced cultures are comprised of cells of the 
granulocytic lineage, and hence may express the defensin genes. To test this 
proposition a differentiation induction was undertaken and RNA was harvested at a 
range of time points. Differentiation was measured by morphological examination, 
with 80% of the cells becoming adherent after 12hrs and no further cell division 
occurring. In addition the cultures were assessed for the ability to reduce NBT and 
the fully induced culture was 37% positive in comparison to 3% positive before the 
induction. This figure is similar to previous reports indicating that the differentiation 
was successful (Koeffler et al., 1981). Northern blot analysis was used to probe for 
the induction of defensin expression during KG1 differentiation. As can be seen in 
figure 6.4 no defensin mRNA can be detected during KG1 differentiation. The blot 
was reprobed with p2 -microglobulin to check the relative levels and the integrity of 
the RNA.
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Figure 6.4: Northern blot analysis of RNA extracted from an KG1 TPA induced 
differentiation time course. Sample: 1, 15|ig of CML RNA, all other lanes contain 
15|ig of RNA extracted from KG1 cells harvested after treatment with TPA ( 1()‘^M) 
for:- 2, 0 mins; 3, 2hrs; 4, 8hrs; 5, 24hrs; 6, 48hrs; 7, 72hrs.
The filter was probed with both a defensin cDNA (panel II) and a p2-mieroglobulin 
cDNA (panel I). The bands generated are of estimated size of 1.1 and 0.75 kd in panels 1 
and II respectively.
6.4 Analysis of the expression of the defensin genes during K562 
differentiation.
This cell line was tested to see if differentiation could induce the expression 
of the defensin genes. Although this cell line has characteristics of immature 
erythroklasfcs, and are able to produce haemoglobin on induction of differentiation 
(Andersson et al., 1979; Rutherford et al., 1979), some granulopoietic markers are 
expressed on differentiation of these cells (Marie et al., 1981). In addition, long term 
culturing in medium deprived of essential nutrients results in the generation of 
precursors of monocytic, granulocytic and erythrocytic cells (Lozzio et al., 1981). 
This cell line most probably represents an early multipotent haemopoietic cell. As 
some granulopoietic markers are expressed on differentiation of this cell line, the 
defensin genes might be expressed, as a component of the granulopoietic 
differentiation program must be activated at least in a subfraction of the cells.
To test this possibility, a differentiation induction was carried out using 
sodium butyrate, and RNA was harvested at a range of time points (see to figure 
6.5). The differentiation was not monitored by quantitative markers, however the 
induction of differentiation was clearly successful as in addition to observable 
changes in morphology the cell pellet becomes red in colour due to the production of 
haemoglobin by these cells. Again no expression of the defensin genes could be 
detected, although this is perhaps not surprising given the predominately erythroid 
phenotype of the differentiated cells.
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Figure 6.5: Northern blot analysis of RNA extracted from a K562 sodium butyrate 
induced differentiation time course. Sample: 1, 15pg of CML RNA, all other lanes 
contain 15p.g of RNA extracted from K562 cells harvested after treatment with sodium 
butyrate (lO^M) for 2, 0 mins; 3, 2hrs; 4, 24hrs; 5, 72hrs
The filter was probed with both a defensin cDNA (panel II) and a P2-™icroglobulin 
cDNA (panel I). The bands generated are of estimated size of 1.1 and 0.75 kd in panels I 
and II respectively.
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6.6 Analysis of inflammatory agents ability to switch on the expression 
of the defensin genes
The loss of expression of the defensin genes was particularly puzzling given 
that it had previously been found to be expressed in these cells. One possible 
explanation was that the previous expression was the result of some kind of 
inflammatory response generated by some unknown factor present in the culture at 
that time. Evidence which lends credibility to this possibility is that in addition to 
defensins being expressed in immature neutrophils, defensin proteins have been 
identified in rabbit alveoli macrophages, and the level of these proteins can be 
increased by challenge with Freunds adjuvant (Lehrer et al., 1981). To test this 
possibility HL60 cells were treated with LPS and adjuvant peptide (which is the 
immunologically active component of freunds adjuvant) to elicit an inflammatory 
response. RNA was harvested 2 hrs and 24 hrs post treatment with these agents (see 
figure 6.6 A) and expression of the defensin genes was assessed. No expression of 
the defensin genes could be detected, although no control to test if the LPS/adjuvant 
peptide had generated an inflammatory response was included in this experiment. 
However, the concentrations employed have been found to be effective by other 
investigators (Hanock et al., 1987).
It could be that the uninduced HL60 cells are not capable of responding to the 
immunological insult as they represent an immature cell which is not fully functional. 
We would perhaps expect that if the expression of the defensin genes could be induced 
by an inflammatory reaction, this would be in a fully differentiated macrophage or 
neutrophil. A second experiment was undertaken to test if the differentiation state of 
the cells would effect its response to the adjuvant peptide and conversely if the peptide 
affected the differentiation state of the culture. HL60 cells were treated with either 
DMSO or TPA with or without adjuvant peptide. RNA and protein were harvested at a
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Figure 6.6: The effect o f  inflammatory agents on defensin gene expression
Figure 6.6 A: The effect of LPS and adjuvant peptide on defensin gene expression 
in HL60 cells. Sample: 1, 15|Xg of CML RNA, all other lanes contain 15|ig of RNA 
extracted from HL60 cells harvested after treatment with:- 2, untreated; 3, 2pg/ml 
LPS for 2hrs; 4, 2|ig/ml LPS for 24hrs; 5, 2(ig/ml adjuvant peptide for 2hrs; 6, 
2jig of adjuvant peptide for 24hrs.
The filter was probed with both a defensin cDNA (panel II) and a p2 -microglobulin 
cDNA (panel I). The bands generated are of estimated size of 1.1 and 0.75 kd in 
panels I and II respectively.
Figure 6.6 B: Northern blot analysis investigating the effect of adjuvant peptide on 
the expression of the defensin genes in HL60 cells induced to differentiate. Sample: 1, 
15|ig of CML RNA, all other lanes contain 15ug of RNA extracted from HL60 cells 
harvested after treatment with:- 2, untreated; 3, DMSO and adjuvant peptide 
(2jLig/ml) for 8hrs; 4, DMSO and adjuvant peptide for 24hrs; 5, DMSO and adjuvant 
peptide for 72hrs; 6, DMSO and adjuvant peptide for 120hrs; 7, TPA and adjuvant 
peptide for 8hrs; 8, TPA for 24hrs; 9, TPA and adjuvant peptide for 72hrs.
The filter was probed with both a defensin cDNA (panel II) and a P2 -microglobulin 
cDNA (panel I). The bands generated are of estimated size of 1.1 and 0.75 kd in 
panels I and II respectively.
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range of time points and defensin message and protein was assessed by northern 
and western blotting. The differentiation state of the cultures was measured by NBT 
staining and morphological examination. The addition of the adjuvant peptide had no 
effect on the differentiation state of HL60 cells, although in the 3-day TPA-induced 
cells the presence of the agent seemed to activate the macrophage-like cells to engulf 
dead cells/debris in the culture (data not shown). As can be seen in figure 6.6 (panel 
II) no expression of the defensin genes could be detected. A positive control was 
included of CML RNA to indicate that the hybridisation was successful, and the 
filter was reprobed with p2 -microglobulin to determine the integrity of the RNA 
(panel I).
One possible explanation for the failure to detect defensin mRNA may be that 
in these cell lines it is particularly unstable. The defensin proteins themselves would be 
predicted to be stable as they are produced and stored prior to there use in the mature 
neutrophil. Hence a western blot may detect transient expression where a northern blot 
would not. A polyclonal antibody raised against a lOmer common to HNP1, HNP2 
and HNP3 (Lamb, 1990) was used in a western blot to determine if defensin protein 
could be detected in HL60 cells. The ability of the defensin proteins to be detected by 
this immune serum is indicated by the positive control of normal peripheral blood 
leukocytes. This detects two low molecular weight bands (panel B, indicated by the 
arrows labelled i and ii), the lower band is of estimated molecular weight of 3kd, and 
is hence likely to correspond to the fully processed defensin proteins. The larger band 
is likely to be the unprocessed defensin which has a predicted molecular weight of 
9kd, and the estimated molecular weight of the band on the gel is approximately 7- 
8kd, and could correspond to this precursor, and/or intermediately processed peptides 
(Valore and Ganz, 1992). These bands are specific as they are not detected by pre- 
immune serum (figure 6.7B panel A), however no defensin protein could be detected 
in HL60 cells (figure 6.7 B lane 2). The two bands indicated by the small arrows are 
non-specific as they are generated by both the pre-immune and immune serum. Having 
established the ability of the serum to be employed successfully to detect defensin
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Figure 6.7 A and B: Western blot anlaysis to determine if HL60 cells contain 
defensin protein.
Immune serum raised against a lOmer common to HNP1, HNP2 and HNP3 was 
employed (Lamb, 1990) to probe western blots. Each sample contained total cellular 
protein from the following sources:- sample 1, 20|ig HeLa; 2, 20|ig HL60; 3, 20|ig 
periphal white blood cells (PWB); 4, 2|ig PWB; 5 ,0.2pg PWB.
Panel A and B represent duplicate filters, incubated with pre-immune and immune 
serum in A and B respectively. Bands which are specific to the immune serum are 
labelled i and ii.
Figure 6.7 C: Western blot analysis investigating the effect of adjuvant peptide on 
the expression of the defensin genes in HL60 cells induced to differentiate.
Immune serum raised against a lOmer common to HNP1, HNP2 and HNP3 was 
employed (Lamb, 1990) to probe western blots. Each sample contained total cellular 
protein from the following sources:- sample h, 20|ig HeLa; c, 2jig PWB; 1, 20|xg 
uninduced HL60; 2, HL60 cells incubated for 24 hrs with adjuvant peptide (2|ig/ml); 
3, HL60 cells incubated for 72 hrs with adjuvant peptide (2|ig/ml); 4, HL60 cells 
incubated for 120 hrs with adjuvant peptide; 5, HL60 cells incubated for 24 hrs with 
adjuvant peptide and DMSO; 6, HL60 cells incubated for 72 hrs with adjuvant peptide 
and DMSO 7, HL60 cells incubated for 120 hrs with adjuvant peptide and DMSO; 8, 
HL60 cells incubated for 24 hrs with adjuvant peptide and DMSO; 9, HL60 cells 
incubated for 72 hrs with adjuvant peptide and TPA.
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proteins, protein samples harvested simultaneosly to the mRNA (see figure 6.6) from 
the previously described experiment were analysed by western blot for the presence of 
defensin peptides.
The result is illustrated in figure 6.7 C, a negative control is protein from the 
HeLa cell line and the positive control is 2|ig of normal white blood cell protein. No 
trace of defensin expression could be detected in any of the HL60 samples (20|ig 
loaded per lane), despite allowing the alkaline phosphatase colourimetic assay to 
develop for several hours (hence the high background). This indicates that the 
defensin proteins are not present in these cells at detectable levels.
6.7 Investigation of the role of methylation in the 'switch off’ of the 
defensin genes.
Any explanation as to why HL60 cells do not express defensin must take into 
account that there are two defensin genes (4 alleles), which would suggest that the 
mutation of defensin transcriptional control sequences is an unlikely method to switch 
off expression of these genes (Lamb, 1990). There is no apparent gross deletions in or 
around the defensin genes as tested by southern blot analysis. Given that mutation of 
the control regions of these genes is unlikely, what are the alternatives to account for 
the loss of expression? Methylation has been implicated in the repression of 
transcription, and could potentially generate epigenetic mutations by methylation of 
key transcriptional control regions. This could potentially occur at a much higher 
frequency than conventional mutation. It has been demonstrated that in tissue culture 
many genes become methylated, including many which remain constitutively 
unmethylated in all tissues in vivo (Antequera et al., 1990). This strongly implicates 
methylation in the repression of these genes in tissue culture. It has been estimated that 
50% of CpG islands, which normally remain unmethylated in vivo, become 
methylated in tissue culture (Boyes and Bird, 1992). The methylation-mediated 
re p re ss io n  co u ld  be a p o ss ib le  m echan ism  to exp lain  why
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Figure 6.8: Northern blot analysis of RNA extracted from an HL60 cultures after 
treatment with 7^ iM 5-azacytidine. Sample: 1, 15pg of CML RNA, all other lanes 
contain 15|ig of RNA extracted from HL60 harvested after treatment with 5-azacytidine 
for:- 2, 0 mins; 3, 2hrs; 4, 8hr; 5, 24hrs; 6, 48hrs; 7, 72hrs; 8, 120hrs; 9, 
144hrs.
The filter was probed with both a defensin cDNA (panel 11) and a P2-microglobulin 
cDNA (panel I). The bands generated are of estimated size of 1.1 and 0.75 kd in panels I 
and II respectively.
defensin gene expression is lost in cell lines. This could either be a direct effect by 
methylation of the defensin genes transcriptional control sequences or act indirectly 
via transcriptional repression of transcription factor(s) which are essential for 
expression of these genes.
To try to switch on the defensin genes, the demethylating agent 5-azacytidine 
was used to treat HL60 cells. This agent can induce differentiation of a number of 
myeloid (and non-myeloid) cell lines including HL60 cells. The HL60 cells were 
treated with 7p.M 5-azacytidine as this was the highest concentration which was not 
cytotoxic (although some cell death was still apparent). The cells we*e cultured in the 
presence of 5-azacytidine for 7 days and RNA was harvested at a number of time 
points. The differentiation was examined by NBT staining (azacytidine induces 
granulocytic differentiation) and morphological examination. This revealed that only 
around 40% of the culture were NBT positive after 7 days in culture, suggesting that 
a large fraction of the cells were still undifferentiated. The levels of defensin mRNA 
were then assessed by northern blot analysis (figure 6.8 panel II), and no expression 
of the defensin genes could be detected. This result*however} does not rule out 
methylation as negatively regulating these genes in cell lines for a number of reasons. 
For example, the demethylation caused by this agent is not complete (i.e. the full 
genome is not demethylated)j hence the defensin gene (or rather important 
transcriptional control regions) may not be demethylated. Another possibility is that 
the defensin genes are demethylated but this occurs after the cells are at a stage of 
differentiation at which expression of the defensin genes does not normally occur as 
a consequence of the differentiation inducing effect of 5 azacytidine. Hence, 
although the defensin genes are no jonger repressed by methylation, positive acting 
transcription factors may no longer be present to activate the unmethylated defensin 
genes.
Classically the methylation status of genes has been analysed by comparing the 
southern blots of DNA digested with the Hpall and Mspl. These restriction enzymes 
cleave DNA at CCGG, although Mspl can cleave both CmCGG and CCGG, Hpall
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Figure 6.9: Investigation of the methylation status o f the DN A flanking the defensin
genes 1 . .
Figure 6.9 A: Southern blot analysis of the methylation status of the DNA flanking 
the defensin genes by Hpall and Mspl digestion. Each lane contains lOfig of genomic 
DNA digested to completion with Hpall or Mspl. The blot was probed with the 200bp 
fragment illustrated in figure 6.9 B. Sample 1, normal peripheral lymphocytes; 2; 
CML1 3, CML2; 4, CML3; 5, HL60. The lower band indicated by an arrow is of 
estimated molecular weight of 1.3kb. The upper band is of high molecular weight as 
there is little movement out of the well.
Differentiatial white cell counts of the CML samples:
CML1 CML2 CML3
0 36 20 PMN
1 24 23 non-segmented bands
1 12 21 metamyelocytes
1 6 12 myelocytes
2 2 6 promyelocytes
90 1 2 myeloblasts
0 4 1 eosinophils
1 4 1 basophils
2 5 3 lymphocytes
0 4 5 monocytes
2 2 4 nucleated RBC
Figure 6.9 B: Control experiment to test if the digestions have gone to completion. 
From each of the digests described in figure legend 6.10 A, 1/10 of the reaction was 
taken and 4|ig of of bluescript plasmid was added. The reaction was incubated for 12 
hrs and the digests were analysed by southern blot using bluescript as a probe.
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can only cleave the unmethylated DNA. Comparison of the restriction patterns 
generated after probing the region of interest gives an indication of whether this 
region of DNA is methylated. To test the hypothesis that the defensin genes are 
repressed by methylation as a result of propagation in tissue culture, comparison of 
the methylation status of the genes (and upstream regions) in a range of samples of 
genomic DNA were assessed by southern blot analysis after digestion with Hpall 
and Mspl. The methylation pattern in CML samples known to express the defensin 
genes, HL60 cells and a sample of lymphocytes were investigated, to test if 
expression of the defensin genes could be correlated to a specific methylation pattern.
It is essential for this experiment that the digestion goes to completion as a 
direct comparison is being made between the two enzymes cleavage patterns. To 
determine that the digestions were complete, after the reactions were set up 1/10 was 
taken and 4p.g of plasmid DNA was added. After incubation for 8 hrs these reactions 
were then run on a gel, southern blotted and probed with plasmid DNA. The results 
can be seen in figure 6.9 B illustrating that all of the plasmid DNAs have been 
digested, indicating that the digests have gone to completion. The remaining 90% of 
the reaction was digested for a further 12 hrs after a second addition of enzyme 
(10U/|J.g of DNA) A small aliquot was ran out on a 1% agarose gel (figure 6.10 A), 
and the remaining was ran on a 2% agarose gel, southern blotted and hybridised 
(with the probe illustrated in figure 6.10 B) and the result can be seen in figure 6.9 
A.
Consideration of the pattern generated by digestion of total genomic DNA from 
these samples, as seen in figure 6.10 A, illustrates that the HL60 genome is grossly 
undermethylated in comparison to that of the samples derived from the patients. This 
result is unlikely to represent a change in the amount of methylation seen during 
normal myeloid differentiation with the HL60 cell line simply representing a relatively 
immature cell. This is indicated as the leukaemic sample 1 contains 90% myeloblast 
cells but still shows a higher level of methylation than does the HL60 sample which is 
comprised of the more mature promyelocyte-like cells.
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Figure 6.10: Investigation o f  the m ethylation status o f the D N A  flanking the
defensin genes
Figure 6.10 A: Ethidium stained gel of genomic DNA digested with Hpall or Mspl. 
Samples of DNA were digested to completion with Hpall (lanes labelled h) and Mspl 
(lanes labelled m), and 2|ig was resolved on a 1% agarose gel. Sample 1, normal 
peripheral lymphocytes 2, CML1; 3, CML2; 4, CML3; 5, HL60.
Figure 6.10 B: Diagram illustrating the probe used for the southern blot analysis as 
described in section 6.6 to investigate the methylation status of the defensin promoter. 
The numbers are relative to the main site of transcriptional initiation of the defensin 
genes.
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Analysis of the southern blot of the gel after hybridisation to defensin 
promoter sequences demonstrated that this sequence in the leukaemic samples 2  and 
3 were unmethylated, generating as expected a single band of 1.3kb (indicated by 
the arrow in figure 6.9 A) as the probe is within a 1.3kb Hpall fragment.. The DNA 
derived from lymphocytes and the HL60 cell line generated this 1.3kb band after 
digestion with M spl, but failed to generate this band using Hpall which generated a 
higher molecular weight band/smear. In addition sample 1 also showed this digestion 
pattern, which is indicative of methylation (as a consequence of the inability of 
Hpall to cleave methylated sites) at the promoter regions.
This results suggests that the DNA derived from HL60, lymphocytes and a 
leukaemic sample containing 90% myeloblasts are methylated across the region 
analysed. However, the CML samples 2 and 3 which express the defensin genes at a 
high level are unmethylated or undermethylated over this region. As the higher 
molecular weight band has just migrated out of the well in the lympocyte and CML1 samples 
after H pall digestion, we would predict that a number of Hpall sites must be 
methylated as this is a frequent cutter. This suggests that the defensin gene and/or 
surrounding sequences are methylated over a relatively large area. As the leukaemia 
sample 1 is comprised of immature blast cells, whereas samples 2 and 3 contain 
more mature cells, this suggests that the defensin genes are constitutively methylated 
and become demethylated only at a precise stage of differentiation in accord with their 
expression. Whether this methylation is causative in repression or simply a 
consequence of non-expression remains to be determined.
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Chapter 7: DNAsel hypersensitivity analysis
As no cell line tested could be induced to express the defensin genes an 
alternative approach was undertaken. The only cells available which expressed the 
defensin genes were peripheral leukocytes derived from CML patients. These samples 
contain varying proportions of myelocytes, in which defensin mRNA is particularly 
abundant and could thus be utilised as expressing cells in the following experiments 
(Weidemann et al., 1989). One method of locating areas important in the transcriptional 
control of genes is to identify areas of chromatin which are hypersensitive to cleavage 
by DNAsel (Wu et al., 1979). This sensitivity to cleavage is a useful indicator, as sites 
of protein-DNA interaction are characterised by apparent gaps in the nucleosomal array. 
These sites often correspond to active promoter or enhancer elements (reviewed in 
Gross and Garrard 1988).
DNAsel hypersensitivity analysis was employed to probe the chromatin 
structure surrounding the defensin genes to identify areas potentially important in the 
transcriptional regulation of these genes. A comparison of the chromatin structure 
encompassing the defensin genes from CML samples, myeloid and non-myeloid cell 
lines was undertaken to determine if any DNAsel hypersensitive sites (DHS) could be 
identified. It would be of interest if any of these DHS were specific to the myeloid 
compartment and/or expressing cells, as these may be generated by transcription 
factors which are restricted in lineage- and/or differentiation stage-specific activity.
7.1 Analysis of the chromatin structure of the defensin genes in the 
HeLa and Raji cell lines.
The chromatin structure of the defensin genes in the epithelial (HeLa) and B- 
cell (Raji) cell lines was tested to determine if any DHS were present in cells outside 
the myeloid compartment. This is important as it is possible for a number of sites to 
be present in all tissues, under all conditions, irrespective of the expression of the
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Figure 7.1: Principle of D NAsel mapping
7 kb
RR \
mtm probe
R - EcoRl site
To identify DNAsel hypersensitive sites, nuclei are isolated and briefly treated with 
nuclease (this brief treatment allows only ‘hypersensitive’ sites to be cleaved), the 
reaction is stopped and genomic DNA is isolated. To determine if any cleavage has 
occurred within a region of interest a southern blot is performed. Consider the 
following example (refer to figure). If the region to be analysed is flanked by EcoRl 
sites, the DNA is digested to completion with this enzyme, the digested DNA is then 
run on a agarose gel and southern blotted. To map any hypersensitive sites a small 
probe whose 3 ’ end is the EcoRl site, is used in a hybridisation. If no DNAsel 
cleavage had occurred within this region a single band of 10 kb would be expected. 
However, if a DNAsel hypersensitive site was present at I, then a fraction of the 
DNA molecules would be cleaved at this site, then in addition to the lOkb band a 7kb 
band would also be generated. A smaller band of 3 kb is not detected as the probe is 
homologous only the 3’ end of the EcoRl fragment. This allows the DNAsel 
hypersensitive site to be mapped with the size of the band generated equal to its 
distance from the 3’ EcoRl site.
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gene. For example, the chicken lysozyme gene contains a number of constitutive DHS 
in addition to both inducible and tissue-specific sites (reviewed in Grewal et al., 1992). 
These sites may be important in mediating the overall level of transcription, or perhaps 
organising a higher order chromatin domain. Clearly for this study, DHS sites which 
are restricted in a lineage- and/or in a differentiation stage-specific manner would be of 
most interest.
The principle of DNAsel hypersensitivity analysis is illustrated in figure 7.1. 
Nuclei were harvested from exponentially growing Raji and HeLa cells and given brief 
treatments with DNAsel prior to isolation of genomic DNA. This DNA was then 
digested with BamHl, fractionated on a 1% agarose gel and southern blotted. The filter 
was hybridised using the probe illustrated in figure 7.2 C. The results of the 
hybridisation can be seen in figure 7.2 A and B illustrating a single band in each lane of 
estimated size of 7.8kb, which would be predicted for a BamHl digest when using this 
probe. No DHS can be detected over the region analysed. This region was 8 kb, 
spanning the full length of the genes and approximately 5kb of upstream sequence 
(illustrated in figure 7.2 C), and was chosen for analysis as it was the full length of the 
genomic clone available. However, it should be remembered that transcriptional control 
elements can occur many kilobases up or downstream of the transcriptional start site 
and hence may not be identified by this analysis.
In addition to identifying DHS, it is possible to obtain an estimate of the relative 
sensitivity of the entire region to cleavage by DNAsel in different cell types. This can 
be done qualitatively by comparing the reduction in intensity of the band (in this case 
the 8 kb fragment) with increasing DNAsel. The lower the concentration of DNAsel 
necessary to reduce the intensity of this band the greater the overall sensitivity of the 
region (providing that the amount of DNA loaded is even and the overall digestion is 
similar - i.e. comparison of the ethidium stains of the gels prior to blotting shows a 
similar level of cleavage). This analysis suggested that in these cell lines, this region 
of the chromatin was relatively insensitive to cleavage suggesting a condensed
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Figure 7.2 A:. Investigation of the chromatin structure spanning the defensin genes 
in the Raji cell line by DNAsel hypersensitivity analysis.
After DNAsel treatment of nuclei, DNA was harvested and 15|Xg was digested to 
completion with BamHl, run on a 1% agarose gel and southern blotted. The filter was 
hybridised to the probe illustrated in the cartoon in figure 7.2 C. Each lane corresponds 
to nuclei treated with DNAsel at 37°C for 5 minutes at a concentration of: Lane 1, 
mock DNAsel treated; 2, l|ig/ml; 3 ,2|ig/ml; 4, 4|ig/ml; 5, 8|ig/ml.
Figure 7.2 B:. Investigation of the chromatin structure spanning the defensin genes 
in the HeLa cell line by DNAsel hypersensitivity analysis.
After DNAsel treatment of nuclei, DNA was harvested and 15pg was digested to 
completion with BamHl, run on a 1% agarose gel and southern blotted. The filter was 
hybridised to the probe illustrated in the cartoon in figure 7.2 C. Each lane corresponds 
to nuclei treated with DNAsel at 37°C for 5 minutes at a concentration of: Lane 1, 
mock DNAsel treated; 2, l|ig/ml; 3, 2|ig/ml; 4 ,4p,g/ml; 5, 8jxg/ml.
Figure 7.2 C: Cartoon illustrating the region of chromatin analysed in this 
experiment. The solid boxes represent the defensin gene exons. The probe is 1 kb long 
and is flanked by the 3 ’ BamHl site (BamHl-Hindlll fragment).
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chromatin organisation. This is discussed in more detail in section 7.3.
7.2 Analysis of the chromatin structure of the defensin genes in normal 
white blood cells and granulocytes.
A problem with the analysis of leukocytes isolated from the peripheral blood of 
CML patients is that they are not a pure source of myelocytes, and will contain later 
stage myeloid cells and lymphocytes. Given the heterogeneous nature of the CML 
samples, it was necessary to determine if any DHS were present in the chromatin 
encompassing the defensin genes in mature myeloid or in lymphoid cells. To 
investigate the chromatin structure of the defensin genes in normal blood cells, white 
blood cells from a normal blood donor were isolated. And as a source of mature 
neutrophils, a sample from a patient with a neutrophilia was analysed (this consisted 
of 92% neutrophils). DNAsel analysis and southern blotting was carried out as 
described in figure 7.3. As can be seen in figure 7.3 A and B no DHS sites could be 
detected in this region for either of these samples.
This result would suggest that any DHS detected in the CML samples represent 
sites within the chromatin structure of the maturation-arrested immature myeloid cells 
present in the peripheral blood of these patients, rather than in the ‘contaminating’ 
mature myeloid or lymphoid cells.
7.3 Analysis of the chromatin structure of the defensin genes in CML 
sam ples
A small number of fresh samples of peripheral blood from patients with 
chronic myeloid leukaemia were available for analysis by DNAsel hypersensitivity. 
Given that over the region of chromatin analysed, no DNAsel hypersensitive sites 
could be detected in either normal leukocytes, epithelial (HeLa) or lymphoid (Raji) 
cells, it is likely that any DNAsel hypersensitive sites identified are present in the
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Figure 7.3: Investigation o f the chromatin structure spanning the defensin genes in
peripheral leukocytes by D N A sel hypersensitivity analysis.
Figure 7.3 A: DNAsel analysis of peripheral leukocytes from a neutrophilia patient 
(sample contained 92% neutrophils).
After the removal of erythrocytes from the sample and DNAsel treatment of nuclei, 
DNA was harvested and 15|ig was digested to completion with BamHl, 
electrophoresed on a 1% agarose gel and southern blotted. The filter was hybridised 
using the probe illustrated in the cartoon in figure 7.3 C. Each lane corresponds to 
nuclei treated with DNAsel at 37°C for 5 minutes at a concentration of: Lane 1, mock 
DNAsel treated; 2, 0.2 |Lig/ml DNAsel; 3, lp-g/ml; 4, 2|ig/ml; 5, 4p,g/ml; 6, 
8(ig/ml.
Figure 7.3 B: DNAsel analysis of peripheral leukocytes from a normal blood 
donor.
After the removal of erythrocytes from the sample and DNAsel treatment of nuclei, 
DNA was harvested and 15|ig was digested to completion with BamHl, 
electrophoresed on a 1% agarose gel and southern blotted. The filter was hybridised 
using the probe illustrated in the cartoon in figure 7.3 C. Each lane corresponds to 
nuclei treated with DNAsel at 37°C for 5 minutes at a concentration of: Lane 1 mock 
DNAsel treated; 2, 0.2 p,g/ml DNAsel; 3, l(ig/ml; 4, 2|ig/ml; 5, 4|ig/ml; 6, 
8|ig/ml; 7, 16(ig/ml.
Figure 7.3 C: Cartoon illustrating the region of chromatin analysed in this 
experiment. The solid boxes represent the defensin gene exons.
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F igure 7 .4  A:. Investigation o f  the chromatin structure spanning the defensin genes
in the peripheral leukocytes from a CML patient (CML4).
After the removal of erythrocytes from the sample and DNAsel treatment of nuclei, 
DNA was harvested and 15fig was digested to completion with BamHl, 
electrophoresed on a 1 % agarose gel and southern blotted. The filter was hybridised 
using the probe illustrated in the cartoon in figure 7.4 B. Each lane corresponds to 
nuclei treated with DNAsel at 37°C for 5 minutes at a concentration of: Lane 1, mock 
DNAsel treated; 2, 1 Jig/ml; 3, 2pg/ml; 4 ,4pg/ml; 5, 8|ig/ml.
Differential white cell counts of the CML sample:
CMLA
20 PMN
12 non-segmented bands
17 metamyelocytes
24 myelocytes
8 promyelocytes
4 myeloblasts
4 eosinophils
2 basophils
4 lymphocytes
3 monocytes
2 nucleated RBC
Figure 7.4 B: Cartoon illustrating the region of chromatin analysed in this 
experiment. The solid boxes represent the defensin gene exons and the open circles 
represent areas of enhanced cleavage by DNAsel.
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immature myeloid cells present in these samples. The CML sample (CML/4) which 
contained the highest proportion of myelocytes (41% myelocytes/metamyelocytes), 
was analysed for DHS as described in the previous experiments and the result can be 
seen in figure 7.4 A. This reveals the presence of two major sites labelled I and II. 
These sites map to span the immediate promoter and sequences within the first intron 
(as illustrated in figure 7.4 B). The site I is more sensitive to cleavage as this appears 
after DNAsel treatment of nuclei at a concentration of 0.5|ag/ml, whereas the site II 
appears only after treatment with l(ig/ml DNAsel (and this concentration of DNAsel 
seems to have generated a much greater amount of digestion than does 0 .5 |Ltg/ml - see 
figure 7.6 C). Comparison between the ethidium stain gels of CML4 and HeLa reveals 
that the chromatin of this region is more sensitive in the CML4 samples (compare 
figures 7.6 C and A). As nuclei treated with 2|ig/ml of DNA show a similar level of 
sensitivity to cleavage when ethidium stained gels are compared, however, when 
blotted and probed with a defensin genomic probe, the HeLa DNA is relatively 
uncleaved in comparison to the CML sample.
In addition to the two major bands labelled I and II there are two minor bands 
indicated just below the genomic 7.8 kb band. These bands are very faint and may 
represent cross hybridisation to a related sequence. An alternative explanation is that 
these are DHS present in cells which comprise a very minor component of the sample, 
perhaps more immature cells than myelocytes. However without purifying different 
populations of cells, further assessment of the significance of these sites cannot be 
undertaken.
A second CML sample was analysed for DHS. This sample is termed CML& 
(15% myelocytes/metamyelocytes) and has a lower proportion of myelocytes, with 
the sample being characterised by relatively more mature myeloid cells than CMM. 
The DHS analysis was carried out as described in the legend to figure 7.5, and the 
result can be seen in figure 7.5 A. The two arrows indicate the sites of enhanced 
cleavage, which map to the positions indicated in figure 7.5 B. These two sites are of 
equal intensity  as both appear after treatm ent of nuclei with 0 .5 |ig  of
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Figure 7.5  A :. Investigation o f  the chromatin structure spanning the defensin genes
in the peripheral leukocytes from a CML patient (CMLfh).
After the removal of erythrocytes from the sample and DNAsel treatment of nuclei, 
DNA was harvested and 15(Xg was digested to completion with BamHl, 
electrophoresed on a 1 % agarose gel and southern blotted. The filter was hybridised 
using the probe illustrated in the cartoon in figure 7.5 B. Each lane corresponds to 
nuclei treated with DNAsel at 37°C for 5 minutes at a concentration of: Lane 1, mock 
DNAsel treated; 2, lfXg/ml; 3, 2|ig/ml; 4, 4|ig/ml; 5, 8|ig/ml.
Differential white cell counts of the CML sample:
Figure 7.5 B; Cartoon illustrating the region of chromatin analysed in this 
experiment. The solid boxes represent the defensin gene exons and the open circles 
represent areas of enhanced cleavage by DNAsel.
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DNAsel (lane 2). It seems that both of these sites are relatively weak in comparison to 
the DHS in C M I/, as there is a general background smearing on which these sites are 
superimposed. This may be a result of the mixed nature of the sample with the DHS 
present in only a sub-population of the cells (perhaps the myelocytes). Lending weight 
to this proposition is that although the DHS may be apparently weak, they are 
generated by a relatively low concentration of DNAsel - suggesting they are 
hypersensitive but only in a fraction of the cells. Also of note is a series of faint bands 
below the marked DHS, present in lanes 3, 4 and 5 resembling a nucleosomal ladder. 
This suggests a depletion of HI over this region - consistent with this area spanning a 
site of transcription. Depletion of HI is often associated with active genes (Wolffe 
1990; Garrard 1989), however the level of nuclease cleavage necessary to generate a 
nucleosomal ladder is higher than that necessary for DHS generation, and these sites 
are unlikely to represent areas of protein-DNA interaction.
7.4 Analysis of the chromatin structure of the defensin genes in HL60 
and HL60gran cells.
As a number of DNAsel hypersensitive sites had been identified in the CML 
samples, it was of interest to determine if the HL60 cell line contained any of these 
sites despite the lack of any defensin mRNA in these cells. This would address the 
question of whether these sites were present only in expressing cells, or if they 
occurred in myeloid cells irrespective of the expression of the genes. DHS analysis was 
carried out on uninduced and fully induced granulocytic cultures of HL60 (HL60gran) 
as described in the legend to figure 7.7. The results of this analysis can be seen in 
figure 7.7. Interestingly, the induced cells seem to have a similar pattern of DHS as the 
sample CMI/1, however these sites are very weak in comparison. Absence of the DHS 
in the uninduced culture could be argued to be simply a result of loading differences 
between the samples. Longer exposure of the filter did reveal the presence of the site 
marked by the major arrow, although it was extremely weak in comparison.
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Figure 7.6: Ethidium bromide stains of DNAsel hypersensitivity gels comparing the 
HeLa cell line and CML and leukocyte samples.
The figures correspond to the ethidium stained gels of the blots illustrated in figures
7.2 B, 7.3 A and B, 7.4 and 7.5.
A: HeLa cell line (figure 7.2 B)
B: normal leukocytes/granulocytes (figure 7.3 A and 7.3 B)
C:CML4 (figure 7.4)
D: CML6 (figure 7.5)
Note each ethidium stained gel is inverted with respect to the southern blots, with the 
lane representing mock DNAsel treated nuclei on the right of the page in this figure.
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Figure 7.7 A:. Investigation of the chromatin structure spanning the defensin genes 
in the HL60 cell line before and after granulocytic differentiation.
Differentiation of the HL60 culture with retinoic acid was performed as described in 
chapter 5. After DNAsel treatment of nuclei, DNA was harvested and 15pg was 
digested to completion with Bam Hl, run on a 1% agarose gel and southern blotted. 
The filter was hybridised to the probe illustrated in the cartoon in figure 7.7 B. Each 
lane corresponds to nuclei treated with DNA sel at 37°C  for 5 minutes at a 
concentration of: Lane 1 and 7, mock DNAsel treated; 2 and 8, 0.5ug/ml; 3 and 
9, l|ig /m l; 4 and 10, 2 (ig/ml; 5 and 11, 4pg/ml; 6 and 12, 8 |ig/ml. The 
arrows indicate areas of enhanced susceptibility to DNAsel cleavage.
Figure 7.7 B: Cartoon illustrating the region of chromatin analysed in this 
experiment. The solid boxes represent the defensin gene exons and the open circle 
represents an area of enhanced cleavage by DNAsel.
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Another point of note is that in the induced culture, the mock DNAsel-treated 
sample shows some cleavage. This is likely to be the result of some endogenous 
nuclease activity which may be upregulated as a result of differentiation of these 
cultures. The significance of the hypersensitive sites found in this cell line are unclear 
given that this site is not particularly hypersensitive to cleavage. This would imply that 
only a sub-population of the cells contain this chromatin structure. In addition, why 
the induced cells have these sites is unknown, given that they are not present in cells 
from a neutrophilia patient. This could be a result of the defective differentiation
program of HL60 cells, or that a fraction of the cells are undifferentiated or partially
*
differentiated (i.e. only around 70% of cells become NBT-positive after the induction) 
and it is in these cells that contain the DHS. A similar experiment using HL60 cells 
after a shorter induction period, however, failed to detect any DHS (data not shown).
General conclusions from DNAsel hypersensitive studies.
- No DHS could be identified outside of the myeloid compartment, or in fully 
differentiated myeloid cells.
- Three sites of potential interest were identified, the immediate promoter, a site 
within the first intron and an upstream region (see figure 7.8). These sites were present 
in the CML samples, although all three do not co-exist in the same sample, 
suggesting they do not all occur at the same stage of differentiation.
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Figure 7.8: Summary of DNAsel hypersensitive sites identified. Cartoon
indicating the structure of the defensin genes and the sites to which the DHS were 
mapped. The plus sign indicates the presence of a DHS in the cell line/ sample 
indicated.
Chapter 8: In vitro binding studies
As the DNAsel hypersensitivity analysis suggested two important sites 
which merited further study, these were investigated by DNA binding studies.
8.1 Sequencing of the HNP1A upstream control regions
The first 239 bp upstream of the main site of transcriptional initiation has 
been previously sequenced (Lamb 1990). This region was re-sequenced and 
extended further upstream and the results can be seen in figure 8.1. Only one base 
differed from that previously determined. The sequence presented in this work is 
almost certainly correct, as all the constructs generated by PCR across this region 
(section 9.3) also had this sequence and the template was identical to that used 
previously (Lamb 1990).
8.2 Analysis of the immediate promoter
This region was selected for further study as this was found to be a DHS, in 
addition very often many genes contain important regulatory regions within the first 
200bp of the transcriptional start site. As the purpose of the project was to identify 
sequences which confer myeloid-specific and differentiation stage-specific expression, 
DNase 1 foot printing of the region -176 to +15 was undertaken using HL60 nuclear 
extract. As this cell line does not express the defensin genes this is not the best choice 
of extract, but was employed for the following reasons. Primarily, the lack of 
availability of CML samples of a size to generate the amount of nuclear protein 
necessary for DNAsel foot printing studies ruled out their use in this study. In 
addition, the heterogeneity of these samples would also pose a problem in the 
interpretation of the results, because it would not allow the identification of myeloid-
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'65°  GATGATCCTA GACAATTGTT TAACCTTAAA CTGTTCATTG GCCAAGCAAA
_601 CAGGGTGATA GTCACCTCTG GGGAACCACA TGCCGCGTGT ACAT C CAG TA
-55i c t c a g g a g a a CCCAAAAATG TCTGTTCCAC ATAGCAACAG AAGCCCAGGT
-501
AGCACTCAGT CTCTCCTGGG TGTTCTCCAA CATCCCAGCT CACCAAATGG
-450 CTTTCATTAG TTTTTATGGT TAGAACCCCA GGTCCTCGGG ACACTGCTTT
-400
AGAAACACAT TCCAAATCCT CCTCTGTGTG CAGGTGGCAA TCCTATCCCA
-350
ATCTCTTTGC AGGGTGTATA CTATGATACG CAGCCAGGCT GTCCCAGAGG
-300
CCTTAAATAT TTCCTTGGTG
MBS
CAGGCAGTTC AGCTTAGCCA CAGCCAATGC
ATCACAGGGt CAACTGTGTT AGGAGCCATT GAGAATCCAT AGTTGGTTGC
-200
TGCCTGGGCC
-150
GAGTTCTACT
TGGCCAGGGC TGACCAAGGT AGATGAGAGG TTCCTCTGTG
MBS
TTAACCTCAC CTTCCCACCA A A T T T C lK il CTG.TCCT1 GC
-100 c
CACCACAATT ATTTAATGGA c c c a a c a g a a AGTAACCCCG GAAAT TAGGA
'50 CACCTCATCC CAAAAGAC C T TTAAATAGGG GAAGTCCACT TGTGCACGGC
TGCTCCTTGC TATAGAA
Figure 8.1: Upstream sequence of the defensin HNP1A genomic clone. The 
numbers are relative to the major site of transcriptional initiation. The TATA box 
homologies are shown in bold, and the putative c-Myb binding sites are labelled MBS. 
The nucleotide at position -94 shows a discrepancy between this sequence and the one 
previously determined (shown above the sequence)
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Figure 8.2 A: D N A se l footprinting o f the region -176 to +15 o f  the defensin
H NP1A promoter.
Footprinting of the promoter fragment -176 to +15 as described in methods. Lane C, 
Maxam and Gilbert C track; lane 1, probe incubated in the absence of nuclear extract; 
lane 2, probe incubated with 200|ig HL60 nuclear extract. The protected regions are 
represented by the shaded boxes. The footprints identified are labelled FP1, FP2 and 
FP3. The positions of these footprints are illustrated on the cartoon of the promoter, 
T=TATA box.
( I
B: Sequence of the promoter illustrating regions of the probe showing 
protected/enhanced cleavage.
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specific transcription factors these samples contain cells from all the haemopoietic 
lineages. Also the cells in the CML samples, unlike a cell line, are not primarily 
arrested at a specific stage of differentiation, but contain a range of immature and 
mature leukocytes. Use of a cell line was necessary as it would be limited to the 
myeloid lineage and arrested at a specific stage of differentiation. The HL60 cell line 
was chosen as it had in the past expressed the defensin genes so it seems likely that 
many of the transcription factors necessary for the expression of this gene will still be 
present in these cells. It seems likely that the lack of expression of the defensins is 
the result of either methylation of important control regions or the loss of a single key 
transcription factor (section 6 .6 ), which would suggest HL60 cells would be the 
next best choice of extract in the absence of an expressing cell line. In addition, the 
use of this cell line would allow changes in a model of human myelopoiesis assessed 
using controlled experimental conditions. Small amounts of nuclear extract from 
CML samples was available and was used in EMSA described in sections 8.3, 8.4 
and 8.5.
This footprinting revealed the presence of three protected regions (see figure 
8.2), the precise locations of these sites were determined by comparison to Maxam 
and Gilbert sequencing reactions of the probe lanes C G+A and T+C.
FP1 -124 to -101 
FP2 -175 to -151 
FP3 -70 to -46
8.3 Investigation of the FP1 DNA binding activities
After finding the region spanning -124 to -101 was protected by HL60 
nuclear extract in DNAse 1 foot printing studies, electrophoretic mobility shift assays 
(EMSA) were employed as a tool to address a number of questions. These were:
1) What is the tissue distribution of this activity i.e. is it myeloid-specific?
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2) Does this DNA binding activity change during differentiation?
3) What are the transcription factor(s) which comprise this activity?
8.3 (i) Tissue distribution of the FP1 DNA binding activity
The use of the EMSA technique offers a number of advantages over 
footprinting; it allows factors which bind the same sequence to be distinguished by 
virtue of the relative mobility's of the DNA-protein complexes, smaller amounts of 
nuclear protein are required and the technique is more sensitive than footprinting. 
Complementary oligonucleotides spanning the protected region of the footprint were 
generated, annealed and radio labelled as described in section 4.17. A series of nuclear 
extracts from a range of cell lines were tested for FP1 DNA binding activity (see figure 
8.3A). This result demonstrates that an HL60 nuclear extract generates a retarded 
complex which, on close analysis is found to be comprised of a doublet of equal 
intensity. The nuclear extract from a CML patient which contained 30% myelocytes 
had no measurable FP1 binding activity. This lack of activity probably reflects an 
absence of FP1 binding proteins in this sample as the integrity of all samples were 
verified by analysis with other labelled oligonucleotides, although minor variations in 
the quality of samples cannot be discounted. Nuclear proteins derived from the 
circulating leukocytes of a patient with neutrophilia were used as source of neutrophils 
(the sample contained 90% neutrophils) and the retarded complex generated can be 
seen in lane 4. This is a surprising result as this FP1 binding activity is lost on 
granulocytic differentiation of HL60 cells (see section 8.3 (ii)), however the complex 
has a different mobility and may be induced by an inflammatory reaction which may 
occur in neutrophilias. The activity of C/EBP transcription factors can be modulated in 
response to inflammation, notably C/EBPp and C/EBP5 and the FP1 binding 
activities may be comprised of transcription factor(s) from this family (see section 8.3 
(iii)). All the other extracts tested generated a complex of similar mobility to that 
generated with HL60 extracts, as well as a number of other complexes from
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nuclear
extract
Figure 8.3: EMSA of FP1 radiolabelled probe, using extracts from a range of cell 
lines and patient samples.
The left hand lane (1), contains probe in the absence of nuclear protein. Each of the 
other lanes contains 10|ig of nuclear extract from the following cell line/sample; HL60, 
chronic myeloid leukaemia leukocytes, neutrophils derived from a neutrophila patient, 
U937, K562, HEL, Raji, Hela.
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both other myeloid cell lines and non-myeloid cell lines including the epithelial cell 
line HeLa.
8.3 (ii) Effect of differentiation on FP1 binding activities
Given that the CML sample had no FP1 DNA binding activity, it was of 
interest to determine if this activity was regulated during differentiation. To test this 
possibility nuclear extracts obtained from a time course o f HL60 TPA and DMSO 
induced differentiation were assessed for their ability to bind labelled FP1 probe in an 
EMSA. The differentiation was assessed during the DMSO induction using NBT 
staining, and by morphological examination during the TPA induction. These 
nuclear extracts were used for all of the following experiments to allow direct 
comparison between different probes eliminating concern that differences could be 
due to the differences in the quality of extracts between inductions /  variations in 
other conditions (although the inductions were repeated).
Figure 8.4 B illustrates the change in FP1 DNA binding activity during 
granulocytic differentiation as measured by EMSA. Interestingly the levels of FP1 
DNA binding activity decrease such that there is little or no activity remaining 8 hours 
post DMSO induction, suggesting that loss of this activity is a rapid event following 
the induction of granulocytic differentiation of HL60 cells. In contrast, during TPA 
induced differentiation (figure 8.4 A) a rapid transient increase in this activity occurs 
before a gradual decrease in the fully differentiated cell to levels similar to those in 
uninduced cells. These results suggested that this factor(s) is regulated in a 
differentiation-stage-specific manner which is dependent on the pathway of 
differentiation.
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Figure 8.4 : EMSA showing changes in the FP1 binding activity during HL60 
differentiation.
HL60 cultures were induced to differentiate using DMSO and TPA and nuclear protein 
was harvested at a range of time points as described in section 8.3(ii). These samples 
were used in the EMSA illustrated in this figure. With the exception of the left hand 
lane, each reaction contained lOpg of nuclear protein. un=uninduced HL60 nuclear 
extract, each of the other labelled lanes refers to the length of time post induction that 
the nuclear extract was harvested. Free probe can be seen at the bottom of the gel.
A: TPA induction. The differentiation induction was monitored by morphological 
examination. Over 90% of the cells became adherent within 24 hours.
B: DMSO induction. The differentiation induction was monitored by NBT staining, 
uninduced cells 5%, 24 hours 10%, 72 hours 45% and 120 hours 82% of cells were 
NBT positive.
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8.3  (iii) C h aracterisation  o f the FP1 DNA b in d in g  activ ity
The identity of the transcription factors which comprise the FP1 binding 
activity was of prime interest given its differentiation stage-specific activity. 
Examination of the sequence of the FP1 oligonucleotide offered a number of clues as 
to possible binding proteins, most notably the presence of a potential c-Myb binding 
site (figure 8.1). This sequence is an almost perfect match for the extended c-Myb 
consensus sequence generated by Watson et al., (1991) using a PCR based selection 
method. In addition, a potential binding site for C/EBP was also present. To gain 
further information as to the nature of these FP1 DNA binding activities an EMSA 
with FP1 probe and HL60 nuclear extract was carried out in the presence of excess 
cold competitor oligonucleotides known to bind a range of transcription factor 
families (figure 8.5 A). This revealed that a symmetric C/EBP binding sequence 
could compete out the FP1 binding complexes. Some competition was also seen 
using FP3 oligonucleotide, the reason for which is discussed in section 8.5 (iii). 
Despite the presence of a perfect c-Myb binding site, no competition was seen using 
100-fold excess of cold c-Myb binding oligonucleotide, suggesting that the complex 
generated with the FP1 probe is not the result of c-Myb binding. A role for c-Myb 
binding this sequence in vivo cannot be ruled out, because no binding of proteins to 
a consensus Myb binding oligonucleotide could be detected (data not shown). This 
suggests that c-Myb is either at an abundance too low to be identified using this 
technique, or alternatively the conditions employed in this assay are not those 
required for c-Myb binding in vitro. Further investigation of the role of c-Myb acting 
at this sequence is discussed in chapter 9.
The results of the competition experiment suggested that the FP1 binding 
activities were C/EBP-like (or rather were capable of binding C/EBP binding sites) and 
a further experiment was undertaken to assess if these activities had another of the 
C/EBP family's properties. The C/EBP family are heat stable (Graves et al., 1986; 
Johnson et al., 1987), and an EMSA was undertaken after HL60 nuclear
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Figure 8.5 A: Analysis of the DNA binding properties of the FP1 binding activities 
by EMSA.
With the exception of lane 1, each reaction contains lOpg of HL60 nuclear extract 
incubated with radiolabelled FP1 probe. Competitor oligonucleotides were included (as 
indicated in the figure) at 100 fold molar excess. The retarded complex I is indicated by 
the arrow, fp=free probe.
The sequence of the sense strand of the competitor oligonucleotides are listed
FP1: GGGTTCCCACCAAATTTCTCAACTGTCCTGCCGG 
FP2: GGTAG ATG AG AGGTTCCTCTGTGG AGTTCTACTTTA A 
FP3: AC AG A AAGTAACCCCGG A AATTAGG AC ACCTCATCCC 
AP2: CCGGCCCCAGGCGT (Oka etaL, 1991)
MYB: TTCGGCATAACGGTTCCGTAGCC (Watson etal., 1992)
C/EBP: GCTGCAGATTGCGCAATCTGCAGC (Grove and Plumb 1994)
PU.l: CGTCCCAAGAGAGGAACCAATCAGCATTG (Klemzetal., 1990)
E74: AGCTTCTCTAGCTG A AT A ACCCGG A A AGT A ACTC ATCGTCG A (Umess 
and Thummel 1990)
PEA3: GATCGAGGAAGTGAGTGAGTAACG (Martin et al., 1988)
Figure 8.5 B: Analysis of the heat stability of the FP1 binding activities by EMSA 
with radiolabelled FP1 probe.
An EMSA was carried out using FP1 radiolabelled probe. With the exception of lane 1 
each reaction contained 10|ig of HL60 nuclear extract given a prior heat treatment The 
lengths and temperatures of these treatments are indicated in the figure. The retarded 
complex is labelled I and the free probe can be seen at the bottom of the gel
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Figure 8 .6 : Distrubution of heat stable FP1 binding activity as measured by EMSA
The distribution of heat stable FP1 activity was tested using EMSA with radiolabelled 
FP1 probe. With the exception of lane 1, each lane contained nuclear protein (5p.g) 
from the cell line indicated in the figure. The lanes indicated by HT correspond to 
reactions set up after the nuclear protein was heated to 90°C for 15 minutes. Free 
probe can be seen at the bottom of the gel. N.B. The K562 sample contained 10pg of 
nuclear protein.
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extract was given a range of heat treatments (figure 8.5 B). This revealed that the 
FP1 binding activities are heat stable, even to 90°C for 15 minutes, suggesting that 
the FP1 binding activity(s) are C/EBP-like.
A question still to be answered was, are the FP1 binding activities in other 
cells the same/similar to those characterised in the HL60 cell line? This was a 
particularly interesting question given the reports that within the haemopoietic system 
the C/EBP family of transcription factors are limited to the myeloid lineages. A range 
of extracts were similarly heat treated to test if the FP1 binding activities in these cell 
lines were also heat stable. As can be seen in figure 8 .6 , after heat treatment of 
nuclear extracts for 15 minutes at 90°C, FP1 binding activity in HeLa and Raji was 
abolished. K562 shows some activity after heat treatment but a reduction in activity 
is apparent. Whether these represent C/EBP-like activities is not clear, but as this cell 
line is not strictly erythroid showing some myeloid characteristics (Marie et a l., 
1981), expression of C/EBP transcription factors would perhaps not be surprising.
The C/EBP family comprises a range of members (section 3.4) capable of 
forming homo and heterodimers, these different dimers generate proteins of different 
molecular weights and would be expected to generate a range of complexes in a 
EMSA if multiple family members were present. This is not the case for the HL60 
extract which has a single major complex (although this is comprised of a doublet). 
To test if this sequence was only binding a subset of C/EBP dimers, a series of 
EMSA were undertaken with a consensus C/EBP binding site used as the probe.
The C/EBP binding activities were assessed during FIL60 differentiation by 
EMSA using aliquots of the same nuclear extracts described in section 8.3 (ii). The 
EMSA of C/EBP binding activity during FLL60 differentiation can be seen in figure 
8.7. Comparison of C/EBP and FP1 binding activities during HL60 differentiation 
suggest they are very similar (cf. figures 8.4 and 8.7). Closer examination however, 
reveals a number of apparent differences. Considering first the DMSO induction 
(figure 8.7 B). This reveals that complex I decreases during differentiation; however, 
the loss of this binding activity is less precipitous than that of the FP1 binding activities
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Figure 8.7 : EMSA showing changes in C/EBP binding activity during HL60 
differentiation.
HL60 cultures were induced to differentiate using DMSO and TPA and nuclear protein 
was harvested at a range of time points as described in section 8.3(ii). These samples 
were used in the EMSA illustrated in this figure. With the exception of the left hand 
lane, each reaction contained lOpg of nuclear protein. un=uninduced HL60 nuclear 
extract, each of the other labelled lanes refers to the length of time post induction that 
the nuclear extract was harvested. Free probe can be seen at the bottom of the gel. 
Retarded complexes referred to in the figure are labelled I and n.
Ai: TPA induction.
Aii: longer exposure of the complexes seen in Ai.
B: DMSO induction.
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(figure 8.4). Another difference is the presence of the higher mobility complex II, 
which is not generated when FP1 is used as a probe. Changes in the intensity of this 
complex do not mirror those of the major complex, perhaps suggesting they are 
generated by different transcription factors. Whether these higher mobility complexes 
represent factors at low abundance, or factors which have a low affinity for this 
oligonucleotide is unknown. Considering the TPA induction (figure 8.7 A), again a 
superficially similar pattern is obtained to that generated when using a FP1 probe, 
but there are a number of differences. The level of complex I in the uninduced extract 
are at least 5-fold greater than that in the fully differentiated cell. This is in contrast to 
the FP1 binding activities which are at similar levels in both uninduced and fully 
differentiated cells. The complex II seems to mirror changes in complex I during this 
induction.
A possible explanation of these results is that the FP1 oligonucleotide binds 
only a subset of C/EBP dimers present in these nuclear extracts, and the pattern 
generated using the C/EBP probe is the result of a number of different dimers 
binding. This could explain why the rate of loss of the C/EBP binding activity is 
slower than that of the FP1 binding activity during granulocytic differentiation. If 
dimers which are differentially regulated, generated retarded complexes of similar 
mobility then the result of the EMSA using the C/EBP probe may represent a 
composite picture of the binding of a number of factors. Evidence supporting this 
proposition can be seen by close examination of the TPA induction (figure 8.7Aii) 
which shows that the complex I is composed of a number of bands of similar 
mobility. Complex II may represent dimers (or a degradation product of complex I) 
which do not bind FP1.
8.4 Investigation of the FP2 DNA binding activities
Similarly to the approach taken to characterise FP1, a number the questions 
where addressed using EMSA with a double-stranded oligonucleotide probe FP2
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8.4  (i) T issue d istribution  o f the FP2 DNA b in d in g  activ ities
Nuclear extracts from a range of cell lines were assessed for FP2 binding 
activities using EMSA (see figure 8 .8 ). Specific complexes are labelled I and II. 
'Non-specific' complexes cannot be competed by the addition of excess cold 'self 
oligonucleotide to the reaction and hence do not correspond to sequence-specific 
DNA binding proteins. Two complexes of similar mobility are generated by nuclear 
extracts derived from the HL60 cell line and the other myeloid cell lines (although 
very faint in the U937 extract). In addition, these two complexes are also generated 
by extracts derived from the pre-B cell line Raji. These complexes, however, seem 
to be absent from the reaction containing the HeLa cell extract, suggesting that 
perhaps these complexes are generated by transcription factors which are restricted to 
the haemopoietic compartment. Clearly, however, it is not possible to determine if 
this is the case without a more widespread screen using nuclear extract from a 
number tissues.
8.4 (ii) Effect of differentiation on FP2 DNA binding activities
EMSA was employed to measure any changes in FP2 DNA binding activity 
during HL60 differentiation (nuclear extracts were those described in section 8.3 
(ii)). Figure 8.9 B illustrating DMSO-induced granulocytic differentiation, 
demonstrates that the two specific complexes I and II remain constant during 
differentiation down this pathway. During TPA-induced differentiation, however, 
(figure 8.9 A) a small increase in FP2 DNA binding activity is apparent. A transient 
increase in the expression of many genes is seen on TPA treatment of HL60 cells 
(e.g. myc, max, ornithine decarboxylase), and may represent a TPA response which 
is separable from the induction of the differentiation program, particularly as in this 
case the response is relatively small. Other than this small increase the levels of these 
two complexes remain unaltered during HL60 differentiation.
nuclear
extract
Figure 8 .8 : EMSA of FP2 radiolabelled probe, using extracts from a range of cell 
lines and patient samples.
Lane 1 contains probe in the absence of nuclear protein. Each of the other lanes 
contains 10 |ig of nuclear extract derived from the cell line/patient sample indicated in 
the figure. Retarded complexes I and II are refered to in the text, free probe can be seen 
at thebottom of the gel.
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Figure 8.9 : EMSA showing no ckvuj«& in the FP2 binding activity during HL60 
differentiation.
HL60 cultures were induced to differentiate using DMSO and TPA and nuclear protein 
was harvested at a range of time points as described in section 8.3(ii). These samples 
were used in the EMSA illustrated in this figure. With the exception of the left hand 
lane, each reaction contained 10|ig of nuclear protein. un=uninduced HL60 nuclear 
extract, each of the other labelled lanes refers to the length of time post induction that 
the nuclear extract was harvested. Specific retarded complexes are labelled I and II, 
ns=non-specific. Free probe can be seen at the bottom of the gel.
A: TPA induction.
B: DMSO induction.
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8.4  (iii) C h aracterisation  o f  the FP2 DN A b inding activ ity
Examination of the sequence of the FP2 sequence revealed a GGAA sequence 
or an Ets box (figure 8.10 B), which is the core homology of the binding sequence 
of the Ets family of transcription factors. Flanking sequences determine which 
particular factors bind with high affinity. Comparison of the FP2 sequence to known 
Ets binding sites (EBS) revealed the highest similarity to the PU.I binding site from 
the SV40 promoter (Klemsz et a l , 1990; figure 8.10 B). To test if the complexes 
present m the HL60 cells had Ets-like binding properties competition EMSA were 
undertaken using a number of Ets binding and other oligonucleotides (figure 8.10 
A).
Cold excess of oligonucleotides FP3, FP1, PU.I and E74 can compete out FP2 
binding activity. With the exception of FP1, all of these oligonucleotides have clear 
similarity to EBS (figure 8.10 B). Although FP1 does not contain a perfect Ets box, it 
does contain two sequences which have sequence similarity to EBS. The two FP2- 
binding complexes I and II generated by HL60 nuclear extract show different DNA 
binding properties. The complex II can be competed out by the addition of excess cold 
PU.I and E74 oligonucleotides to the reaction, whereas the upper complex I is 
competed only partially by these oligonucleotides. Both complexes can be competed 
with FP1 and FP3 oligonucleotides. There are two possible explanations for these 
results; the two complexes may be generated by distinct DNA binding proteins, or 
may be two forms of the same protein. If the latter is correct this could be the result of 
alternative splicing, post-translational modification, or the complex II may be a 
cleavage product of complex I. As previously mentioned a number of ETS proteins 
contain PEST sequences (section 3.5), which make them particularly susceptible to 
cleavage. Also cleavage of the Ets proteins can alter their DNA binding properties, as 
limited proteolysis of Ets-1 increasing its affinity for the PEA3 sequence (Lim et al., 
1992). If the lower complex lost similar sequences it is possible that its
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Figure 8.10 Ai: Analysis of the DNA binding properties of the FP2 DNA binding 
activities using EMSA.
Each lane with the exception of lane 1 contains 10|ig of HL60 nuclear protein. 
Unlabelled competitor oligonucleotides were included (as indicated in the figure) at 100 
fold molar excess. Arrows indicate retarded DNA-protein complexes I and n.
The sequence of the sense strand of the competitor oligonucleotides are listed
FP1: GGGTTCCCACCAAATTTCTCAACTGTCCTGCCGG 
FP2: GGTAGATGAGAGGTTCCTCTGTGGAGTTCTACTTTAA 
FP3: AC AG A AAGTAACCCCGG AAATTAGG AC ACCTCATCCC 
AP2: CCGGCCCCAGGCGT (Okaetal., 1991)
MYB: TTCGGCATAACGGTTCCGTAGCC (Watson etal., 1992)
C/EBP: GCTGCAGATTGCGCAATCTGCAGC (Grove and Plumb 1994)
PU.I: CGTCCCAAGAGAGGAACCAATCAGCATTG (Klemzetal., 1990)
E74: AGCTTCTCTAGCTGAATAACCCGGAAAGTAACTCATCGTCGA (Umess 
and Thummel 1990)
PEA3: GATCGAGGAAGTGAGTGAGTAACG (Martin et al., 1988)
Aii: Longer exposure of the complexes present in Ai
B: Diagram illustrating the Ets binding sequences used in this study.
181
Ai
competitor _  _ u. u. z. — u
nuclear extract _  + + + + + +
(HL60)
X
cs A
u ec N
u u <
+ + +
-  4
Aii
B P E A 3 C G A G G A A G T G
E 7 4 A C C C G G A A G T A
P U  . I A G A G G A A C  T T
N F - J B A G C A G A A G C A
F P 2 A G A G G A A C C T
F P 3 C C C G G A A A T T
F P l C A A G G A C T T G
T G A G A A A T T T
Wasylyk et al. (1990)
Urness and Thummel (1990) 
Klemsz et al (1990)
Shin and Koshland (1993)
DNA binding properties would be altered and could explain its ability to be 
competed by a wider range of EBS.
The evidence suggests that the FP2 binding proteins are Ets family members, 
however, a number of known Ets family members may comprise these activities. 
These complexes appear to be limited to the haemopoietic compartment (although 
they could not be detected in erythroid cells) suggesting that possibly PU.I (Spi-1) 
or Spi-B which have a limited tissue distribution and would be predicted to bind to 
this sequence with high affinity (Klemsz et al., 1993; Galson et a l., 1993) may 
generate one or both of these complexes.
8.4 (iv) Spi-1 binds to the FP2 sequence
The transcription factor PU.I was a strong candidate to comprise the FP2 
DNA binding activities as: this factor is restricted to the haemopoietic compartment, 
it binds the PU.I sequence, it generates a high mobility complex and in some 
nuclear extracts it produces two complexes of similar mobility as result of cleavage at 
the PEST sequence (Pahl et a l , 1992; Galson et a l,  1993). To determine if PU.I 
could bind the FP2 sequence, Spi-1 was generated in vitro to use in an EMSA (Spi-1 
is the mouse homologue of PU.I; the proteins are 98% identical at the amino acid 
level). Spi-1 RNA was generated by in vitro transcription of the full length cDNA 
and this was then translated using a reticulocyte lysate as described in section 4.18. A 
duplicate translation was carried out which was labelled by the addition of ^^S- 
methionine. A portion of this translation was resolved on SDS-PAGE (section 4.21 
ii). Autoradiography revealed that the majority of the label was incorporated in a 
single product of approximately 40 kDa, which is the size expected for a full length 
translation of Spi-1 (Zhang et a l ,  1993). An EMSA was then carried out using 
radiolabelled FP2 as a probe and the unlabelled Spi-1 programmed reticulocyte 
lysate. This experiment revealed that Spi-1 could bind to this sequence (figure 8.11 
A). The Spi-1-specific complexes are labelled SI and SII in the figure. These
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complexes can be eliminated by inclusion of excess cold competitor FP2 
oligonucleotide but not FP1, indicating that the later has an affinity for this factor 
which is lower than that of FP2.
As Spi-1 could bind the FP2 sequence, the mobility of the FP2 binding 
complexes generated by HL60 nuclear protein and the Spi-1 primed reticulocyte 
lysate were compared by EMSA. The results of this experiment can be seen in figure 
8.1 IB, illustrating that the major complex generated using the Spi-1 reticulocyte 
lysate SI, has a very similar mobility as the HL60 FP2 binding complex I. This 
evidence lends weight to the proposition that the FP2 binding activity I is the PU.I 
transcription factor. Whether the lower complex represents PU. 1 after cleavage at 
the PEST sequence is unknown.
Figure 8.11 EM SA showing Spi-1 binds the FP2 sequence.
A: EMSA using Spi-1 reticulocyte lysate and FP2 radiolabelled probe. To test if the 
Spi-1 transcription factor could bind to the FP2 sequence, in vitro 
transcription/translation of a Spi-1 template (Nibbs 1993) using reticulocyte lysate (as 
described in section 5 of methods) was employed in a EMSA. Lane 1 probe alone; 2, 
10|il mock RT lysate; 3, 10|il Spi-1 RT lysate; 4, lOpl Spi-1 RT lysate + 100 fold 
excess competitor FP2 oligonucleotide; 5, IOjllI Spi-1 RT lysate + 20 fold molar excess 
FP2 oligonucleotide; 6, lO t^l Spi-1 RT lysate +100 fold molar excess of FP1 
oligonucleotide. SI and SII refer to Spi-1 specific complexes. The lower mobility 
complexes are also present in the mock translation. Free probe can be seen at the 
bottom of the gel.
B: EMSA comparing the mobility of HL60 nuclear extract FP2 binding activities and 
Spi-1
Comparison of the mobility of the DNA binding activities present in HL60 nuclear 
protein to in vitro transcribed/translated Spi-1 by EMSA using FP2 radiolabelled 
probe. Lane 1, probe alone; 2, 10pl mock RT lysate; 3, lOpl Spi-1 RT lysate; 4, 10pg 
HL60 nuclear extract. Complexes generated by HL60 nuclear extract are labelled I and 
n. Free probe can be seen at the bottom of the gel.
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8.5 Investigation of the FP3 DNA binding activities
The region protected by HL60 nuclear extract spanned -70 to -46 (figure 8.2) 
and was termed FP3. As with FP1 and FP2, the EMSA was used as an approach to 
investigate the DNA binding properties of these activities.
8.5 (i) Tissue distribution of the FP3 DNA binding activities
The tissue distribution of the FP3 DNA binding activity was assessed by 
EMSA using radiolabelled FP3 probe (figure 8.12). Using HL60 nuclear extract, 
two intense retarded complexes of low mobility are generated, a third low mobility 
complex is also sometimes generated but fails to produce consistent results in 
competition experiments. Complexes of similar mobilities are also generated with 
nuclear extract derived from U937, K562, Raji, and HeLa cell lines. Interestingly, 
similar activities are not generated using extracts derived from a neutrophilia and a 
CML patient’s peripheral blood leukocytes; this is discussed in section 8.5 (ii). In 
addition to the factors generate complexes I and n, a number of other complexes are 
also generated, although not when HL60 nuclear extract is employed (figure 8.12). 
This suggests that a number of factors which are capable of binding this sequence in 
vitro are relatively common.
8.5 (ii) Changes in FP3 DNA binding activity during differentiation
An EMSA was carried out using nuclear extracts derived at different time 
points during induced HL60 differentiation using labelled FP3 as a probe. Considering 
the DMSO induction first (see figure 8.13 B), the three low mobility complexes I, II
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Figure 8.12 : EMSA of FP3 radiolabelled probe using nuclear extracts from a range 
of cell lines and patient leukocyte samples.
With the exception of lane 1, all other lanes contain 10pg of nuclear extract from the 
following source: 2, HL60; 3, CML leukocytes; 4, neutrophils derived from a 
neutrophilia patient; 5, U937; 6 , K562; 7, HEL; 8 , Raji; 9, Hela. The arrows 
indicate the retarded complexes discussed in the text. Free probe can be seen at the 
bottom of the gel.
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Figure 8.13 : EMSA showing changes in the FP3 binding activity during HL60 
differentiation.
HL60 cultures were induced to differentiate using DMSO and TPA and nuclear protein 
was harvested at a range of time points as described in section 8.3(ii). These samples 
were used in the EMSA illustrated in this figure. With the exception of the left hand 
lane, each reaction contained 10|ig of nuclear protein. un=uninduced HL60 nuclear 
extract, each of the other labelled lanes refers to the length of time post induction that 
the nuclear extract was harvested. u=upper complexes, M ow er complexes. Free 
probe can be seen at the bottom of the gel.
A: TPA induction.
B: DMSO induction.
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and III are labelled U, and all change proportionally during HL60 differentiation. 
There is little change in the activity of any of these complexes until the 5 day time 
point, with any differences before this point attributable to differences in the quality 
of the extracts, as this activity seemed particularly sensitive to degradation. As this 
DNA binding activity is particularly sensitive, it is pertinent to ask if the loss of 
activity seen after 3 days is a real effect or the consequence of degradation during 
preparation. The lack of any comparable FP3 binding activity in the extract derived 
from leukocytes from a neutrophilia patient (90% neutrophils) suggests that the loss 
of this activity in fully differentiated HL60 cells is a reflection of the lack of FP3 
binding proteins as consequence of differentiation to a neutrophil-like cell. However, 
it could be argued that the fully differentiated cells contain relatively more proteases, 
which increases the degradation of this sensitive activity, duringpreparationof the 
nuclear extract.
If the FP3 binding activity is present until late in granulocytic differentiation, 
then the lack of FP3 binding activity in the CML sample is surprising. This sample, 
however, contained only 30% myelocytes with the majority of the remaining cells 
comprising PMNs and lymphocytes. As the FP3 binding activity is not present in 
fully differentiated neutrophils this would be expected to reduce the signal, although 
it should still be easily detectable. It may be that the ease of degradation of the FP3 
binding activities resulted in loss of this activity in this sample as the CML samples 
are left at room temperature for some hours before they are obtained for analysis. The 
higher mobility complex labelled 1 remains relatively unchanged in intensity during 
differentiation, and this complex is present at the 5 day time point although slightly 
reduced in intensity.
Consideration of the TPA induction reveals a large rapid induction of FP3 
binding activity (complexes labelled U) 10 minutes after treatment (see figure 8.13 A) 
of at least 14-fold. However as the most intense complex had clearly exceeded the 
linear response of the autoradiograph, this figure is an under estimation. The level of 
FP3 binding activity then falls back to levels 3-fold higher than in the uninduced cell
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on the completion of differentiation. This large rapid increase of activity only seen 
when inducted to differentiate along the monocytic lineage is intriguing, but whether 
this activity plays a causal role in the process o f differentiation remains to be seen. 
The higher mobility complexes L are transiently increased but then remain relatively 
unchanged.
8.5 (iii) Characterisation of the FP3 DNA binding
Examination of the FP3 sequence identified similarity to an Ets-binding site 
(see figure 8.10 B), which is remarkably similar to the Drosophila Ets-binding E74 
sequence (Urness and Thummel 1990). A number of Ets binding sequences and a 
range of other oligonucleotides were tested to see if they could compete out the FP3 
binding complexes in an EMSA. The result can be seen in figure 8.14 A. 
Considering complexes I and II, the oligonucleotide E74 was the most effective 
competitor. In addition, weak competition was observed using the oligonuceotides 
FP1, FP2, PU.I and PEA3, all of which are similar to Ets binding sites. 
Considering the relative affinities of these oligonucleotides for FP3 DNA binding 
activities I and II, the properties are similar to those of Ets-1, as the sequences 
which compete most efficiently are those which can bind Ets-1 with high affinity. 
Although less information is available concerning relative affinities of Ets-2 for 
different sequences, the information that is available suggests that it is similar to that 
of Ets-1 (W asylyk et al., 1990; Fisher et al., 1991). Given the broader tissue 
distribution of Ets-2 (Bhat et al., 1987) this is perhaps a stronger candidate for the 
FP3 binding complexes I and II than Ets-1.
Complex III gives inconsistent results on repeats for unknown reasons. 
Complex IV, has a similar mobility to FP2 binding complexes I and II, and its 
binding properties are similar to those of FP2 complex I (upper), which suggests 
they may be generated by the same transcription factors.
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Figure 8.14 A: Analysis of the DNA binding properties of the FP3 binding activities 
using EMSA with a radiolabelled probe.
Each reaction with the exception of lane 1, contained lOjag of HL60 nuclear protein. 
Unlabelled competitor oligonucleotides were included (as indicated in the figure) at 100 
fold molar excess. Retarded complexes are labelled, I, II, III and IV. Free probe can 
be seen at the bottom of the gel.
The sequence of the sense strand of the competitor oligonucleotides are listed
FP1: GGGTTCCCACCAAATTTCTCAACTGTCCTGCCGG 
FP2: GGTAGATGAGAGGTTCCTCTGTGGAGTTCTACTTTAA 
FP3: ACAGAAAGTAACCCCGGAAATTAGGACACCTCATCCC 
AP2: CCGGCCCCAGGCGT (Oka et a l , 1991)
MYB: TTCGGCATAACGGTTCCGTAGCC (Watson et al., 1992)
C/EBP: GCTGCAGATTGCGCAATCTGCAGC (Grove and Plumb 1994)
PU .l: CGTCCCAAGAGAGGAACCAATCAGCATTG (Klemz et al., 1990)
E74: AGCTTCTCTAGCTGAATAACCCGGAAAGTAACTCATCGTCGA (Urness 
andThummel 1990)
PE A3: GATCGAGGAAGTGAGTGAGTAACG (Martin et a l ,  1988)
F igure  8.14 B: Fli-1 binds the FP3 sequence in vitro.
EMSA with FP3 radiolabelled probe comparing the complexes generated using Fli-1 
(Nibbs et a l,  1994) primed reticulocyte lysate (RT) and HL60 nuclear extract. With 
the exception of lane 1, each lane contained either 10|il of RT lysate or 10|ig of HL60 
nuclear extract. Competitor oligonucleotides when included were at 100-fold molar 
excess as indicated in the figure. Lane 2, 10ql mock RT lysate; lane 3, 10|al Fli-1 RT 
lysate; lane 4, lOjig of HL60 nuclear extract; lane 5, 10|il of Fli-1 RT + FP2 
competitor; lane 6 ; 10pl Fli-1 RT + of FP1 competitor and lane 7; 10|il of Fli-1 RT + 
FP3 competitor.
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8.5 (iv) Fli-1 binds the FP3 oligonucleotide
Another possible candidate for the FP3 DNA binding activities was the 
ErgB/Fli-1 (human/mouse) transcription factor, as this factor is expressed in HL60 
cells (Watson et al., 1992) and it binds to the E74 sequence with high affinity (Zhang 
et al., 1993). In addition, although FP3 binding activities of similar mobility are 
present in a number of cell lines, the transfection data (see Chapter 9) suggest that 
this sequence may confer myeloid specificity and the ergB gene is expressed in a 
tissue-restricted fashion (Watson et al., 1992). To test if this factor could bind the 
FP3 sequence, this protein was generated by in vitro transcription and translation in 
a reticulocyte lysate. A duplicate translation was carried out simultaneously 
containing ^^S-labelled methionine. An aliquot of this translation was 
fractionated on SDS-PAGE (4.21 ii) and autoradiography revealed that the majority 
of the label was incorporated into a doublet of equal intensity of apparent molecular 
weight around 50 kDa, which has been reported previously (Zhang et al., 1993).
Referring to figure 8.14 B, it can be seen that the f l i - 1 programmed lysate 
can bind to the FP3 sequence and generate two low mobility complexes and a high 
mobility complex, which is a superficially similar pattern of complexes to that 
generated using HL60 nuclear extract, i.e. a low mobility doublet and a higher 
mobility complex. However, direct comparison to the complexes generated using 
HL60 nuclear extract, reveal that, although the pattern is the same, the Fli-1 
complexes have a significantly higher mobility. It seems unlikely that the differences 
in mobility are the result of using the mouse fli-1  cDNA as the template, as these 
proteins are 96% identical at the amino acid level, and most changes are conservative 
with predicted molecular weights of 51 kDa and 50.98 kDa for mouse and human 
respectively. However, the proteins may be m odified post-translationally 
differentially in cells and cell free extracts which may affect their mobilities.
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8.6 Ets-2 and PU .l are expressed in this HL60 cell line.
As the strongest candidates for the FP2 and FP3 DNA binding activities are 
PU .l and Ets-2, respectively, it was necessary to demonstrate that these factors are 
expressed in this particular cell line. In addition the other cell lines, HeLa, Raji and the 
T-cell line CEM were also included on this blot. This would allow the expression of 
the gene to be correlated with the results of both the DNA binding studies, and the 
activities of these sequences in transfection studies in these cell lines (Chaptet 9)
Figure 8.15 A reveals that ets-2 is expressed most highly in the HeLa cell line 
but is also expressed in the HL60 cells. Three transcripts can be detected, these are of 
sizes 3.5, 2.9 and 1.6 kb. A previous study of ets-2 expression in the HeLa cell line 
reported transcripts of 4.7, 3.2 and 2.7 kb present (Watson et al., 1988). The reasons 
for the differences between the studies is unkown, although the HeLa cell line used in 
this study was HeLaS3 which is a subline which can grow in suspension.
In figure 8.15 B, the same filter was re-probed with Spi-1 (96% identical to 
the human PU .l gene), reveals that this a single band of the expected size (Smith et 
al., 1989) is present in the HL60 and the Raji cell lies. This result is as expected as this 
factor has a limited tissue distrubution and has been termed a macrophage and B-cell 
specific factor. The relatively low intensity of the band generated with the Raji RNA 
sample is partially the result of the comparative underloading of this sample compared 
to that of the HL60 sample.
Figure 8.15 C shows that the RNA was intact as this panel shows the result of 
re-probing the filter with a p-2microglobulin probe as a loading control.
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Figure 8.15: ets-2 and PU .l are expressed in the HL60 cell line.
Each panel represent the same filter probed with
A: a full length ets-2 cDNA (Watson et al., 1988)
B: a 400bp 5 ’ PU.l cDNA fragment (Smith et al., 1991)
C: a full length p2-microglobulin cDNA (Sugg et al., 1981)
Each lane contains 15(ig of RNA extracted from the following cell lines (from left 
right) CEM, Raji, HeLa and HL60 (lanes 1-4).
Figure 8.15: ets-2 and PU.l are expressed in HL60 cells
Chapter 9: Transfection studies
9.1 Optimisation of the conditions for transient transfection of HL60 cells
A necessary aspect of the work was the transfection of a myeloid cell line to 
test the transcriptional properties of a series of promoter deletion constructs. This was 
problematic as although a number of reports of transfection of the HL60 cell line have 
appeared in the literature, reproducibility between laboratories has been a problem and 
previous attempts in this group had proved unsuccessful. As these experiments were 
essential to link in vitro binding activities to transcriptional activities, an attempt to 
transfect and optimise the conditions for the HL60 cell line was undertaken.
For the initial experiments the reporter gene luciferase was used for two 
reasons: firstly, it has been reported to be the most sensitive of the available reporter 
genes (Williams et al., 1989; Brasier et al., 1989) and, secondly, this reporter gene 
has been used successfully in one report of transfection into HL60 cells and more 
extensively in the promonocytic cell line U937 (Pahl et al., 1991; Pahl et al., 1993; 
Yamada et al., 1988). This gene was under the control of the SV40 promoter, which 
is an extremely powerful promoter and has been demonstrated to be active in HL60 
cells (Reisman and Rotter 1989). The transfection protocol followed was 
electroporation using the conditions suggested by Dr Zhu Jing-de (personal 
communication) who was successfully transfecting the myelomonocytic mouse cell 
line WEHI, and the conditions employed are described in the section 4.20. The cells 
were harvested 18 hours post-transfection and a luciferase assay was carried out 
however, no luciferase activity could be detected in these cells.
One possible explanation as to why HL60 cells are so difficult to transfect is 
that they are phagocytic cells whose function is to ingest and degrade foreign particles, 
consequently the cytoplasm is full of degradative enzymes. As the protocol for the 
assay of most reporter genes involves the lysis of the cells as a first step, this will
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release proteases from intracellular granules. It had been noted that the generation of 
intact nuclear protein from myeloid cell lines and HL60 in particular was difficult. This 
problem with proteolytic cleavage had been previously noted by other workers (Galson 
and Housmann 1989). To overcome this problem, a secreted reporter gene rather than 
luciferase was used. Secreted reporter genes had been used successfully (M.Grove 
personal communication) in transfecting the mouse macrophage RAW cell line at high 
efficiency. These cells also have abundant proteases stored in the cytoplasm. The 
secreted placental alkaline phosphatase gene was employed as a reporter gene 
(Henthom et al., 1988), as the assay does not involve lysis and release of cytoplasmic 
proteases. A repeat of the previous experiment was undertaken using the alkaline 
phosphatase reporter gene cotransfected with the luciferase reporter gene. The protocol 
was as described in the previous experiment, with 10|ig of pSV2ASPAP and lOfig of 
pGL2-promoter plasmids. In addition, the cell line HeLaS3 was also transfected as a 
positive control for the luciferase assay. Given that the lysis of the cells may generate 
proteolysis, the luciferase assay was carried out using a cocktail of protease inhibitors 
(section 4.16 (i). Although no luciferase activity could be detected, alkaline 
phosphatase activity was easily detected in the medium (data not shown), suggesting 
that either the alkaline phosphatase assay is more sensitive than the luciferase assay or 
that degradation of the luciferase protein on lysis of the cells is a problem.
Comparison of the results of the HeLa and HL60 cell lines revealed that the 
efficiency of transfection into HL60 was significantly lower than that into the HeLa cell 
line. However, given a successful (if low efficiency protocol), it was possible to 
optimise the conditions for this cell line. Initially, the voltage employed was varied 
between 125V and 350V however no improvement on the 250V originally used could 
be detected. Similarly, the capacitance of 960|iF could not be improved upon. 
Increasing the amount of DNA however, significantly increased the transfection 
efficiency in a linear fashion between 5 and 20|ig (figure 9.1).
The alkaline phosphatase activity is very stable, and the level of this activity 
should accumulate in the medium with time, implying that the longer post transfection
200
Figure 9.1 A: The effect of plasmid concentration on efficiency of transfection into 
HL60 cells. Electroporation at 250V, 960pF of 5 x 1 ()6 HL60 cells was carried out as 
described in secion 4.20. The reporter plasmid pSVA2SPAP was included at 
concentrations of 0, 5,10 and 20ug. The medium was assayed for heat stable alkaline 
phoshatase activity 18 hours post transfection. The assay was allowed to develop for 2 
hours, and then the OD at 495nm was measured. The average activity from triplicate 
samples in two independent experiments is represented in the histogram.
Figure 9.1 B: The effect of carrier DNA on the efficiency of transfection into HL60 
cells. Electroporation was carried out as decribed in figure 9.1 A. Transfections were 
carried out using 45|ig of bluescript (BS); 5fig of pSVA2SPAP plasmid (AP); 5|J,g of 
pSVA2SPAP and 45jig of bluescript (AP+BS); 5pg of pSVA2SPAP and 45|ng of 
sonicated salmon sperm DNA (AP+ssDNA). The phosphatase assay was allowed to 
develop for 2 hours and then the OD at 495nm was measured. The average activity of 
triplicate samples from two independent experiments are represented in the histogram.
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Figure 9.1 A: The effect of plasmid concentration on the transfection efficiency of
HL60 cells
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Figure 9.1 B: The effect of carrier DNA on the efficiency of transfection into HL60 
cells
AP activity
AP+BS AP+ssDNA
transfected DNA
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the medium is tested the greater the activity. It important to determine the optimal time 
point to sample the medium after the transfection, as it was necessary to sample the 
medium when the highest activity could be obtained but prior to the loss of a linear 
increase in activity. To determine a time course of alkaline phosphatase activity, a 
transfection was undertaken and a number of samples of medium were taken at 
different time points. The alkaline phosphatase activity was measured and plotted 
against time post transfection (figure 9.2 A). Suprisingly this experiment revealed that 
70% of the total alkaline phosphatase generated was released into the medium within 
the first 18 hours. This result is consistent with that reported by Pahl et al., (1991), 
who found optimal luciferase activity 14 hours post electroporation of the 
promonocytic cell line U937. However, for other cell lines this result is atypical, as 
many protocols assay the reporter gene activity five days after transfection, after the 
medium has been changed. Although the plasmids do not contain a eukaryotic origin of 
replication and would not therefore be replicated we would perhaps expect the plasmid 
to remain transcriptionally active for a longer period. Clearly the rapid loss of reporter 
gene activity could be explained by rapid loss of the plasmid by degradation. An 
alternative explanation is that the SV40 promoter shows a serum response in this cell 
line, as the transfection procedure involves the addition of some fresh medium (1ml of 
fresh medium to 4ml of conditioned medium). To eliminate this possibility, the effect 
of the addition of replacement of the medium with fresh or conditioned medium to 
transfected cells 2 and 3 days post transfection was tested. The addition of fresh 
medium had no significant effect on the generation of alkaline phosphatase activity 
(figure 9.2 B).
These results suggest that the transfected plasmid is rapidly destroyed after 
entering the cells so an experiment was undertaken to test if carrier DNA could increase 
the reporter genes activity by acting as as competitor. In this experiment 5|ig of 
pSV2ASPAP plasmid was transfected along with 10-fold excess of carrier DNA. The 
result can be seen in figure 9.1 B, which clearly illustrates a large increase in activity 
with the inclusion of 10-fold excess of the bluescript plasmid, although the inclusion
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Figure 9.2 A: Time course o f the generation of alkaline phosphatase activity post 
transfection. HL60 cells were electroporated with 5|ig of pSVA2SPAP and 45|ig of 
bluescript as described in section 4.20. Samples of medium were taken from the 
transfected cells at the time points indicated in the figure. The alkaline phosphatase 
activity was measured and the results are presented as a proportion of maximum 
activity. The average activities of four and three duplicates from two independent 
transfections are represented in the histogram.
Figure 9.2 B: The effect of serum stimulation on the SV40 promoter in HL60 cells. 
HL60 cells were transfected with 5pg of pSVA2SPAP and 45|ig of bluescript as 
described in section 4.20, with the exception that each transfectant was split into two 
flasks after electroporation. The samples were then given the following treatments. D2, 
these samples were resuspended in conditioned medium two days post transfection. 
D3, these samples were resuspended in conditioned medium three days post 
transfection. D2+medium, was resuspended in fresh medium two days post 
transfection. D3+medium, was resuspended in fresh medium 3 days post transfection. 
Samples of medium were taken 24 hours after this change in medium. The 
phosphatase assay was allowed to develop for 8 hrs and then the OD at 495nm was 
measured . The average activities of the results o f triplicate tranfections from two 
independent experiments are illustrated in the histogram.
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Figure 9.2A : Tim e course o f alkaline phosphatase activity post transfection o f
HL60 cells.
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Figure 9 2  B : The effect of serum stimulation on the SV40 in HL60 cells.
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of sonicated salmon sperm DNA had no effect. By what mechanism the inclusion of 
earner plasmid DNA increases the alkaline phosphatase activity is unknown, although 
the the inclusion of excess plasmid had no effect on the time course of relative alkaline 
phosphatase activity generation, perhaps suggesting that the increase in DNA may 
increase the efficiency of electroporation rather than inhibiting the degradation of 
plasmid DNA (data not shown).
Summarising the results, the optimal protocol requires: electroporation at 250V 
960uF, the use of secreted reporter genes and the inclusion of excess carrier plasmid 
DNA. For the transfections that are employed in the following sections, 5|ig of test 
plasmid was included with 10-fold excess of bluescript plasmid. It was also noted that 
linearisation of the template significantly increased the efficiency of transfection. 
However, for transient assays circular DNA was employed as it represents a more 
physiological template. Although no rigorous experiments were undertaken to test the 
observation, it is clear that the cells must be growing optimally for high efficiency 
transfection into this cell line.
9.2 Generation of a series of reporter constructs
A number of sites in the defensin promoter were identified as interacting with 
sequence-specific DNA binding proteins in vitro (chapter 8 ). To test what contribution 
these sequences made to the activity of the promoter a series of promoter fragments 
were cloned upstream of a promoterless reporter gene. The plasmid pOGH (Snelden et 
a l., 1986), which is a pUC12 based plasmid that contains a promoterless human 
growth hormone gene, was used as the basic vector. Fragments from the defensin 
genomic clone HNP1A were inserted upstream of the human growth hormone gene in 
the pOGH plasmid as described in figure 9.3. The constructs were termed pOGH-X, 
where X refers to the number of nucleotides upstream of the major transcription start 
site of the defensin gene cloned into the pOGH vector. The constructs in figure 9.3 2 
were generated by PCR from a plasmid template containing an HNP1A genomic clone
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Figure 9.3: Schematic representation o f the generation o f the reporter constructs
used in this study.
1 The promoterless pUC12 based pOGH plasmid containing the human growth 
hormone gene was used as a basic vector. Fragments of the defensin promoter were 
cloned in front of the human growth hormone gene using the restriction sites shown in 
the diagram. 2 Fragments overlapping the site of transcriptional initiation were 
generated by PCR using a plasmid template containing a defensin HNP1A genomic 
clone of the upstream regions. The primers contained restriction sites at the 5' ends and 
were used to clone these fragments (these oligonucleotides were 2 0 bp in length, 
with the nucleotide position X representing the first of these 20 bp. Inaddition, each 
oligonucleotide also had a restriction site 5’ to this sequence) into the pOGH vector. 
These constructs were labelled pOGFI-X where X refers to the number of nucleotides 
upstream of the transcriptional start site cloned in front of the human growth hormone 
gene. 3 Two other constructs were generated using pOGH-239 as a vector. Fragments 
isolated by restriction digestion of a defensin HNP1A genomic clone were cloned into 
the HincII site of pOGH-239 after they had been blunt-ended by klenow filling.
RI = EcoRI 
Hdlll = Hindlll 
Hell = HincII
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Figure 9.3: Schematic representation of the genration of reporter gene constructs 
used in this study.
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using the oligonucleotides with restriction site ends. All fragments generated by PCR 
were sequenced on both strands after cloning. The constructs pOGH-1100 and 
pOGH-850 were generated by cloning inserts into the HincII site of pOGH-239. The 
inserts were derived by HincII/EcoRI or HincII/Hindlll digestion of the HNP1A 
genomic clone. The fragments were blunt-ended by klenow filling in the restriction site 
ends prior to cloning into the pOGH-239 HincII digested vector.
9.3 Comparison of the activities of the reporter constructs in HL60, Raji 
and HeLa cells
One of the central aims of this project was to identify sequences which can 
confer myeloid-specific transcriptional activities on promoters and to characterise the 
proteins which mediate this effect. As the defensin gene is regulated in a strictly 
myeloid-specific manner in vivo, the reporter constructs described in section 9.2 were 
employed to test if this promoter was sufficient to confer this specificity. The 
constructs were introduced by transient transfections into HL60 (myeloid), HeLa 
(epithelial) and Raji (B-lymphoid) cell lines. The activities of the constructs were then 
compared in these cell lines to determine if any activity was limited to the myeloid cell 
line. It was of particular interest to correlate the in vitro DNA binding data described in 
chapter 8 with the results of these transfections.
The transient transfections were carried out by electroporation using the 
conditions described in section 9.1. In addition to the reporter constructs, 5[ig of the 
pSV2ASPAP plasmid was added to allow variations in transfection efficiency to be 
corrected. To allow comparison of the activities of different constructs between cell 
lines, it is necessary to have a standard reference promoter against which they can be 
compared. By talcing a promoter which has a similar level of activity in all cell types it 
is possible to compare the activity of different constructs in a number of cell lines by 
comparison of the activities of these constructs relative to this standard promoter. For 
the purpose of this study the herpes simplex virus thymidine kinase promoter was used
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in the pTKGH plasmid. This promoter is very commonly used in studies of this 
nature, as it is assumed to have equal activity in the cell lines tested, but it is worth 
bearing in mind that it is unlikely that any promoter has the same level of activity in all 
cell types.
9.3 (i) HL60
The results of transfecting HL60 cells are illustrated in figure 9.4. Most notable 
is that the construct pOGH-82 has the highest activity, and the inclusion of sequences 
between -105 and -130 repress the reporter gene expression. Sequences further 
upstream than -239 further repress the activity of the promoter. The region spanning 
-130 to -140 may contain a weak positive-acting sequence, although its full effect 
could be obscured by the repression generated by the -105 to -130 sequence. The 
simplest interperation of these results is that the reason for the high activity of the 
pOGH-82 construct is a result of the inclusion of the FP3 sequence, which binds a 
positive-acting regulator of transcription. In addition the smallest construct pOGH-32, 
which includes the proximal TATA box, up-regulates the expression of the reporter 
gene. This could be due simply to the inclusion of a TATA box which acts as a 
minimal promoter. Interestingly, immediately 3' of the TATA box is a putative Ets- 
binding sequence, whose sequence suggests that it could bind PU .l. This sequence 
can be seen to be weakly footprinted in the figure 8 .2 , but whether this plays any role 
in vivo remains to be seen.
The low level of activity seen when the sequences between -130 and -105 are 
included in the reporter construct suggests that the FP1 element may act as a repressor 
element in this promoter. This would be an intriguing possibility given that the FP1 
binding activity is rapidly down-regulated only on granulocytic differentiation, which 
corresponds to the expression of this gene. Inclusion of the 5' TATA box within the 
sequences -105 and -82 (see figure 8.2 B) also results in a reduced activity in 
comparison to that seen using the pOGH-82 fragment. It could be argued that the 
presence of this TATA box results in a change in the site of transcriptional initiation
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Figure 9.4: Histogram illustrating the average activity (table 9.4) of the pOGH- 
defensin reporter constructs after transient transfection into HL60 cells. Each bar 
represents the average activity of duplicate transfections in 8 independent experiments. 
The cartoon indicates the positions of the footprints in relation to the promoter reporter 
constructs.
Table 9.4: Human growth hormone activity o f the pOGH-defensin promoter 
constructs after transient transfection into HL60 cells. Xjig of the reporter construct 
(for pOGH, 5|ig was added and for each of the other constructs an equivalent molar 
amount was added), 5qg of pSV2ASPAP and bluescript to a total of 50|ig were 
cotranfected into HL60 cells as described in section 9.2. The medium was sampled 18 
hours post transfection and 1 OOjLil was assayed for human growth hormone activity by 
radioimmunoassay as described in chapter 4.20(iii). The figures represent counts per 
minute after normalising transfection efficiency using the pSV2ASPAP as an internal 
standard. The results are from 8 independent experiments, and the average and 
standard deviation are indicated in the table.
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Figure 9.4: Illustrating the average activity of the pOGH-defensin promoter
constructs after transfection into HL60 cells
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Table 9.4: Human growth hormone activity of HL60 cells transiently transfected 
with pOGH-defensin reporter constructs
EXP1 EXP2 EXP3 EXP4 EXP5 EXP6 EXP7 EXP8 Averag Std dev
POGH 5049 3176 4892 3060 2131 3221 4123 3076 3591 1006
PTKGH 6715 5122 9849 6157 5157 7664 8753 6994 7051 1661
POGH-1150 4127 3171 2111 1013 2117 2189 2953 2011 2461 936
POGH-850 3156 2233 1534 3080 1943 2790 3122 2315 2521 607
POGH-239 13725 10114 7894 4960 9768 8795 8893 8699 9106 2442
POGH-176 14132 11013 8943 11593 11042 10187 12376 11378 11333 1521
POGH-140 23992 21402 21707 14321 10143 11405 11578 16571 16389 5378
POGH-130 11978 9155 7768 15231 8543 7143 10687 12321 10353 2728
POGH-105 43171 40111 37442 23453 30922 27685 28754 31201 32842 6745
POGH-82 68921 63125 50143 40146 55894 52690 49885 61032 55229 9041
POGH-32 29460 32130 27485 11043 21031 23987 21087 24536 23844 1 6473
2 1 2
and the reduced level of transcription could be a result of interference by the attempted 
assembly of two preinitiation complexes. Clearly to determine if this is the case the 
site(s) of transcriptional initiation of these constructs needs to be determined; 
however, the low efficiency of the transfection into these cell lines would generate very 
low levels of message, and its relatively limited lifespan would mean the determination 
of the transcription start site(s) would require the production of stable transfectants.
9.3 (ii) Raji
The results of the transient transfection of the pOGH-reporter constructs into 
this cell line are straight forward to interpo^ (see figure 9.5). The positive control 
pTKGH construct gives a relatively high signal, and the promoterless pOGH plasmid 
has essentially no activity. The pOGH-32 and pOGH-82 have similar background 
levels of expression as the pOGH plasmid. All of the larger constructs have essentially 
no promoter activity, repressed below even that seen with the promoterless pOGH. 
These results suggest that this promoter has no activity in B-cells.
9.3 (iii) HeLa
The results of the transient transfection of the pOGH-defensin promoter 
constructs into this cell line can be seen in figure 9.6. The interpad'Ai&A of the results 
generated using this cell line are complicated by the high level of activity of the pOGH 
construct in this cell line, which is similar to that seen in the HL60 cell line. However, 
although in the HL60 cell line the defensin promoter had significantly higher activity 
than the pOGH construct, this is not seen when the constructs are introduced into 
HeLa cells. As can be seen in the figure the inclusion of the sequence containing FP3 
results in a small up-regulation of reporter gene activity. Inclusion of sequences further 
upstream reduce the activity of the reporter gene to below the level of the promoterless 
pOGH. As the activity of the constructs in this cell line are all lower than those with 
the tk promoter, the most straightforward explanation of the results is that the defensin 
promoter shows a much elevated level of expression in the myeloid (HL60) rather than
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Figure 9.5: Histogram illustrating the activity (table 9.5) of the pOGH-defensin 
reporter constructs after transient transfection into Raji cells. Each bar represents the 
average of four independent experiments.
Table 9.5: Human growth hormone activity of the pOGH-defensin promoter 
constructs after transient transfection into Raji cells. X |ig of the reporter construct (for 
pOGH, 5fig was added and for each of the other constructs an equivalent molar 
amount was added), 5pg of pSV2ASPAP and bluescript to a total of 50p.g were 
cotranfected into Raji cells by electroporation using the same conditions as those 
described for HL60 cells. The medium was sampled 18 hours post transfection and 
1 0 0 |il was assayed for human growth hormone activity by radioimmunoassay as 
described in chapter 4.20(iii). The figures represent counts per minute after 
normalising transfection efficiency using pSV2ASPAP as an internal standard. The 
results are from 4 independent experiments, and the average and standard deviation 
are indicated in the table.
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F ig u re  9.5: Illustrating the average activity o f the pOGH-defensin reporter
constructs into Raji cells
POGH 
PTKGH 
POGH-1150
construct p o g h - s s o
POGH-239 
POGH-176 
POGH-105 
POGH-82 
POGH-32
Table 9.5: Human growth hormone activity of Raji cells transiently transfected with 
the pOGH-defensin promoter constructs
EXP1 EXP2 EXP3 EXP4 AVE SD
POGH 313 400 60 317 272 147
PTKGH 13424 14005 3523 12432 10849 4926
1150 0 5 0 0 1 3
850 25 30 0 0 14 16
239 8 0 0 5 3 4
176 34 20 0 15 17 14
105 49 25 0 14 22 20
82 262 300 0 120 170 137
32 250 300 37 125 178 119
12000
C P M
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Figure 9.6: Histogram illustrating the average activity (table 9.6) of the pOGH- 
defensin reporter constructs after transient transfection into HeLa cells. Each bar 
represents the average of 7 independent experiments.
Table 9.6: Human growth hormone activity of the pOGH-defensin promoter 
constructs after transient transfection into Hela cells. X |ig of the reporter construct 
(for pOGH, 5|ig was added and for each of the other constructs an equivalent molar 
amount was added), 5|ig of pSV2ASPAP and bluescript to a total of 50jig were 
cotranfected into HeLa cells by electroporation using the same conditions as described 
for HL60 cells. The medium was sampled 18 hours post transfection and 100|il was 
assayed for human growth hormone activity by radioimmunoassay as described in 
chapter 4.20(iii). The figures represent counts per minute after normalising transfection 
efficiency using the pSV2ASPAP as an internal standard. The results are from 7 
independent experiments, and the average and standard deviation are indicated in the 
table.
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F ig u re  9.6: Illustrating the average activity of the pOGH-defensin promoter
constructs after transient transfection into HeLa cells
POGH 
PTKGH 
POGH-1150
construct POGH-850 
POGH-239
POGH-176
POGH-105
POGH-82
POGH-32
CPM
Table 9.6: Human growth hormone activity of HeLa cells transiently transfected with 
the pOGH-defensin reporter constructs
0 3000 6000 9000 12000
expl exp2 exp3 exp4 exp5 exp6 exp7 averag std de
POGH 4101 2330 3392 3632 3219 4122 3367 3451 609
PTKGH 12873 8976 11134 9810 10167 8975 12456 10627 1580
POGH-1150 2101 1899 2011 2132 2580 3101 2936 2394 478
POGH-850 1299 2123 1997 1856 3108 2310 2256 2135 545
POGH-239 2290 2134 2101 1865 3102 2749 2693 2419 439
POGH-176 2789 1228 1992 2256 1863 2184 2394 2100 486
POGH-105 4001 2430 3011 2662 3145 4389 3927 3366 742
POGH-82 7197 4511 5677 6227 6753 5219 4845 5775 997
POGH-32 5113 3122 4886 5112 6219 6391 5871 5244 1104
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the epithelial (HeLa) compartment. A high level of pOGH activity is seen in both HeLa 
and HL60 cell lines, although in the latter cell line the defensin promoter has a much 
greater activity than pOGH, this is not seen when the reporter constructs are 
introduced into HeLa cells.
Conclusions
In summary, the first 80 bp of the promoter seems to confer some myeloid 
specificity on the promoter when activities are expressed relative to the either the tk 
promoter or the promoterless pOGH plasmid (table 9.7). It is of interest however to 
note that in the HeLa cell line the pOGH-82 construct does have some activity, and 
inclusion of sequences further upstream than -82 represses activity below the level 
seen in pOGH in both HeLa and Raji transfections. This repression seems to be mainly 
a result of the inclusion of the sequences -82 to -105, which include the 5’ TATA box. 
It could be that the attempt to assemble two preinitiation complexes results in the 
interference of the low level of transcription generated in these cell lines using the small 
constructs.
Two of the sequences which had been indentified as footprints using HL60 
nuclear extract have significant effects on the expression of the reporter gene. The 
construct pOGH-82 includes the FP3 sequence and shows the highest activity in HL60 
cells, suggesting that the FP3 binding activities are positive regulators of this 
sequence. The inclusion of the FP1 sequence in the construct pOGH-130 leads to a 
significant reduction in the activity of this promoter suggesting that the FP1 binding 
activities are acting as a repressor. The effect of the FP2 sequences may well be 
masked by the repressive effect of the FP1 sequence which significantly reduces 
expression. The other sequences which were of interest were the putative c-Myb 
binding sites, although c-Myb binding activity could not be detected in nuclear 
extracts. Further experiments were undertaken to investigate the role of c-Myb in the 
regulation of this gene.
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Table 9.7: The relative activities of the pOGH-defensin promoter constructs in the 
cell lines. The activities are expressed relative to the activity of the pTKGH plasmid, 
which is given an arbitrary value of 1 in each cell line.
HL60 Raji Hela
PTKGH 1.00 1.000 1.00
POGH-1150 0.35 0.000 0.23
POGH-850 0.36 0.001 0.20
POGH-239 1.29 0.000 0.23
POGH-176 1.60 0.002 0.20
POGH-140 2.32 . m
POGH-130 1.47 • m
POGH-105 4.65 0.002 0.32
POGH-82 7.80 0.016 0.54
POGH-32 3.34 0.016 0.49
POGH 0.51 0.025 0.37
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9.4 (i) T he defen sin  gene is a target for c-M yb tran sactivation
Given that the promoter contained two potential c-Myb binding sites (figure 
8 .1), and its expression pattern suggests that this gene would be a good candidate 
gene for regulation by c-Myb, it was decided to test reporter constructs to determine if 
they could be transacttoatJ by exogenous c-Myb. The expression construct pJ4myb 
containing a full length mouse cDNA under the control of the Moloney murine 
leukaemia virus LTR , and a similar construct with a small deletion which prevents c- 
Myb from binding to DNA (pJ4mybAR3), were kindly provided by Dr.R.Watson. In 
addition the Myb binding sites in the pSVnMCAT plasmid (provided by Dr.R.Watson) 
were removed by restriction enzyme digestion and cloned upstream of the tk promoter 
to act as a positive control for c-Myb responsiveness.
A series of the pOGH-defensin promoter constructs described in section 9.2 
were co-transfected with the c-Myb expression vector (5fig of pOGH-X; 5|ig of 
expression vector; 5pg of pSV2ASPAP) into the HL60 cell line. This cell line already 
contains endogenous c-Myb, but the inclusion of the sequence between -130 and -105 
which contained the putative c-Myb binding site acted as a repressor in the transient 
transfection experiments. A hypothesis to explain these results is that the C/EBP-like 
factor that binds this sequence in vitro is a repressor which is rapidly lost on 
differentiation, allowing c-Myb to bind and activate expression of the gene. By 
elevating the levels of c-Myb by the introduction of an expression vector we might 
expect to relieve this repression. The results of this experiment can be seen in figure 
9.8. Clearly the expression of exogenous c-Myb in this cell line transactivates the 
reporter constructs which contain a single c-Myb binding site (pOGH-130, -176 and 
-239). The transactivation is of the order of around 3.5-fold. In addition, the largest 
construct tested (pOGH-850) contains a second potential c-Myb binding site centered 
around nucleotide -240, and is up-regulated approximately 5-fold by exogenous c-
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Figure 9.7: FP1 - a composite C/EBP-Myb binding sequence?
C A C C T T C C C A  C C A A A T T T C T  
G T G G A A G G G T  G G T T T A A A G A  G T
C A C C A C A
G A  A C G G T G G T G T
C/EBP homology
—  Myb homology
B C7EBP Repression
Activation
mm 9 9 9 9
Figure 9.7 A: The FP1 sequence from the defensin promoter. Putative C/EBP and 
Myb binding sequences are illustrated by the shaded boxes. B: Potential protein-DNA 
interactions at the FP1 sequence. The possible consequences of these interactions on 
the promoter activity are indicated in the figure. This is discussed in detail in section
9.4 (i).
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Figure 9.8: Histogram illustating the effect of exogenous c-myb expression on the 
activity of the pOGH-defensin promoter constructs in HL60 cells. Each bar represents 
the average activity from the results in table 9.8.
Table 9.8: The effect of exogenous c-myb expression on the activity of the pOGH- 
defensin promoter constructs in HL60 cells. An equimolar amount of the pOGH- 
defensin reporter construct (5|ig for pOGH and an equimolar amount of the other 
constructs), 5pg of pSV2ASPAP, 5pg of pJ4myb or pJ4AmybR3 (where apropriate) 
and bluescript to a total of 50pg were cotransfected into HL60 cells as previously 
described in section 9.2. The medium was sampled 18 hours post transfection and 
lOOjil was assayed for human growth hormone activity by radioimmunoassay as 
described in chapter 4.20(iii). The figures represent counts per minute after 
normalising transfection efficiency using the pSV2ASPAP as an internal standard. The 
average activity and standard deviation are shown in the table.
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F igure 9.8: Illustrating the effect o f exogenous c -myb expression on the activity of
the pOGH-defensin promoter constructs in HL60 cells
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Table 9.8: The effect of exogenous c-myb expression on the activity of the pOGH- 
defensin promoter constructs in HL60 cells
expl exp2 exp3 exp4 exp5 exp6 exp7 exp8 averag std dev
POGH 5049 3176 4892 3060 2131 3221 4123 3076 3591 1006
PTKGH 6715 5122 9849 6157 5157 7664 8753 6994 7051 1661
POGH-850 3156 2233 1534 3080 1943 2790 3122 2315 2521 607
POGH-239 13725 10114 7894 4960 9768 8795 8893 8699 9106 2442
POGH-176 14132 11013 8943 11593 11042 10187 12376 11378 11333 1521
POGH-130 11978 9155 7768 15231 8543 7143 10687 12312 10352 2727
POGH-32 29460 32130 27485 11043 21031 23987 21087 24536 23844 6473
PTK-MBS 6551 7551 4556 5673 - - - 6082 1274
850+myb 13430 10699 4695 12134 10224 13451 15431 11437 3462
239+myb 34567 38675 - - - - - 36621 2904
176+myb 36823 34159 - - - - - 35491 1883
130+myb 37806 36272 27913 43189 27649 21002 31875 32241 7453
32+myb 31763 27312 27531 13476 19753 25611 23562 24144 5987
MBS+myb 18776 20114 18112 16943 - - - 18486 1323
850+mybd 3155 2422 1150 3753 2165 - - 2529 991
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myb expression. Clearly, however, a large amount of extra sequence is included in 
this construct and the fragment which is c-Myb responsive needs to be further mapped.
It has been reported that the c-Myb protein can activate the expression of genes 
such as hsplO without binding to DNA (Foos et al., 1993). To test if the ability of c- 
Myb to transactivate this promoter is dependent on DNA binding (rather than activating 
the gene by titrating out an essential cofactor/component of the basal transcription 
machinery - 'squelching'), the mutant c-myb in the expression vector was employed 
as the protein generated fails to activate transcription because it does not bind DNA. 
This mutant was unable to transactivate the expression of the pOGH-850 reporter 
construct. This suggests that the ability of c-Myb to bind to DNA is essential for its 
activity at this promoter. Possibilities which cannot be excluded are that the mutant is 
not expressed or translated or stable in this cell line, although these seem unlikely as 
both pJ4myb and pJ4mybAR3 expression plasmids are identical except for an 
inactivating deletion in the DNA binding domain of c-myb.
9.4 (ii) c-Myb fails to transactivate the defensin gene in HeLa cells
To determine if the transactivation of the defensin promoter seen in HL60 cells 
could be repeated in non-haemopoietic cells, the above experiment was repeated in the 
epithelial cell line HeLa. However, in this case no transactivation of the pOGH- 
defensin promoter constructs could be seen using the c-myb expression vector (figure 
9.9). The reasons for the lack oftransactivation uv HeLa cells is not clear, but there are 
a number of possible explanations. The first possibility is a failure to generate c-Myb 
in this cell line. The promoter should be active in this cell line, however, c-Myb itself 
may not be active, perhaps as a result of abnormal phosphorylation or rapid 
degradation. This is suggested by the inability of this construct to transactivate the 
synthetic c-Myb-responsive promoter (figure 9.9) which was increased 3-fold in the 
HL60 cell line in response to exogenous c-myb expression (figure 9.8). Other
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Figure 9.9: Histogram illustating the effect of exogenous c-myb expression on the 
activity of the pOGH-defensin promoter constructs in HeLa cells. Each bar represents 
the average activity from the results in table 9.9.
Table 9.9: The effect of exogenous c -myb expression on the activity of the pOGH- 
defensin promoter constructs in HeLa cells. An equimolar amount of the pOGH- 
defensin reporter construct (5p.g for pOGH and an equimolar amount of the other 
constructs), 5p,g of pSV2ASPAP, 5[ig of pJ4myb or pJ4AmybR3 (where apropriate) 
and bluescript to a total of 50p.g were cotransfected into HeLa cells as previously 
described in section 9.2. The medium was sampled 18 hours post transfection and 
100p,l was assayed for human growth hormone activity by radioimmunoassay as 
described in chapter 4.20(iii). The figures represent counts per minute after 
normalising transfection efficiency using the pSV2ASPAP as an internal standard. The 
average activity and standard deviation are shown in the table.
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Figure 9.9: Illustrating the effect of exogenous c-myb expression on the activity of
the pOGH-defensin promoter constructs in HeLa cells
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Table 9.9: The effect of exogenous c-myb expression on the activity of the pOGH- 
defensin promoter constructs in HeLa cells
expl exp2 exp3 exp4 average Std dev
PTKGH 2143 3187 3359 2179 2717 646
POGH-850 677 511 812 695 673 123
POGH-239 1534 2118 2674 1769 2023 495
POGH-32 2133 3124 4111 2378 2936 889
PTKGH-MBS 1892 3016 3190 1899 2499 700
850+Myb 813 512 917 892 783 186
239+Myb 1889 2512 2895 3128 2606 468
32+Myb 2234 3016 3379 2457 2771 521
MBS+Myb 2078 2917 3673 2017 2671 783
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explanations such as the absence of another factor essential for promoter activity are 
possible.
9.5 Use of point mutants to investigate the composite Myb-C/EBP element
Given that the promoter could be transactivated by exogenous c-m yb  
expression when the FP1 sequence was present, the role of this sequence was further 
investigated by the generation of FP1 point mutants which would be predicted to 
abolish either C/EBP or c-Myb binding (figure 9.10 A). The putative c-Myb and 
C/EBP binding sequences can be seen in figure 9.7. The ability of the mutants to bind 
the FP1 activities was tested by EMSA. FP1 radiolabelled probe was incubated with 
F1L60 nuclear extract, and competitor oligonucleotides were included as indicated in 
figure 9.10B. This reveals that, as predicted, the mutant muC fails to compete with 
the wild-type sequence for binding of FP1 binding protein(s). The c-Myb binding 
mutant muM however also competes less efficiently for the FP1 DNA binding 
protein(s) than the wild-type sequence. Whether the FP1 muM mutant would bind c- 
Myb less efficiently than the wild type is unknown, as I was unable to translate c-myb 
RNA in a reticulocyte lysate (data not shown). Clearly this is an important experiment, 
and the approach of expressing this protein in bacteria could be undertaken. The point 
mutations however would be predicted to abolish binding as the C at nucleotide -109 
(mutated to A) and the G at nucleotide -107 (mutated to C) were found in 51 and 46 
out of a total of 51 potential c-Myb binding sites generated by the selection from 
random oligonucleotides (Howe and Watson 1991).
These mutant constructs were transiently transfected into HL60 cells to assay 
the effect of the mutations on both the basal activity in these cells and the ability to 
respond to exogenous c-myb expression. The results can be seen in figure 9.11. 
Contrary to expectations, the muC mutant shows a reduced level of activity compared 
to the wild-type construct. This is suprising as the wild-type FP1 sequence seems to 
act as a repressor when included in the promoter constructs. If C/EBP-like binding
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Figure 9.10 A: Illustrating the sequence of the mutant promoters. The pOGH-130 
contains the wild type sequence of the defensin HNP1A from -130 to +10. The 
constructs muM and muC are identical except for the point mutations which are 
indicated by the shaded boxes.
B: Investigation of the DNA binding properties of the mutant FP1 sequences. An 
EMSA was carried using radiolabelled FP1 oligonucleotide and HL60 nuclear extract 
as described in methods. HL60 nuclear extract (5|ig) was included in the reactions as 
labelled in the figure. Competitor double-stranded oligonucleotides were added at 50- 
fold molar excess as indicated in the figure. The sequence of the sense strand of these 
mutant oligonucleotides are listed.
w t : AAGCTTACCAAATTTCTCAACTGTCCTAAGCTT 
muC: AAGCTTACCAAAGGTATCAACTGTCCTAAGCTT 
muM: AAGCTTACCAAATTTCTCAAATCTCCTAAGCTT
228
AAAGCTTCCCACCAAATTTCTCAACTGTCCTTGCCACC POGH 130 
A A G CTTCCCA CCA A^^I& CA A CTG TCCTTG CCA CC nuiC 
AAGCTTCCCACCAAATTTCTCAABrgrCCTTGCCACC muM
HI - point mutant
B
. I -
c o m p e t ito r  
n u c le a r  e x tr a c t
S u
3 3 «
-  S S *
o  o  o  oo o o c
J J J J
X S S I
Figure 9.11: Histogram illustrating the effect of expression of exogenous c-myb on
the FP1 mutant promoters in HL60 cells. Each bar represents the average activity of
the results in table 9.11.
Table 9.11: The effect of exogenous c-myb expression on the human growth 
hormone activity of the FP1 mutant promoter constructs after transient transfection into 
HL60 cells. 5|ig of the FP1 mutant promoters, 5p.g of pSV2ASPAP, 5|J.g of pJ4myb 
(where apropriate) and Bluescript to a total of 50fig were cotransfected into HeLa cells 
as previously described in section 9.2. The medium was sampled 18 hours post 
transfection and lOOpl was assayed for human growth hormone activity by 
radioimmunoassay as described in chapter 4.20(iii). The figures represent counts per 
minute after normalising transfection efficiency using the pSV2ASPAP as an internal 
standard. The average activity and standard deviation are shown in the table.
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Figure 9.11: Illustrating the activity of the FP1 mutant promoters in HL60 cells and
their response to exogenous c-myb expression
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Table 9.11: Human growth hormone activity of the FP1 mutant promoters 
in transiently transfected HL60 cells and in response to exogenous c-myb 
expression
1 2 3 4 5 6 7 8 averag std dev
PTKGH 6178 9643 3987 7654 5432 8539 7859 7122 7051 1801
muC 3785 2342 2412 2442 1765 2764 2248 - 2536 625
muM 1238 1398 2187 1916 1018 1756 1176 - 1527 432
POGH-130 9155 8195 14237 12456 8828 9654 7561 12345 10303 2395
muC+Myb 23971 13048 19865 27566 22317 25164 17895 - 21403 4536
muM+Myb 8161 7979 14572 11571 8659 9123 7925 - 9712 2487
130+Myb 31984 33168 42106 35431 28563 31875 25438 - 32652 5278
activity at FP1 was responsible for this repression, we might expect the muC 
sequence to have a higher activity than the wild-type sequence. The muM construct 
also shows reduced activity with respect to the wild-type construct. This would be 
expected if the c-Myb positively regulates the gene through this sequence as c-Myb is 
present in these cells (Pedrazoli et al., 1989). Clearly it is necessary to determine if c- 
Myb can still bind to the muC mutant as this could explain the reduced activity of this 
construct with respect to the wild-type sequence.
The ability of these constructs to be transactivated by the c-Myb expression 
vector was also tested. The results can be seen in figure 9.11. The wild-type promoter 
shows the highest level of activity when c-Myb is expressed in these transients. 
However, both of the mutant promoters muC and muM are transactivated by 
exogenous c-myb expression. The interperation of these data is complicated and is 
discussed in detail in Chapter 10.
9.6 Effect of differentiation on the activity of the constructs
In addition to the identification of m yeloid-specific sequences, the 
identification of the sequences which control the differentiation-stage-specificity of the 
expression of this gene was of particular interest. The long-term aim of the project was 
to characterise the proteins that would mediate this specificity to provide an insight into 
the control of differentiation and how this process may be subverted in leukaemia. 
Most of the work in this study has employed the HL60 cell line as a model of 
myelopoiesis. The advantage of this cell line is that the cells can be readily induced to 
differentiate. As the FP1 activity was rapidly down-regulated during DMSO-induced 
differentiation the effect of this rapid loss of the putative repressor could be tested by 
transient assay after DMSO treatment. Unfortunately treatment of the cells with DMSO 
led to a reduction of the transient transfection efficiency which made this approach 
unpracticable. Not only was the efficiency of transfection significantly different 
between induced and uninduced cells, but also, there was concern that the cells into
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which DNA entered were a subpopulation of cells. This necessitated the generation of 
stable cell lines containing the constructs, allowing the assay of activity over the 
relatively long differentiation time course. Although this laboratory had successfully 
generated stable transfectants using the neomycin resistance gene as a selectable marker 
(K. Ryan personal communication), this gene interferes with the differentiation of this 
cell line (von-Melcher and Housman 1988). The use of the marker histidinol 
dehydrogenase was employed as an alternative but variations in the sensitivity of the 
cells between experiments made this approach unsuccessful.
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Part 4: Discussion
10.1 Investigation of defensin gene expression
(i) Survey of cell lines for defensin gene expression
Previous data provided strong evidence that the defensin genes were 
expressed only in myelocytes. In summary, expression has been detected in 
myelocytes in normal bone marrow by in situ hybridisation, the peripheral blood 
of CML and occasionally in ANLL patients (consistent with the presence of 
myelocytes in these samples, Daher et al.y 1989). In addition, expression has 
previously been reported in HL60 cells (Daher et al.y 1989;Wiedemann et al., 
1989).
The levels of defensin mRNA are relatively high in cells that express these 
genes (e.g. peripheral blood samples from CML patients consistently have very 
high levels despite consisting of a heterogeneous population of cell types, of 
which only a fraction consist of myelocytes), as these genes encode proteins 
which comprise a major component of granule protein in neutrophils. Clearly if a 
myeloid cell line was maturation arrested at a myelocyte-like stage of 
differentiation, if they were representative of their normal or leukaemic 
counterparts, then we would expect them to express the defensin genes. To date, 
no myelocyte like cell line has been isolated, presumably because this represents 
a relatively late stage of differentiation. HL60 cells however, are predominantly 
promyelocytic in nature. Expression of the defensin genes in these cells could be 
a result of some transcription occurring in the immediate precursor to the 
myelocyte. Alternatively, as the HL60 cell line is comprised of a heterogeneous 
population of cells, expression could be within a more mature sub-population. 
Although around 90% of HL60 cells are promyelocytic, the other 10% of the 
population are more mature cells which have/are spontaneously differentiating
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(Collins et al., 1977). Variation between different sub-lines can occur with earlier 
passages showing a greater propensity to spontaneously differentiate. This could 
explain why some lines express the defensin genes and others do not, however, 
it is unlikely to explain why the line in this laboratory ceased to express these 
genes. Analysis of 6 sub-lines of HL60 (Lamb 1990) suggested that expression 
of these genes is not common in this cell line. If the lack of expression of the 
defensin genes was a result of simply HL60 representing a more primitive cell, 
then induction of differentiation of this cell line would be expected to activate 
expression of this gene. Expression of these genes could not be detected and 
western blot analysis could detect no production of protein during a time course 
of induced differentiation of this cell line.
A number of other myeloid cell lines were also analysed for expression of 
the defensin genes. These cell lines appear to represent more primitive 
progenitors than the HL60 cell line. The logic of this approach was that if for 
some reason expression of the defensin genes was selectively disadvantageous 
then cells may evolve such that they are not expressed. However, if these more 
primitive cells can be induced to differentiate through the defensin expressing 
myelocyte stage then there would be no selective disadvantage to expressing these 
genes as the cells will be committed to terminal differentiation. However, again 
no expression of the defensin genes could be detected.
A large range of cell lines which might be predicted to express the 
defensin genes were tested for expression without success. There were two 
possible explanations. The first is that the defensin proteins cannot be tolerated 
(i.e. selectively disadvantageous) in tissue culture and hence cells rapidly evolve 
to switch off expression. The second is that the environment in vitro is such that 
the differentiation program/ myeloid phenotype is aberrant, perhaps due to lack 
of stromal contact or absence of soluble regulatory molecules. If the latter 
explanation is correct how can we explain the previous detection of defensin gene
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expression in cell lines? One possibility is that the expression was the result of an 
inflammatory reaction, rather than a consequence of the differentiation status of 
the cells. Although the defensin proteins have been identified almost exclusively 
in neutrophils, they have been reported to be present in rabbit alveolar 
macrophages; in addition, the levels of these peptides were increased when the 
rabbits were challenged with the inflammatory agent Freunds Adjuvant (Lehrer et 
al.y 1981). Although defensin peptides have not been detected in human 
macrophages it is not inconceivable that under certain circumstances they may be 
induced to express the defensin genes. Along similar lines, an indirect effect of 
an inflammatory reaction could induce expression; a culture of HL60 cells 
contains a small amount of mature macrophage and neutrophil-like cells and these 
may respond to a pyrogen by the generation of cytokines such as IL-6 or G-CSF. 
These factors may induce differentiation or the activation of a subset of genes 
which are a component of the differentiation program. It is also possible that 
these factors may synergise with DMSO to induce a more representative 
differentiation program. These questions were addressed by treating cells with a 
combination of inflammatory and differentiation-inducing agents; however, no 
defensin either at mRNA or protein level could be detected.
A component of the serum used at the time may have an activity which 
potentiates differentiation and is necessary for the expression of the defensin 
genes. However, to test this possibility requires the comparison of batches of 
serum which are unobtainable. Clearly why the defensin genes are not expressed 
is a mystery, and any explanation must take into consideration that there are two 
different genes present in HL60 cells suggesting that direct mutation is an 
unlikely mechanism (as there are no gross deletions around the genes). One 
possibility investigated in this study was that methylation was responsible for 
repressing gene expression.
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(ii) The role of methylation in the repression of defensin gene
expression
Hypomethylation has long been correlated with gene expression and two 
classes of promoters can be identified with respect to methylation:
1) Genes that are CpG rich and are often constitutively unmethylated, 
generally a characteristic of housekeeping genes.
2) Genes which are methylated in all tissues in which they are not 
expressed; this methylation pattern is characteristic of tissue-specific genes.
The defensin genes appear to be an example of the latter, being 
methylated in all non-expressing cells tested, including a sample from a 
leukaemia patient which contained 90% myeloblasts, suggesting that in immature 
cells of the granulocytic lineage the defensin genes are also methylated and 
demethylation occurs during differentiation. The general problem in the 
interpretation of studies of this nature is that the data is correlative i.e. does the 
demethylation precede the transcription or is it a consequence? However, much 
emerging data suggests that methylation may play a key role in the regulation of 
gene expression. This was discussed in the Introduction in section 2.1(ii), and 
involves two potential mechanisms; namely, either the methylation of key 
transcription factor binding sites which prevents the binding of the appropriate 
factor, or the binding of repressor proteins specifically to methylated DNA. 
Evidence from a number of laboratories suggests that the second mechanism may 
be particularly important in the repression of CpG-rich promoters, and the 
inactivation of genes in tissue culture as a result of methylation of sites not 
normally methylated in vivo (Boyes and Bird 1991; Antequera et al., 1991).
Are either of these mechanisms likely to be important in the repression of 
the defensin genes? As the defensin genes appear to be methylated in cells which
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do not express the defensin genes in vivo (e.g. lymphocytes), whether the 
defensin genes are methylated in HL60 and as a consequence are not expressed, 
or simply are methylated as a result of not being expressed, is difficult to 
determine. If we postulate that these genes are repressed in HL60 by methylation, 
how is this to be mediated? As the defensin genes are highly expressed at the 
correct stage of differentiation one would predict that in these cells powerful 
promoter and/or enhancer elements would mediate this. It appears that the 
repression of transcription by the binding of proteins to mCpG is dependent on 
the density of mCpG surrounding the gene. A highly methylated gene is 
repressed in a transient transfection assay irrespective of the presence of a 
powerful enhancer. In contrast, a weakly methylated promoter is repressed but 
only in the absence of an enhancer (Boyes and Bird 1992). Analysis of the 
sequence available of the defensin HNP1A genomic clone reveals that this is not 
a particularly CpG dense gene and no CpG island has been identified. This would 
suggest that the binding of repressors to methylated DNA is unlikely to be the 
mechanism of repression in these cells. Alternatively, as there is a moderate 
number of CpG residues throughout the sequenced regions, and the HL60 
genome appears to be grossly under-methylated in comparison to both that of the 
lymphocytes and all of the leukaemia samples studied (see section 6.6, figure 
6.9), it may be that higher levels of mCpG binding proteins, MeCPl or MeCP2 
are available to mediate a repressive effect on those sequences which are 
methylated in this cell line (Boyes and Bird 1991).
Perhaps a more attractive model to explain the repression is the 
methylation of sequences which bind key transcription factors. The FP3 sequence 
mediates expression of reporter constructs in transient transfection in HL60 cells 
and appears to bind an Ets family member(s) (see section 8.5iii). The FP3 Ets- 
binding sequence CCGGA is methylated in HL60 cells. The result of methylation 
of this residue on the affinity of Ets family proteins for this sequence is unknown
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but the binding of Ets-1 and Fli-1 to the almost identical E74 sequence requires a 
C immediately 5' of the GGAA sequence for high affinity binding (Fischer et al., 
1991; Zhang et al., 1993). This suggests that the presence of a methyl group at 
this site could potentially prevent binding. Another area that may be an important 
region in the regulation of these genes is the first intron. This site has been found 
to contain a DNAse 1 hypersensitive site in expressing cells suggesting it may be 
important in the regulation of these genes, although data on the factors which 
bind to this site remain to be elucidated. The first intron contains a high 
proportion of CpG residues in this region and hence could play a role in either 
preventing binding of transcription factors or may even bind to MeCP-like 
proteins preventing access of other transcription factors or altering the structure of 
the chromatin.
If the defensin genes are repressed by methylation then why is this 
repression not relieved by 5-azacytidine treatment? Obviously, this agent has a 
global effect on gene expression, as is apparent by its ability to induce 
differentiation. It is possible that although the defensin genes become 
demethylated as a result of the treatment, other changes within the cell 
transcriptional machinery may mean that the combination of transcription factors 
required for defensin gene expression is no longer present This is not an unlikely 
scenario given that the defensin genes are expressed only during a very narrow 
window of differentiation, suggesting the specific regulatory regime for 
expression of these genes is very limited.
(iii) Why are the defensin genes not expressed in tissue culture?
Are the defensin genes not expressed because they are selectively 
disadvantageous to growth in culture? This is a possibility given the 
destructiveness of the defensin peptides to cells. Although these molecules are
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sequestered to the granules and must be cleaved to become active, a small 
amount of leakage may be fatal. The HL60 cells have an incomplete 
differentiation program and do show some granule abnormality which may mean 
the defensins are not stored as well as they are in vivo (Newburger et al., 1979; 
Olsson et al.y 1981). What effect the defensins would have within cells is 
unknown but in addition to the ability to puncture plasma membranes, they are 
very potent inhibitors of protein kinase C which may affect the growth and 
differentiation properties of the cells (Charp et al., 1988).
As discussed previously, many genes are switched off in culture by 
methylation, presumably those which are not necessary for growth. The 
culturing of cells in high serum conditions places a high selective pressure for 
cells which can replicate more rapidly. The work of Bird and Boyes (1992), 
suggested that 50% of CpG islands were methylated in L and 3T3 cells indicating 
a massive switch off of non-essential gene expression. The loss of expression of 
genes which are non-essential for growth may include transcription factors which 
may play a role in generating the mature phenotype, and the early passage HL60 
cell lines show a higher propensity to spontaneously differentiate than do the later 
passages. The loss of expression of the defensin genes may be a direct effect as a 
result of its non-essential nature and perhaps deleterious effects on growth. 
Alternatively, it may reflect an indirect mechanism such as the loss of a 
transcription factor which predisposes the cells to spontaneously differentiate 
which is involved in generating the mature phenotype. Loss of such a factor 
would be advantageous as the cells would have a selective advantage, but this 
loss may affect the pattern of induced differentiation as those genes which are 
regulated by this transcription factor will no longer be expressed.
As discussed in section 10.4, a C/EBP-like factor appears to play a key 
role in the regulation of defensin gene expression. One potential candidate is 
C/EBP|3, which has been implicated in the chicken to be involved in generating
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the mature myeloid phenotype. If this is the case it may be that this factor can 
synergise with c-Myb on the defensin promoter to transactivate gene expression. 
Loss of this factor may generate a cell line less likely to differentiate 
spontaneously which would hence have a growth advantage (or alternatively, the 
activation of the negative regulator of C/EBPp (LIP) activity could be up- 
regulated). In addition the C/EBP family can mediate growth arrest in heptatic and 
adipose tissue (Buck et al., 1994). Clearly if a family member(s) mediates a 
similar effect in myeloid cells, loss of this factor’s activity would be selectively 
advantageous for growth and possibly contribute to the imbalance between 
growth and differentiation that is manifested as maturation arrest seen in 
leukaemia.
10.2 DNAsel hypersensitivity analysis
The DHS analysis was undertaken to provide some information as to 
areas of chromatin that may play some role in the control of defensin gene 
expression in vivo. A comparison was made between the chromatin structure 
around the defensin genes in both myeloid and non-myeloid cells and samples 
from both normal and CML samples. The CML samples were used as a source of 
defensin-expressing cells; this allowed us to assess if there were any sites which 
were ubiquitous, lineage-specific, differentiation-specific or correlated with 
expression of the gene. Clearly, interpretation of the results is not 
straightforward as a consequence of the CML samples being comprised of a 
mixed population of cells. Fortunately for this study, there seems to be no DHS 
in cells outside the myeloid compartment or in fully differentiated granulocytes 
which allows us to assume that the DHS identified in the CML samples are within 
the chromatin of the immature myeloid cells within these samples.
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A summary of the DHS identified in this study are presented in figure 
7.8. What does the presence of these hypersensitive sites tell us? As the sites 
were only found in myeloid cells and at a particular stage of differentiation, one 
could conclude that these sites could be generated by transcription factors that are 
restricted in activity to these cells (alternatively a combination of factors that are 
unique to these cells). Clearly identification of these factors would be of prime 
interest not just in regard to the regulation of the defensin genes, but to the 
regulation of myeloid-specific gene expression as myeloid-specific transcription 
factors (if they exist) have yet to be identified. In addition if these factors are only 
active in immature cells of the myeloid lineages, they could be candidates for 
activation in leukaemogenesis.
A question to be addressed is, what are the functions of these DNAse 1 
hypersensitive sites in vivol It seems that all of the sites which have been studied 
in detail to date have an important biological function, and in addition to sites 
important in transcriptional control, have been implicated in occurring at sites of 
replication origins, attachment to the chromosomal matrix and topoisomerase II 
binding sites (Gross and Garrard 1988). As the defensin genes do not contain 
DHS over the region assessed outwith the myeloid compartment, it seems likely 
that the DHS identified was involved in the transcriptional control of these genes.
The difficulty with this study, is that the classical approach of 
footprinting these sites to identify any specific footprint is complicated by the 
mixed nature of the CML samples. It is possible to utilise mixed populations of 
cells and carry DHS analysis and compare the sites to differential cell counts, as 
if a specific cell type contains a DHS the intensity will be directly proportional to 
the number of these cells in the population. However the proportion of any given 
nuclear protein will not directly reflect the differential cell count as any DNA 
binding activity present could be the result of a small population of cells highly 
expressing the factor, or a large population of cells with low levels. As many
243
transcription factors can bind to sites in vitro which they never occupy in vivo, 
implicating a specific footprint in transcriptional control would be difficult.
10.3 The use of HL60 as a model system
A problem was faced in progressing this project. The DNAse 1
analysis had suggested areas which may be important in mediating the 
transcriptional control of these genes, however, an extension of the work was 
problematical. One approach would be simply to characterise more CML samples 
(when they became available) for DHS to allow a correlation between particular 
sites and the proportion of certain cell types in the samples, allowing the 
identification of the stage of differentiation which the sites were hypersensitive. 
However, without a method of purifying particular cell types from these samples 
to allow characterisation of DHS by in vitro DNA binding studies, this approach 
would be of limited use. The use of mixed populations of cells in DNA binding 
studies is not desirable, even if the cell type of interest is in the majority. This is 
for two reasons, most obviously the source of DNA binding activity cannot be 
determined. Secondly, the nuclear extract taken from a sample does not 
represent a freeze frame of the transcription factor complexes present at the time 
of preparation of the extract. Rather, most transcription factors can dimerise and 
this can take place in vitro, often very rapidly. It is possible that complexes can 
be generated which do not exist in any of the cells present in vivo. A further 
disadvantage of the use of CML samples is that they cannot be employed in 
transfection assays. This is because the different cell types in the samples are 
likely to have very different transfection efficiencies, rendering any results 
unrepresentative (in addition, these samples could only be transfected at an 
extremely low efficiency).
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To obtain the information which was the goal of the project i.e. the 
identification of transcription factors which mediate myeloid and differentiation- 
stage-specific expression, it was necessary to utilise a model human 
myelopoiesis. The HL60 cell line was employed as it would provide a number of 
useful advantages. Primarily this is a cloned cell line which hence can provide 
relatively large amounts of material for analysis. This cell line can be induced to 
differentiate with a number of different agents to either monocytic/macrophage or 
granulocyte like cells. This differentiation is well characterised and is 
accompanied by easily monitored changes in morphology, as well as by simple 
markers (reviewed in Collins 1987). This allows changes in the activity of 
transcription factors to be assessed using controlled experimental conditions, in 
addition the activity of reporter constructs can be assessed by introduction into 
this and other non-myeloid cell lines.
Clearly as this cell line does not express the defensin genes, this is not an 
ideal model. However, it is likely the lack of expression is the result of the loss 
of a single transcription factor, and as all genes are regulated by numerous DNA 
protein interactions, analysis of this promoter in these cells is likely to yield 
much information. In addition, as the aim of the project is to identify 
transcription factors which mediate myeloid and differentiation-specific 
expression then, if any reporter constructs show any myeloid-specificity or 
differentiation-stage-specificity in transfection assays, the identification of the 
transcription factors which mediate it is likely to be of interest, even if it does not 
represent the complete picture of the defensin transcriptional regulation.
For these reasons, the approach taken was to analyse the immediate 
promoter by DNA binding studies comparing nuclear protein from myeloid and 
non-myeloid cell lines and transfection assays of defensin promoter-reporter 
constructs in myeloid and non-myeloid cell lines. This allows a correlation to be
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made between specific DNA binding activities and the ability to mediate 
transcription of reporter constructs.
10.3 (i) Transient versus stable transfectants
The analysis of promoter control regions cloned in front of a reporter gene 
can be undertaken using either stable or transient transfections. Each of these 
approaches has both advantages and disadvantages. The use of transient 
transfection has the major advantage of allowing rapid analysis of promoter 
constructs, but has a number of disadvantages. These include the introduction of 
many copies of a plasmid into a cell, which represents an unphysiological 
situation, as any cell will normally contain only two copies of a gene (for a single 
copy gene). This can lead to spurious results, in particular if a promoter 
sequence under analysis contains an element which binds a low abundance 
transcription factor. This effect of template being in excess can be seen if a 
titration is undertaken, where an increase in the amount of plasmid introduced 
into a cell will produce a corresponding increase in promoter activity only up to a 
certain concentration, when the level of a specific transcription factor(s) becomes 
limiting. To minimise this problem it is necessary to use the lowest concentration 
of template DNA possible in the transfection. In the transient transfections 
employed in this study 5p,g of plasmid was typically used; however, in HL60 
cells a relatively small difference was seen between the promoteriess pOGH and 
the thymidine kinase promoter driven pTKGH plasmids. The small difference in 
activity between these constructs does not seem to be a result of saturation of the 
system as a reduction in the level of DNA does not increase the relative difference 
between them (data not shown). Similarly the activity of the SV40 promoter 
showed a linear increase in activity up to 20fig in these cells, suggesting that 5|ig 
is not a high amount of template to be introduced into these cells, although the
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exact level will vary between promoters. Previous reports of transfection into this 
cell line have reported the use of 5fig (Pahl et al., 1991).
The other major problem with transient transfections is that the plasmids 
will not have the same chromatin structure as the endogenous gene, as although 
templates will be incorporated into core nucleosomes they may not have a 
’positioned organisation' of nucleosomes into which the endogenous gene is 
organised. However in this case this may be an advantage as the endogenous 
defensin genes are not expressed in this cell line.
In addition to the above considerations, the method of transfection itself 
can have profound effects on cells. Electroporation causes considerable cell death 
and will elicit a range of responses including the activation of signal transduction 
pathways which will regulate transcription factors. An example of this has been 
documented, with transcription of the CD1 lb endogeneous gene being increased 
after electroporation of U937 cells (Pahl et al., 1991). However, as this method 
was the only one available (in addition other methods of transcription themselves 
have problems e.g.i calcium phosphate transfection could result in the activation 
of signal transduction pathways as calcium is an important second messenger) it 
was employed in these studies bearing these limitations in mind.
The use of stably transfected cells has a number of advantages over 
transients. The integration of the plasmid DNA into the chromosomes allows the 
assay of promoter activity of DNA within the context of chromatin, which can 
allow the assay of certain sequences which act to enhance transcription only when 
integrated into normal chromatin as they may have an effect in mediating 
chromatin structure (e.g. the Drosophila scs elements, cf. section 2.1). In 
addition, the copy number of plasmid templates will be low in comparison to a 
transiently transfected cell, as only a small fraction of those plasmids introduced 
will become integrated into the host cells’ genome. The sensitivity of stable in 
comparison to transient transfections is much higher as almost all cells will
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contain integrated plasmid. This greater sensitivity allows the direct analysis of 
reporter gene RNA and determination of the transcription start site if required. A 
further advantage of stable transfections is that they allow the effects of treatments 
to be measured over relatively long time periods, as for example the induction of 
differentiation of the HL60 cell line.
There are however, a number of drawbacks to the use of stable 
transfectants both practical and theoretical. Practically, the time-consuming 
nature of generating these cell lines is a limitation to their use. In addition, a 
number of considerations must be taken into account when stable transfections 
are employed. The DNA which is integrated is often in the form of concatamers; 
this could have a number of potential consequences which could generate 
unrepresentative results when analysing transcriptional control elements. The 
random integration of the DNA into different areas of the chromosomes subjects 
the promoter to position-dependent effects (see section 2.1) To control for this 
the use of a number of cloned stably transfected cell lines mixed together should 
be employed to obtain an average activity. Perhaps the most important 
consideration, when comparing the activity of a number of constructs, is to 
determine that the amount of DNA integrated into each of the cell lines is similar. 
This is because, broadly speaking, the expression of a gene will increase with 
increasing copy number. As a consequence, it is perhaps best to compare a 
range of constructs for relative activity using transient transfection, although a 
comparison using both methods would be ideal.
A study of the effect of differentiation on the activity of the reporter 
constructs during HL60 granulocytic differentiation would require the generation 
of stable cell lines. This is because although rapid changes could potentially be 
measured by transient transfection after DMSO treatment, this treatment 
significantly reduced the efficiency of transfection. The effect of other inducers of 
differentiation were not tested for their effect on the efficiency of transfection,
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but it is possible that an agent such as retinoic acid may allow transfection to 
occur unimpeded. However, as the effect of this agent on the DNA binding 
activities identified in this study were unknown and the regulation of defensin 
gene expression was not identical during DMSO and retinoic acid induced 
differentiation (Lamb, 1990), this agent was not employed.
10.3 (ii) The transfection of myeloid cell lines
Myeloid cell lines are recognised as particularly difficult to transfect and 
electroporation seems to be the method of choice for transfection into these cell 
lines. However work in this study, and other published work suggests that this 
may be partially due to approach. It had been noted in a study by Pahl et al., 
(1991), that the activity of reporter constructs rapidly diminished after 14 hours 
post transfection. The results in this work are in keeping with this finding, with 
no appreciable reporter gene activity detectable after 24 hour.
Perhaps the most important factor in determining the success of 
transfection into myeloid cell lines is the choice of reporter genes, with the use of 
secreted reporter genes being essential. A direct comparison between the sensitive 
luciferase assay and the secreted placental alkaline phosphatase (SPAP) reporter 
revealed that only the later could be detected. This result is not surprising given 
that the cytoplasm of these cells is full of degradative enzymes, and lysis of 
these cells will generate a particularly hostile environment for proteins which may 
prevent success of any reporter gene assay which involves the lysis of cells.
This interpretation is in keeping with the inability to detect p-galactosidase 
or CAT activity after transfection of plasmids expressing these reporter genes into 
HL60 cells, despite the electroporation protocol being successful at introducing 
DNA into these cells at a high enough level to detect both SPAP and secreted 
human growth hormone reporter genes. The use of secreted reporter genes may
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be of general use in the transfection of other myeloid cell lines, as transfection of 
the mouse macrophage RAW cell line was only successful when the secreted 
reporter genes SPAP and human growth hormone were employed. Neither [3- 
galactosidase nor CAT could be detected although a direct comparison was not 
made (Grove 1994).
Perhaps for a similar reason, the inclusion of excess non-specific plasmid 
DNA also increased the efficiency of transfection. In this case the activity of a 
nuclease may be responsible for degrading incoming DNA. The excess DNA may 
be acting as a competitor, although whether the excess DNA in fact stimulates 
greater up take of DNA cannot be eliminated. The reason for sonicated salmon 
sperm DNA being unable to increase the transfection efficiency is unclear but 
could be due to the putative nuclease being specific for supercoiled DNA.
10.4 Analysis of the defensin promoter
10.4 (i) What transcription factor(s) comprise the FP1 DNA 
binding activities?
As discussed in section 8.3 the FP1 binding activities in nuclear extract 
derived from HL60 cells seem to be comprised of C/EBP-like binding factors as:
-there is a recognisable C/EBP binding site within the FP1 sequence.
-point mutation of this putative site abolishes binding activity.
-the FP1 binding activities can be competed with the inclusion of excess C/EBP 
binding oligonucleotide in an EMSA.
-they are heat stable to 90°C.
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If we presume that the activities are generated by C/EBP family members, 
what factors are likely to comprise it ? One possible candidate is C/EBPa, and 
this factor is expressed in HL60 cells. C/EBPa is present in uninduced cells and 
is down-regulated as the cells differentiate to either granulocytes or macrophage 
(Scott et al., 1992). The western blot analysis in this study revealed two bands of 
similar size, which was interesting given that the FP1 activity is comprised of a 
doublet of similar mobility. If the FP1 binding activity was to be comprised of 
C/EBPa, then the slight differences in the time course of down-regulation (24 
hours versus 8 hours) during DMSO differentiation could be explained by 
differences between the cell lines, or because the DNA binding activity of the 
protein (which is measured in this work) falls more rapidly than the protein levels 
(measured in the published study). C/EBPa is not present in normal 
macrophages so the presence of FP1-binding activity in TPA-treated HL60 cells 
could be explained as a reflection of the incomplete nature of the differentiation of 
this cell line if the FP1-binding activity was comprised of C/EBPa.
Other potential candidates to comprise the FP1 binding activity are 
C/EBPp and C/EBP8. There is no information as to the regulation of the C/EBPP 
or C/EBP5 at the protein level in human myeloid cells, but in the mouse cell line 
32D cl3 , differentiation toward granulocytes induced by G-CSF results in an 
up-regulation of C/EBPp and a minor down-regulation of C/EBP5 (Scott et al.,
1992). If the situation in HL60 cells is analogous, this would suggest that the 
C/EBPa is most likely to comprise the FP1 binding activity as there appears to be 
no FP1 activity in fully differentiated granulocytes (8.3 (i)). We would perhaps 
expect that, if the HL60 cells were similar to the mouse 32D cells, there would 
be an up-regulation of C/EBPP during granulocytic differentiation, however, no 
up-regulation of C/EBP consensus oligonucleotide binding activity could be 
detected by EMSA. It is possible to argue that, as the 32D cells are relatively 
immature, the up-regulation of C/EBPP only occurs in progenitors as a
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consequence of lineage commitment (towards the myeloid lineage) and in the 
more mature HL60 cells maximal levels have been achieved as a consequence of 
its relatively mature phenotype. The suggestion that C/EBPP may be involved in 
lineage commitment is also suggested by work in chick cells, where the C/EBPp 
homologue NF-M is rapidly induced in MEP cells when induced to differentiate 
along the myeloid lineage. As the changes of the C/EBPp activity during HL60 
differentiation are unknown, it is not possible to eliminate this factor as 
comprising the FP1-binding activity.
C/EBPP is also regulated post-translationally and can be induced to 
translocate to the nucleus in response to TPA, kinases or LPS in chick 
macrophages (Katz et al., 1993). The transient up regulation of the FP1 DNA- 
binding activity on TPA stimulation (8.4 (ii)) may be a reflection of this. Whether 
the human C/EBPP can respond to TPA in this manner is unknown, but 
interestingly C/EBPp is known to be directly regulated by IL-6 which has 
important effects (in addition to the regulation of acute phase proteins in the liver) 
on haemopoietic cells including stimulating the development of neutrophils and 
macrophage from GM-CFC (Metcalf 1989; Suda et al., 1988). This IL-6 
response is also conferred on heterodimers which could mean that any dimers 
containing this factor could mediate a response to IL-6 (Poli et al., 1990). It will 
be of interest to determine if the suggested importance of C/EBPP in 
differentiation is a result of its regulation by signal transduction pathways such as 
regulation by IL-6 and whether other differentiation signals such as G-CSF act 
through this factor.
Only limited work using EMSA with C/EBP-binding oligonucleotides 
with human myeloid cell nuclear extract has been published. One study utilised a 
fragment of the chick cMGF promoter which binds to NF-M. This suggested that 
in HL60 a single complex of low mobility bound to this sequence, and that in 
mature granulocytes there was no C/EBP activity but mature macrophages had
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NF-M activity. This is a similar pattern to that of the FP1-binding activities and 
these workers suggest that these represent myeloid-specific novel factors on the 
basis of the sizes of cross-linked complexing experiments (Haas et al., 1992). 
Whether this represents a novel C/EBP family member restricted to the monocytic 
compartment remains to be seen, but clearly the FP1-binding activity would be a 
candidate to comprise this NF-M activity.
A study of the expression of C/EBPa and NF-IL6 (C/EBPp) in a number 
of myeloid cell lines at the mRNA level and by western blot has been published. 
In this study, C/EBPa mRNA, is slowly lost on TPA treatment of HL60 cells 
(lost by 12 hours) whereas it is rapidly lost on differentiation of the cells along 
the granulocytic pathway .This result would be in keeping with the FP1-binding 
activity being comprised of C/EBPa. Functional DNA-binding activity of 
C/EBPp was measured using biotinylated oligonucleotide-capture and western 
blotting. This revealed two bands of similar mobility, and this active protein fell 
to a third of the maximal levels seen at 24 hours ondifferentiationof HL60 cells 
with TPA.
Clearly the data available suggest that any of C/EBPa, C/EBPp, 
C/EBP5 or a novel factor could comprise the FP1 DNA-binding activities and the 
situation is further complicated by the ability of the C/EBP factors to dimerise 
(Poli et al., 1990; William et al., 1991; Cao et al., 1991). As all of the C/EBP 
family dimers tested can homo- and hetero-dimerise we would perhaps expect a 
range of different C/EBP-binding complexes to be present in HL60 nuclear 
extracts, as this cell line co-expresses a number of family members. Since many 
of these dimers have similar affinities for a number of C/EBP binding sites (in 
vitro), we would perhaps expect the FP1-binding activities to represent a 
composite picture of all the C/EBP complexes present in the cells. Given that 
C/EBPa and C/EBPP have different molecular weights (C/EBPp and C/EBP5 
have similar weights) we might expect a range of complexes of different
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mobilities to be generated using a C/EBP-binding sequence and a HL60 nuclear 
extract in an EMSA assay. However, no significant difference in the size of the 
FP1-binding complexes can be detected.
Comparison between the pattern of retarded complexes generated using a 
symmetric C/EBP binding site and a FP1 oligonucleotide with HL60 nuclear 
extract in a EMSA reveals a very similar pattern, although they appear to be 
distinct. Comparing the patterns of retarded complexes generated during HL60 
differentiation using these two oligonucleotides suggests that the FP1 
oligonucleotide is binding a subset of those bound by the C/EBP oligonucleotide 
all of which have a similar mobility. As discussed in section 8.3(ii) the TPA 
induction results in a transient rise and a gradual reduction to basal levels of FP1- 
binding activity in the fully induced cell. In contrast, the C/EBP oligonucleotide 
binding levels in the fully induced cell are approximately 1/10 those seen in the 
uninduced cell. This result could be explained if certain C/EBP 
homo/heterodimers are showing differences in affinity between these two sites. 
Different homo/heterodimers can show differences in affinity for different 
C/EBP-binding sites, as has been demonstrated for the serum albumin site D 
(Roman et al., 1990).
To determine which factors are binding this sequence in vitro could be 
approached using the techniques of biotinylated oligonucleotide capture and 
western blotting and/or super shifting experiments using antibodies specific to the 
known C/EBP family members. Whether only a specific dimer binds in vivo, 
however is more difficult to determine.
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10.4 (ii) What transcription factors comprise the FP2 DNA binding
activities?
As discussed in section 8.4(iii), the DNA binding studies suggested that 
the FP2 binding activities had the properties of Ets transcription factors. The 
properties of these activities suggested that candidates to comprise them were 
PU.l (Spi-1) and SpiB. This was suggested as:
-The relatively high mobility of the retarded complex generated in an EMSA using 
FP2 oligonucleotide and HL60 nuclear extract (Pahl et al., 1992; Wasylyk et al., 
1992; Galson et al., 1993).
-The tissue distribution of this activity as detected by gel shift analysis.
-The FP2 binding activities (using HL60 nuclear extract) could be competed by 
excess cold PU.l sequence found in the SV40 promoter (Klemsz et al., 1990).
-In vitro translated PU.l has a similar mobility (in an EMSA when bound to FP2 
oligonucleotide) as the FP2 complex I (8.4 (iv)).
Two complexes of similar mobility to these have been previously noted 
using extracts from HL60 and U937 cells when EMSAs have been undertaken 
using an Ets binding sequence from the C D llb promoter (Pahl et al., 1992;
1993). The upper complex could be super shifted using antisera raised against 
PU.l, and in vitro translated PU.l generates a similar mobility complex in an 
EMSA (Pahl et al., 1992). It has been suggested that the lower complex is a 
degradation product as a result of a cleavage at the PEST sequence present in this 
protein. In this study the lower complex is not shifted by the addition of antibody; 
this would be predicted as cleavage at the PEST sequence would liberate a C- 
terminal sequence which contains a DNA binding domain lacking the peptide
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against which the antibody was raised. The ability of N-terminal deletion mutants 
to bind DNA has been documented using in vitro translated PU.l deletion 
constructs (Wasylyk et al., 1992). Presuming the complexes represent PU.l and 
a degradation product the question remains, does the degradation product 
represent degradation during the process of making nuclear extract or are both of 
these complexes present in vivo? The difficulty of making undegraded nuclear 
extracts from HL60 cells has been documented (Galson and Housmann 1989) 
and the B-cell line Haftl generates only a band with the mobility of the upper 
complex (Pahl et al., 1992). It could be argued that the two complexes are a result 
of breakdown during the procedure as B-cells contain a lower concentration of 
proteases. However, it could be a reflection of the in vivo situation as the ratio of 
the two complexes appears to remain constant during differentiation; we would 
perhaps expect the ratio to be more variable if this degradation was a result of the 
isolation procedure. It has been suggested that protein interactions at the PEST 
sequence may protect the protein from degradation in Haftl cells (Pongubala et 
al., 1992), suggesting that the cleavage may be regulated in vivo.
If the degradation product is present in similar amounts as the full length 
protein in myeloid cells what are the functional consequences? Perhaps the 
obvious one is the cells will contain proteins with functional DNA binding 
domains which may have lost the ability to transactivate gene expression. This 
might suggest that there will be competition for available sites. The loss of 
domains which may be involved in protein-protein contacts at particular 
promoters may also have important consequences. The ability of a truncated 
mutant of the Ets family to have profound effects on cellular processes has been 
documented. A truncated Ets-2 protein (lacking a transactivation domain) 
expressed under the control of an actin promoter could block CSF-1 dependent 
transformation of NIH 3T3 cells expressing the CSF-1 receptor (Langer et al., 
1992). Clearly it is difficult to speculate without further data, but one could
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postulate that the truncated putative negative regulators could switch off a subset 
of PU.l target genes (or other Ets family members targets), particularly as in this 
study it appears that these complexes do have separable DNA binding properties 
(8.4 iii).
It has not been determined conclusively that the identity of the FP2 DNA- 
binding activities are generated by the PU. 1 transcription factor, and a number of 
the binding properties of these complexes could cast doubt on this proposition. 
Most obvious is the finding that the PU.l binding oligonucleotide from the SV40 
PU box does not compete as efficiently as the FP3 and E74 sequences which 
contain a C triplet 5* to the GGAA sequence (8.4(iii)). All of the previously 
identified elements which bind PU. 1 contain a purine at these sites. This may 
suggest that the complex is not comprised of the PU. 1 transcription factor (or 
alternatively, it may have its binding properties altered by post-translational 
modification in this cell type). However, in vitro translated PU. 1 can bind to the 
FP2 site with high affinity. The closely related SpiB gene could be a candidate as 
it would be predicted to have a similar molecular weight and hence possibly 
generate a similar retarded complex (Ray et al., 1992).
10.4 (iii) What transcription factors comprise the FP3 DNA binding 
activities?
Competition experiments have indicated that the FP3 binding activities can 
bind a number of Ets sequences. As discussed in section 8.5(iii), the high 
mobility complex iv (generated in an EMSA using HL60 nulcear extract and FP3 
probe) seems to have very similar properties as upper complex I generated in a 
EMSA using the FP2 oligonucleotide and HL60 nuclear extract (section 10.4(i)
2). This complex can be competed by sequences capable of binding PU.l, and in 
vitro translated PU.l generates a retarded complex with the same mobility as that
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generated using HL60 extracts with FP3 probe. That the lower complex (perhaps 
cleaved PU.l) does not bind further suggests that the factors comprising FP2 
complexes I and II have separable DNA binding properties.
The main complexes generated in an EMSA with HL60 nuclear extract 
and FP3 probe I, II and III are competed by only FP3 and E74 oligonucleotides 
(section 8.5 (iii)). These two oligonucleotides are similar in sequence and the E74 
sequence which has been demonstrated to bind to Ets-1, Ets-2 and Fli-l/ErgB 
with high affinity (Klemsz et al., 1990; Fischer et al., 1991; Zhang et al., 1993). 
Of these Ets-2 is expressed in the HL60 cells, and interestingly, a number of 
different transcripts can be detected (section 8.6). What the functional 
significance of these different transcripts are is unknown, but the generation of a 
number of complexes with the FP3 probe could be explained by postulating a 
number of different forms of Ets-2 proteins binding to this sequence. 
Alternatively, the complexes 1,13 and in  could be generated by post-translational 
modification. Although Ets-2 is expressed in HL60 cells and is likely to bind this 
site with high affinity, the high level of the defensin-reporter gene pOGH-82 
activity (which contains the FP3 sequence) in HL60 cells in comparison to Raji 
and HeLa would perhaps suggest that the transcription factor which mediates this 
expression has a restricted distribution (section 9.3). However, HL60 does not 
have the highest levels of Ets-2 mRNA (when compared to HeLa and Raji cell 
lines), and this factor has a widespread tissue distribution. It could be argued that 
the tissue-specificity seen in the transient assays is the result of the comparison to 
the HS V thymidine kinase promoter which could have different activities in these 
cell lines. This is suggested as the inclusion of the FP3 sequence (i.e. comparing 
activities of the pOGH-32 and pOGH-82 constructs in transient assays) does 
elevate transcription to some degree in these cell lines. However, it is 
significantly lower than that seen in HL60 cells (section 9.3).
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The very large up-regulation of FP3-DNA binding activity in response to 
TPA treatment could be explained if these activities are comprised of Ets-2, 
which has been reported to be phosphorylated in response to this treatment or in 
response to growth factors (Bhat et al., 1989 and 1990; Boulukos et al., 1990). 
However, as the elevated activity of the pOGH-82 construct in HL60 cells (in 
comparison to HeLa and Raji cell lines) seems unlikely to be mediated by Ets-2, 
other candidates should be considered. One possibility is ErgB/Fli-1, which is 
expressed in HL60 cells and could potentially mediate tissue-specific gene 
expression given its restricted expression (Watson et al., 1992). However, this 
factor generates complexes with significantly different mobilities in an EMSA 
(when translated in vitro) than the FP3 DNA binding activities present in HL60 
nuclear extract, although it does bind with a high affinity to the FP3 sequence. In 
addition the FP3 binding activities seem to show a broad tissue distribution. It is 
possible that the FP3 binding activity detected in HL60 cells is comprised of Ets- 
2, given that this factor is expressed in these cells and can bind this sequence 
with high affinity. However, the myeloid specificity seen in the transient 
transfection experiments could be mediated by a separate transcription factor 
(such as ErgB), which may be low in abundance or difficult to detect under the 
conditions employed in the assay. If the activity mediated by the FP3 sequence 
(i.e. pOGH-82) in transients, is generated by the transcription factors detected in 
HL60 nuclear extracts by EMSA, then we would predict a large increase in 
reporter gene activity after introduction into HL60 cells and TPA treatment, given 
the very rapid and strong up-regulation of these binding activities as a result of 
this treatment.
The TPA induction of HL60 cells results in a very rapid increase in the 
activity of this factor. The rapid response suggests that this is perhaps a direct 
effect, perhaps by PKC-mediated phosphorylation of this factor. Whether this is 
involved in the induction of the differentiation program or is just a coincidental
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TPA response is unknown. However, as a dominant negative mutant of Ets-2 
can block CSF-1 mediated activity (Langer et al., 1992), this suggests that genes 
regulated by Ets family members may be required for proliferation and 
differentiation within the monocytic compartment. The API complex has also beery 
implicated as a potential mediator of macrophage differentiation (e.g.Studzinski 
and Brevli 1987), and as Ets and API often act in conjunction on some 
promoters (Wasylyk et al., 1989 and 1990; Seth and Papas 1990), it could be that 
these factors acting together are important in committing cells to differentiate 
along this lineage.
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10.4 (iv) The defensin gene is a target for c-Myb regulation
One of the most interesting results of the work is the suggestion that the 
defensin gene is a target of the product of the proto-oncogene c-Myb. To date 
very little is known about the targets of c-Myb, and although tentative evidence 
has implicated a number of genes the chicken mim-1 is the only gene which has 
been conclusively demonstrated to be regulated by this protein. Identification of 
the targets of both the normal and oncogenically activated forms is likely to give 
an insight into the mechanisms by which this gene can contribute to 
leukaemogenesis and confer a specific differentiation phenotype.
The evidence in this study is suggestive in that reporter constructs can be 
transactivated in response to c-Myb and their expression is dependent on the 
presence of Myb binding sites. Transactivation by c-Myb can occur in the 
absence of DNA binding, as has been demonstrated for the activation of the 
hsplO gene (Klempnauer et al., 1989; Kanei-Ishii et al., 1994). However, DNA 
binding is required for the transactivation of the reporter constructs as a mutant of 
c-Myb which cannot bind DNA fails to transactivate (section 9.4). Clearly this 
does not demonstrate that the endogenous gene is regulated by c-Myb as the 
conditions of a transient assay are somewhat removed from the normal in vivo 
situation.
The results produced using the point mutant of the FP1 sequence 
predicted to fail to bind c-Myb, are difficult to interpret. The mutant shows a 
reduced activity in HL60 cells, as would be predicted as these cells contain 
endogenous c-Myb. However, this mutant is still capable of transactivation by 
exogenous c-Myb. There are a number of possible explanations. The first is that 
the mutant promoter still binds to c-Myb. The reason for the reduced activity in 
HL60 cells could be explained by the reduced affinity of this sequence in vitro
261
for the FP1 binding activities. Hence this sequence could still be transactivated by 
c-Myb. The second possibility is that although c-Myb does not bind this mutant 
site with high affinity, the extremely high level of this factor generated by 
exogenous expression allows the reporter construct to be transactivated. A 
comparison of the response of mutant and wild type promoters to a titration of the 
c-Myb expression plasmid would be informative. A third possibility is that the 
transactivation by exogenous c-Myb is both a direct and indirect effect. The 
reduced activity of the mutant in HL60 cells is the result of a failure to bind to this 
sequence and the transactivation is the result of the regulation of the activity of a 
different factor. To distinguish between the possibilities it will be necessary to 
determine the relative affinities of c-Myb for these sequences in vitro.
The transcriptional control of the defensin genes and that of the mim-l 
gene are very similar. Both appear to be targets for c-Myb, a C/EBP factor is an 
important mediator of expression and binds at a composite Myb-C/EBP element 
in the defensin gene. Ets proteins could potentially be involved in the regulation 
of the defensin genes, and Ets-2 has been demonstrated to transactivate the mim- 
1 promoter in transient assays synergistically with c-Myb (Dudek et al., 1992). 
Along with the similar restricted nature of the genes expression in both the 
chicken and human, the location of the protein in neutrophilic granules suggests 
that they may be homologues. A simple comparison carried out in this study 
revealed only limited homology, and the proteins are quite different in size. 
However T.Graf has evidence that the defensin genes are the human homologues 
of mim-l (personal communication).
Clearly if the defensin genes are the human counterparts of the chicken 
mim-l this adds weight to the proposition that the defensin genes are targets for 
regulation by c-Myb. It must be remembered that in this work only the defensin 
genomic clone HNP1A was analysed and evidence suggests that there are two 
defensin genes per haploid genome perhaps generated by the result of a recent
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duplication and hence may be similarly regulated (Lamb 1990). However a third 
protein termed HNP4 , seems to be considerably diverged and its regulation 
during myelopoiesis is unknown (Wilde etal., 1989).
As the c-Myb protein is required for proliferation in haemopoietic tissues 
it would perhaps be expected to have target genes which are involved in the cell 
cycle or proliferation. It seems unlikely that the defensin gene has a functional 
role in promoting proliferation or in the maturation arrest seen in CML patients 
myelopoiesis. Although it has been demonstrated that the defensins are mitogenic 
for fibroblasts and epithelial cells, this is probably to generate repair at wound 
sites and a role of this gene in transformation seems unlikely.
In addition to the role of c-Myb in proliferation, it has been suggested 
that this protein plays an essential role in differentiation. Evidence of this is 
discussed in section 3.4, but it is relevant to note that c-Myb is required for 
induced differentiation of HL60 along the granulocytic pathway but not the 
monocytic pathway, perhaps suggesting that 'c-Myb conditioned proliferation' is 
necessary to acquire a granulocytic phenotype (Ferrari et al., 1990). As the 
defensin genes are an important component of the granulocytic phenotype, they 
may be one of a number of target genes regulated by c-Myb which are involved in 
generating a specific differentiation phenotype.
10.4 (v) Mechanisms of the regulation of differentiation-stage- 
specific expression of the defensin genes
The defensin genes are expressed during a narrow window of 
differentiation in the myeloid compartment. Given the data obtained in this study 
by transfection analysis and DNA-protein interaction studies on the promoter, it 
is possible to postulate attractive hypothesis to explain how the expression of 
these genes are controlled during differentiation. A number of assumptions
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(which may not be correct - discussed later) must be made, the first of which is 
that the differentiation-stage-specific expression is mediated by the action of 
DNA-protein interactions taking place at the immediate promoter (i.e. the first 
250bp). Other DHS sites are present in the CML samples so other regions may be 
involved in some aspects of transcriptional control. The second assumption is that 
HL60 is a model cell line which reflects the regulation that takes place in vivo; 
clearly some differences must exist due to the lack of expression in this cell line. 
If however the lack of expression is the result of methylation as a result of 
propagation in tissue culture then the results may be more representative of the in 
vivo  situation. Bearing in mind these caveats the data seem to suggest 
mechanisms which may be relevant to the regulation of these genes in vivo.
Three transcription factors/DNA binding activities are likely to be of key 
importance, due to their ability to transactivate/repress expression of the reporter 
constructs and the modulation of their levels/ activity during differentiation. These 
are:
1) c-Myb
2) FP1 (C/EBP)
3) FP3 (Ets)
Evidence implicating c-Myb in transactivating the defensin promoter has 
been discussed in the previous section. This factor is down-regulated during 
HL60 differentiation, although the levels of protein are not completely depleted 
until late in differentiation of the HL60 cells (Pedrazzoli et al., 1989) and activity 
of this protein is necessary for the granulocytic differentiation of HL60 cells as 
this is blocked by antisense treatment of these cells (Ferrari et al., 1990).
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The FP1 DNA binding activities are 
rapidly down-regulated during granulocytic differentiation and FP3 is present 
until late in the granulocytic differentiation pathway. A diagrammatic 
representation of the changes in DNA binding activities during HL60 
differentiation is shown in fig 10.1.
Two basic hypothesis can be put forward to incorporate the data into a 
model explaining the differentiation-stage-specific regulation of defensin gene 
expression (illustrated in figure 10.2). The first makes the assumption that the 
FP1 activity is acting as a repressor, as the inclusion of this sequence results in 
down regulation of the reporter gene activity. The alternative explanation is that 
the FP1 binding activity is a positive regulator of transcription which rather than 
repressing reporter gene activity, redirects transcription through the 5' TATA 
element. Considering the first hypothesis, if the FP1 binding activity is acting as 
a repressor, then the activity of the defensin gene could be explained as occurring 
only in the absence of the FP1 binding factors. This repression could be both 
direct and indirect in that it reduces the activity of the promoter via a positive 
action and in addition it may function to prevent the binding of c-Myb to a site 
which is juxtapositioned (refer to figure 9.7). As the C/EBP family members are 
present in immature myeloid cells (Scott et al., 1992; Ness et al., 1993), this 
sequence may mediate repression of the defensin genes in cells less mature than 
myelocytes. Loss of this activity during granulocytic differentiation of HL60 cells 
occurs by 8 hours, allowing expression of the defensin genes to be positively 
activated by the FP3 binding activities (this sequence mediates high level 
expression in reporter constructs) and c-Myb which can transactivate these 
constructs. As the FP1 binding activity is not lost during monocytic 
differentiation of HL60 cells this could explain why the defensin genes are not 
expressed in this lineage.
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Figure 10.1: Changes in the FP1, FP2 and FP3 DNA binding activity during 
HL60 differentiation. The DNA binding activity scale is arbitrary as the absolute 
levels of these activities with respect to each other are unknown. The 
granulocytic differentiation is induced by DMSO and monocytic differentiation by 
TPA. The granulocytic differentiation is completed by 5 days and the monocytic 
by 3 days after the addition of the appropriate inducer.
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Figure 10.2 : Potential models to explain the differentiation-stage-specific 
expression of the defensin genes
Figure 10.2 A: Model to explain the differentiation stage specific expression 
of the defensin genes, with the FP1 binding activity acting as a repressor. The 
cartoons illustrate protein-DNA interactions occurring on the promoter in myeloid 
cells at different stages of differentiation. The consequences of these interactions 
are indicated in the figure. In this scenario, repression of the gene occurs in 
immature cells as a result of the presence of the FP1 repressor activity. Lack of 
expression in the granulocyte is a consequence of the loss of the positive 
mediators of this genes activity, c-Myb and the FP3 binding activity. Expression 
occurs in during a window in which the FP1 activity is absent and c-Myb and 
FP3 binding activity are present. B: An alternative model is illustrated where the 
FP1 binding activity is a positive regulator of defensin gene expression. In this 
figure, potential interactions occurring at the defensin-reporter constructs pOGH- 
82 and pOGH-140 are indicated. In this scenario, FP1 binding activity and c- 
Myb together activate transcription positively. However at least in transient 
transfections the lower activity of pOGH-140 with respect to pOGH-82 could be 
a consequence of the attempted assembly of two pre-initiation complexes.
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Although this is an attractive hypothesis, the results from transfection 
with the point mutants suggest that the FP1 binding activity does not repress 
transcription of this gene. The mutant construct muC, which binds to the FP1 
with a lower affinity than the wild-type sequence, has a reduced activity.This 
suggests that the FP1 binding activity is a positive regulator of defensin gene 
expression, and the lower activity of the construct containing the wild-type FP1 
sequence could be a result of the redirection of transcription through the 5' TATA 
box.
If the FP1 binding activity is a positive regulator of transcription, how do 
we explain the differentiation-stage-specific regulation of the defensin genes? The 
loss of defensin expression could be the result of the loss of the positive 
activators of expression. If the expression of the defensin genes is dependent on 
the presence of the FP1 binding factor then the lack of defensin expression in 
mature cells of this lineage could be the result of the loss of this factor during 
granulocytic differentiation. In addition, the positive regulators of the reporter 
constructs FP3 and c-Myb are not active in mature granulocytes.
Clearly, why the defensin gene is not expressed in more primitive cells 
than myelocytes remains to be determined, however, it is still possible that the 
regulation is through the FP1 element. If the human haemopoietic system reflects 
that of the chicken, then the expression of the C/EBP family will not occur until 
the progenitors are committed to the myeloid lineage. It may be that a particular 
pattern of C/EBP family expression will modulate the activity of the FP1 
factor(s). For example, the protein LIP which is generated by translation 
beginning at an internal AUG of the C/EBP(3 transcript (Descombes and Schibler
1991), and negatively regulates C/EBP activity in sub-stoichiometric amounts, 
could control FP1 activity. This factor modulates C/EBP activity during adipose 
differentiation in mice, although whether a similar factor is generated in human 
myeloid cells remains to be seen. Similarly, why the defensin genes are not
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expressed in monocytes is also unknown as all of the positive regulators appear 
to be present during HL60 granulocytic differentiation, although c-Myb is not 
present in mature monocytes. It may be that the activity of c-Myb is rapidly 
switched off during monocytic differentiation perhaps by regulation of 
phosphorylation, as this factor is not required for monocytic differentiation but 
is essential for granulocytic (Ferrari et al., 1990). Alternative explanations are 
possible, such as sequences not analysed could be important mediators of 
defensin expression. The role of post-transcriptional control of defensin message 
could play an important role in the both the differentiation-stage-specific and 
lineage-specific (monocytic versus granulocytic) expression as the defensin 
message is relatively stable, suggesting that destabilisation of the message could 
be important in the reduction of defensin message levels (Lamb 1990). Clearly it 
would be interesting to analyse transcription rates during induced differentiation 
of HL60 cells with TPA and DMSO by nuclear run-on experiments. However as 
a defensin-expressing line of HL60 could not be found, this approach was not 
possible.
Although the evidence suggesting that the FP1 binding factor(s) is a 
positive regulator of defensin expression there are a number of caveats. The first 
is that the relative affinities of c-Myb for the mutant and wild-type promoters are 
not known, hence it is possible that the reduced activity of the muC mutant in 
HL60 cells could be the result of a reduced affinity for c-Myb rather than for the 
FP1 binding factor(s). A second consideration if FP1 sequence is directing 
transcription through the 5’ TATA sequence is whether this represents the 
situation in vivo ? Although, both transcription start sites are employed in CML 
cells, the 3' site is clearly the major site of transcriptional initiation (Lamb 1990). 
It may be that the transient assay gives an artefactual result because it allow the 
attempted assembly of two pre-initiation complexes (given the relatively relaxed 
state of the chromatin in the assay), which would not happen in the normal
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chromatin context. Hence it may be that if stable transfected cell lines were tested 
the inclusion of this sequence may up-regulate the expression of the reporter gene 
further.
What role does this second transcription start site play in vivo ? The 
functional consequences of the different transcripts are unknown, but could 
affect the stability of the message. It is possible that the 5' TATA box may direct 
transcription of the gene in response to a separate set of transcription factors. The 
identification of defensin proteins in rabbit alveoli macrophages after immune 
challenge, indicate that these genes may be expressed in cells other than 
myelocytes. C/EBPP and C/EBP5 can have their activity mediated by 
inflammation (Poli et al., 1991), and could direct transcription through this 
second start site as a result of binding to the FP1 sequence. These possibilities are 
highly speculative, and it will be important to determine transcriptional start sites 
in stably transfected cell lines to gain further insight into how these sequences are 
mediating their effects.
10.4 (vi) The defensin genes and myeloid-specific gene expression
Transcription factors which are limited strictly to the myeloid lineage 
remain to be identified (if they exist). A limited number of genes whose 
expression is restricted to the myeloid compartment have been studied to 
determine the transcription factors which mediate this specificity. If there are no 
myeloid-specific transcription factors, then how is this lineage-specific 
expression achieved? The CD lib  gene, which is expressed only in 
myelomonocytic cells, has been demonstrated to show myeloid-specific 
expression and the transcription factor PU.l is necessary for this activity (Pahl et 
al., 1992). However, this is not myeloid-specific in the sense that only the cell 
lines U937 and HeLa were compared. As the PU.l gene is expressed in B-cells
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also (Klemsz et al., 1990), whether this promoter would be transactivated in 
these cells is unknown, suggesting that other sequences are likely to be important 
in this process. Many genes can show an elevated expression when reporter 
constructs are introduced into an expressing rather than a non-expressing cell 
line, but this is often only reflects a component of the tissue-specific regulation 
of the endogenous genes. The study of liver-specific gene expression liver may 
provide a model for the tissue-specific expression of myeloid genes, as no 
transcription factor which is strictly limited to the liver has been identified. 
Intensive study of a number of genes has suggested that the combination of a 
number of elements which bind transcription factors, which are expressed at 
elevated levels but not restricted to the liver, together generate a liver-specific 
promoter or enhancer (Rouet et al., 1992; reviewed in Dai and Darnell 1992).
The data from the transfection experiments (Chapter 9) suggest that the 
promoter is myeloid-specific, although it must be remembered that only HL60 , 
Raji and HeLa cells have been tested using transient assays. Other sequences may 
be important in the myeloid specificity of this gene, as the effect of more distal 
sequences may be obscured by the repressive effect of the FP1 sequence. Linker 
scanning mutation would be necessary to determine if these sequences make a 
contribution. The possibility that other elements are likely to be important in the 
transcriptional control of these genes is suggested by the detection of 5' DNAse 1 
hypersensitive sites elsewhere (Chapter 7). Although there may be other elements 
involved in the generation of myeloid specificity, the analysis of the transcription 
factors which elevate expression in HL60 relative to HeLa is likely to be 
informative. The inclusion of the FP3 binding sequence elevates the level of 
transcription with respect to that seen in HeLa or Raji cells (although in HeLa 
some weak activity is generated). This result suggests that this activity is 
mediated by a factor absent (or inactive) or present at reduced levels in Raji and 
HeLa with respect to HL60 cells. As discussed in section 8.5 this sequence binds
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an Ets-like activity(s), and could be comprised of the transcription factor Ets-2. 
This factor however, has a relatively broad tissue distribution, and is expressed 
at a higher level in the HeLa cell line than in the HL60. Hence it may be unlikely 
that Ets-2 is mediating this elevated expression in the transient transfection 
experiments into these cell lines. It may be that another factor, which is less 
abundant or undetectable by gel EMSA using these conditions, may be mediating 
this response rather than the FP3 binding activities detected. ErgB, which has a 
limited tissue distribution, and is expressed in HL60 cells (Watson et al., 1992), 
could be responsible for the elevated expression of the constructs in HL60 cells. 
This factor can bind to the FP3 site with high affinity when translated in vitro 
and hence may play a role in vivo.
The constructs show some up-regulation in HeLa cells when the FP3 
sequence is included, and this weak activity may be generated by Ets-2 which 
may bind this sequence in these transient assays but perhaps not the endogenous 
gene. An alternative explanation is that the levels of active Ets-2 are relatively 
higher in HL60 cells than in HeLa cells, or interaction with another factor which 
is present only in the HL60 cells is required for Ets-2 to be active on this 
promoter. It is interesting to note that the mim-l gene could be transactivated by 
expression of Ets-2 synergistically with c-Myb (Dudek et al., 1992). Whatever 
the Ets family member responsible for this activity, it seems likely that this it will 
contribute to the tissue-specificity of the promoter.
The second site of protein-DNA interactions which are of interest in terms 
of myeloid specificity is the FP1 sequence. This element binds to a C/EBP like 
factor and c-Myb. Constructs which contain this element can be transactivated by 
c-Myb, suggesting that c-Myb may be important in the expression of the 
defensin genes. C-Myb is restricted to the haemopoietic lineage and has been 
suggested to generate a combinatorial myeloid-specific signal in conjunction with 
C/EBP (Ness et al., 1993; Burke et al., 1993). Although in this study it is not
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clear whether C/EBP is acting as a repressor or as an activator, both scenarios 
would have important implications for the myeloid-specific regulation of this 
gene. If the FP1 binding activities are positive regulators of defensin expression, 
then the myeloid-specific expression of the defensin genes can be explained 
similarly to the mim-l gene with C/EBP and c-Myb providing a myeloid-specific 
signal as this lineage appears to be the only one in which these two factors are co­
expressed. If the FP1 binding factor(s) is a repressor of defensin expression, 
then this activity may be important in preventing expression in the monocytic 
compartment. As all of the DNA binding activities found to date which may be 
positive regulators of the defensin gene expression are also present in HL60 cells 
that are differentiating along the monocytic pathway (i.e. FP2, FP3 and c-Myb). 
The defensin genes are not expressed during monocytic differentiation and this 
may be a result of the continued presence of the FP1 DNA binding activities 
repressing activity in this pathway.
Does C/EBP have a role in repressing/activating gene expression in other 
tissues of the haemopoietic compartment? Evidence suggests that there is no 
C/EBP activity outside the myeloid compartment and that is in keeping with the 
data here, although this is purely circumstantial and a detailed analysis of C/EBP 
expression by northern blot has not been undertaken. The reason for the lack of 
expression of the defensin genes in erythroid cells (if C/EBP acts as a repressor 
and is absent) could be due to the lack of expression of the Ets family members 
such as ErgB/Fli-1, which may not be expressed in erythroid cells (Watson et al., 
1992). However, the activity of the defensin-reporter constructs have not been 
tested in an erythroid cell line.
The effect of the FP2 sequence in the transient transfections may be 
obscured by the negative effect of the FP1 sequence, but the DNA binding data 
suggests that this sequence may bind PU.l (Spi-1) (see section 8.4iv). As this 
protein is present in HL60 cells (Watson et al., 1992; Pahl et al, 1992), it may
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also be involved in the myeloid-specific expression of the defensin genes, 
although this factor is not strictly limited to cells in the myeloid compartment, 
being expressed also in B-cells and at low levels in CFU-E and mast cells 
(Klemsz et al., 1990; Galson et al., 1993b).
Although there is no real data to support the proposition, it is possible 
that methylation could play a key role in the tissue-specific expression of the 
defensin genes (or the differentiation-stage-specific expression). This is because 
the gene is methylated in immature cells which do not yet express the gene (and 
non-expressing tissues). However, as discussed in section 6.7, this could 
simply reflect demethylation as a consequence of transcription. Demethylation of 
specific sequences has been shown to be important in the tissue-specific 
regulation of a number of genes, including the gene encoding histone H2b in 
which demethylation of specific sites is involved in testis-specific transcription 
(Choi and Chae 1991). Stage-specificity has been demonstrated to be mediated by 
demethylation of a single CpG residue in a control region of the mouse M- 
lysozyme gene. A single CpG residue in a 3' enhancer of this gene is methylated 
in immature macrophages, and demethylation of this site with differentiation 
allows the binding of a ubiquitous transcription factor and transcriptional 
activation (Klages et al., 1992). As the FP3 sequence is capable of binding to a 
number of factors (as tested by EMSA using nuclear extracts from a range of 
sources), it may be that methylation of this sequence contributes to repression in 
inappropriate tissues in vivo.
10.5 (i) General conclusions
The aim of this project was to use the defensin gene as a model which 
because of its restricted expression pattern, could be studied to identify 
transcription factors which may be involved in myeloid-specific and/or
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differentiation-stage-specific gene regulation. This was undertaken with the 
general aim of understanding both the normal control of myelopoiesis and how 
this may be altered to generate maturation arrest and leukaemia. Of particular 
interest would be transcription factors whose activities are rapidly modulated on 
the relief of this maturation arrest by the induction of differentiation, as this may 
indicate factors whose down/up-regulation is necessary for differentiation to 
occur. How successful has this study been in contributing to answering these 
questions? A number of transcription factors have been implicated in the control 
of this gene. Of these, c-Myb is a target for leukaemic transformation and has an 
essential role in both proliferation and differentiation in the haemopoietic system. 
Work from a number of laboratories has implicated c-Myb as an important 
mediator of the myeloid phenotype. They suggest that c-Myb generates this 
myeloid-specificity by interaction with a C/EBP family member. A similar 
interaction is seen on the defensin promoter, suggesting that this 'combinatorial 
myeloid-specific signal' seen in the chicken system may have parallels in the 
control of human myelopoiesis. In this work, the FP1 binding activities (C/EBP- 
like) are lost rapidly on HL60 granulocytic differentiation and C/EBP factors are 
more slowly down-regulated. This and the involvement of these factors in 
differentiation control in other systems, begs the question, is the C/EBP family a 
potential target for leukaemic transformation and an involvement in maturation 
arrest? No data are available suggesting alteration in C/EBP family members in 
leukaemia. However a translocation present in many myxoid liposarcomas have 
been demonstrated in a number of patients to rearrange one of the 
CHOP/GADDI53 alleles (Aman et al., 1992). This implicates the alteration of 
this gene in the development of these cancers. Perhaps by altering the activity of 
the C/EBP family of transcription factors and blocking differentiation, as this 
factor is induced on differentiation of 3T3 blasts to adipocytes and is believed to 
be a negative regulator of C/EBP activity (Ron and Habener 1992).
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The Ets transcription factors which comprise the FP2 and FP3 binding 
activities have not been conclusively identified; however, candidates are PU.l, 
Ets-2 and ErgB. The mouse homologues of PU.l and ErgB, Spi-1 and Fli-1, 
respectively, are both involved in virally induced erythroleukaemia as a result of 
insertional activation (Bear et al., 1989; Seth et al., 1992). These transcription- 
factors, when over-expressed, may block erythroid differentiation: Spi-1 is over 
expressed in mouse erythroleukaemia cells and is down-regulated on DMSO 
induced differentiation of these cells (Galson et al., 1993). Ets-1 and Ets-2 
transform fibroblasts when they are over-expressed and are located (as are other 
Ets genes) near sites which are often translocated in leukaemia (reviewed in 
Papas et al., 1990), though they have yet to be demonstrated to play a causal role 
in human leukaemia. The one bona fide example of involvement of an ets gene in 
human cancer is a characteristic reciprocal translocation between 1 lq24 and 
22ql2 seen in Ewing’s sarcoma. This translocation fuses a portion of the fli-1 
gene to a putative RNA binding protein which results in ectopic expression of the 
chimeric gene (Delattre et al., 1992). Clearly the Ets family of transcription 
factors merit further investigation to determine what role they may play in the 
generation of human leukaemia.
An interesting observation of this study is the rapid changes in DNA 
binding activity of FP1 and FP3 binding proteins on differentiation, in a lineage- 
specific manner. That is, the FP1 binding activity is down-regulated on 
granulocytic differentiation, but remains relatively unchanged on monocytic 
differentiation, whereas the FP3 binding activity is rapidly up-regulated only on 
induction of monocytic differentiation. The rapidity of the responses may suggest 
that these factors play a regulatory role in lineage determination, where 
commitment to a particular differentiation pathway requires the loss/activation of 
these factors. However, as with all observations of this nature, whether these
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rchanges are causal or a consequence of the differentiation program, remains to be 
tested.
(ii) Future prospects
Despite the problem of the defensin genes not being expressed in a model 
system, this research has opened up a number of potential avenues of fruitful 
research. This further work falls into two categories. The first is a continuation of 
the study of the regulation of this gene, and the second is the role of a number of 
the transcription factors (which have been implicated in the regulation of the 
defensin gene) in myeloid differentiation.
The first of these is a logical extension of the work presented here which 
leaves a number of questions unanswered or in need of further confirmation. 
Perhaps most obviously is the confirmation of the identity of the transcription 
factors which comprise the FP1, FP2 and FP3 activities. As a number of 
candidates have been implicated, this question could be addressed directly with 
antibodies employing super shift studies. As, however, the factors may be 
comprised of transcription factors which are novel, or ones against which no 
antibodies are available, the estimation of the molecular weights of the complexes 
would be informative. This could be undertaken by the use of biotinylated 
oligonucleotide capture with labelled nuclear extracts or UV. cross-linking of 
HL60 extracts to bromodeoxyuridine oligonucleotide probes.
The defensin genes are regulated in a differentiation-stage-specific 
manner, and the data in this study have allowed us to generate a model for this 
very specific transcriptional control. Clearly, the effect of differentiation along 
both pathways on the activity of the reporter constructs would be informative. 
This would allow us to test if the model holds in this cell line. This approach 
would require the generation of stable HL60 cell lines containing the reporter
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rconstructs used in this work. The generation of stably transfected cell lines has 
been successfully undertaken in this laboratory using the neomycin resistance 
gene as a selectable marker (Kevin Ryan personal communication). A problem 
for these studies is that this marker affects the differentiation properties of this cell 
line (von-Melcher and Housman 1988), which is clearly not ideal for these 
studies. As an alternative the histidinol dehydrogenase gene was used a selectable 
marker which does not have this problem (Hartman and Mulligan 1988), but 
problems with the sensitivity of the cells varying with the density of the culture, 
and the generation of histidinol-resistant cells in mock transfected cultures, 
prevented use of this marker. Work currently underway (K.Ryan personal 
communication) suggests the use of the hygromycin resistance gene will provide 
a successful protocol for the generation of these lines.
The suggestion that the defensin genes are the homologues of the chicken 
m im -l gene also merits further study. Given the ability of C/EBP family 
members in conjunction with c-Myb to switch on expression of myeloid-specific 
genes in heterologous cell types when over-expressed, experiments to test if 
these transcription factors can act in a similar manner to induce expression of the 
defensin and lysozyme or other myeloid-specific genes would be interesting. 
Similarly, further work on the composite Myb-C/EBP element to test if these 
transcription factors can bind simultaneously would be interesting.
More generally with respect to C/EBP, this work has added weight to the 
suggested importance of these factors in myeloid differentiation. Clearly further 
work is merited, to determine if the C/EBP family is restricted to the myeloid 
compartment. Data from this work shows that the FP1 binding activities are lost 
very rapidly during induced granulocytic but not monocytic differentiation. This 
suggests the intriguing possibility that this factor(s) could be involved in lineage 
choice, between the monocytic and granulocytic lineages, perhaps with C/EBP 
activity in general playing an important role in committing progenitors to the
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rmyeloid lineage, and individual C/EBP family members determining the 
granulocytic/monocytic choice. It will be important to determine if the results in 
the HL60 cell line can be repeated in other cell lines during differentiation, to 
assess if this pattern of FP1 binding activity is representative of that which takes 
place in vivo or is an artefact of this cell line. Given the suggested important role 
of this family of transcription factors in differentiation, it would be particularly 
interesting to express these transcription factors constitutively in the HL60 cell 
line to determine if they can change the differentiation properties of this cell line. 
To assess the effect of FP1 factor(s) it must be first determined which C/EBP 
members comprise this activity. Other interesting experiments using this approach 
could be the use of dominant negative mutants of C/EBP (Ness et al., 1993; Ron 
and Habenauer 1992) in transfection studies. It is possible that negative 
regulators of C/EBP activity could play a role in vivo in the myeloid 
compartment as the rat C/EBPP (LAP) has two translation start sites which 
generate a full length protein and a truncated protein LIP. This truncated protein 
can negatively regulate C/EBP activity at sub-stoichiometric amounts, and its 
level is regulated during hepatocyte differentiation (Descombes and Schibler
1991).
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